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Abstract 
The aim of this thesis is to further define the entry and trafficking pathways 
of the dermonecrotic toxin family composed of related AB toxins whose members 
induce dermonecrosis upon injection into animal skin.  The dermonecrotic toxins 
Pasteurella multocida toxin (PMT) from Pasteurella multocida (P. multocida), 
cytotoxic necrotizing factors 1, 2, and 3 (CNF1, 2 and 3) from Escherichia coli (E. 
coli), the cytotoxic necrotizing factor Y (CNFY) from Yersinia pseudotuberculosis 
(Y. pseudotuberculosis), and the dermonecrotic toxin (DNT) from Bordetella 
species are related by sequence similarity and share similar intracellular GTPase-
protein targets.  PMT, CNF1, CNF2, CNFY, and DNT are bacterial exotoxins that 
are responsible for a wide range of human and zoonotic diseases.  
The potent mitogenic toxin from Pasteurella multocida (PMT) is the major 
virulence factor associated with a number of epizootic and zoonotic diseases caused 
by infection with this respiratory pathogen.  PMT is a glutamine-specific protein 
deamidase that acts on its intracellular G-protein targets to increase intracellular 
calcium, cytoskeletal, and mitogenic signaling. PMT enters cells through receptor-
mediated endocytosis and then translocates into the cytosol through a pH-dependent 
process that is inhibited by ammonium chloride (NH4Cl) or bafilomycin A1 
(BafA1). However, the detailed mechanisms that govern cellular entry, trafficking, 
and translocation of PMT remain unclear. Co-localization studies described herein 
revealed that while PMT shares an initial entry pathway with transferrin (Tfn) and 
cholera toxin (CT), the trafficking pathways of Tfn, CT, and PMT subsequently 
diverge, as Tfn is trafficked to recycling endosomes, CT is trafficked retrograde to 
the ER, and PMT is trafficked to late endosomes.  This study implicates the small 
regulatory GTPase Arf6 in the endocytic trafficking of PMT. Translocation of PMT 
from the endocytic vesicle occurs through a pH-dependent process that is also 
dependent on both microtubule and actin dynamics, as evidenced by inhibition of 
PMT activity in our SRE-based reporter assay, with nocodazole and cytochalasin 
D, respectively, suggesting that membrane translocation and cytotoxicity of PMT is 
dependent on its transfer to late endosomal compartments. In contrast, disruption of 
Golgi-endoplasmic reticulum (ER) trafficking with brefeldin A (BFA) increased 
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PMT activity, suggesting that inhibiting PMT trafficking to non-productive 
compartments that do not lead to translocation, while promoting formation of an 
acidic tubulovesicle system more conducive to translocation, enhances PMT 
translocation and activity.  
CNF1, CNF2, and CNF3 are virulence factors of pathogenic E. coli.  
Pathogenic E. coli are responsible for a wide range of diseases including intestinal 
infections, urinary tract infections, septicemia, neonatal meningitis, pneumonia, and 
hemolytic-uremic syndrome.  CNFY is an exotoxin produced by pathogenic 
Yersinia pseudotuberculosis.  DNT is an exotoxin produced by Bordetella species 
that induces the lesions characteristic of atrophic rhinitis.  The CNFs and DNT 
modify and activate Rho proteins with CNF1 preferentially modifying RhoA and 
Cdc42, CNF2 preferentially deamidating RhoA and Rac1, and CNFY acting as a 
selective activator of RhoA.  The work reported in this thesis uses the SRE assay to 
compare activation of SRE signaling pathways among the CNFs and DNT.  These 
results show that CNF2 and CNFY are the strongest activators of SRE signaling 
pathways.  SRE activity peaks at a concentration of 100 ng/mL for CNF1 and 
CNF2, while concentrations of 1 µg/mL CNFY elicited the highest SRE activation.  
DNT elicited minimal SRE response, presumably due to paucity of DNT cell-
surface receptors on HEK 293T/17.   
It has been previously demonstrated that the CNFs are dependent upon 
endosomal acidification for translocation into the cytosol.  The results reported 
herein demonstrate that while high concentrations of agents of endosomal 
acidification (BafA1 and NH4Cl) inhibit translocation of CNFs, low concentrations 
of these inhibitors actually enhance the activity of CNF1 and CNF2.  Furthermore, 
a region of the N-terminus, residues 199-267 of CNF1, was identified in which the 
pI and charge of CNF1/2 differ from that of CNF3/Y, DNT, and PMT and tertiary 
structural changes that occur in this region with changing pH may be responsible 
for the increase in CNF1/2 activity.  These results also demonstrate that the CNFs 
translocate from the late endosomes as treatment with nocodazole inhibits their 
activity.  Treatment with nocodazole, which inhibits the progression from early to 
late endosome, was able to inhibit the NH4Cl-induced increase in CNF1 activity.  
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Taken together these results support a model in which the CNFs translocate from an 
acidified late endosome.  In the case of CNF1 and CNF2, small concentrations of 
inhibitors of this acidification may be able to increase CNF1/2 activity by altering 
the pH and thereby altering tertiary structure and folding of the toxin proteins to 
make translocation more favorable. 
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Chapter 1:  Introduction 
 
 
1.1  Bacterial Exotoxins  
 The aim of this thesis is to further define the entry and trafficking pathways of the 
dermonecrotic toxin family of bacterial exotoxins that are responsible for a wide range of 
human and zoonotic diseases.  The dermonecrotic toxins Pasteurella multocida toxin 
(PMT) (73) from Pasteurella multocida (P. multocida) (reviewed in (136, 138)), 
cytotoxic necrotizing factors 1 (15), 2 (26, 27, 99) and 3 (95, 126) (CNF1, 2 and 3) from 
Escherichia coli (E. coli) (reviewed in (67)), the cytotoxic necrotizing factor Y (CNFY) 
(47, 77) from Yersinia pseudotuberculosis (Y. pseudotuberculosis) (reviewed in (67)), 
and the dermonecrotic toxin (DNT) (107, 133) from Bordetella species (reviewed in 
(39)). These toxins are classified as exotoxins because they are secreted from bacterial 
cells in contrast to endotoxin, or LPS, which is a part of the bacterial membrane.   
There are three known types of bacterial exotoxins.  Type I toxins include 
superantigens which cause non-specific activation of T-cells by binding to both the MHC 
II on macrophages and T-cell receptors (reviewed in (127)).  Type II toxins include 
membrane damaging toxins such as the pore-forming toxins streptolysin-O and 
Escherichia coli hemolysin (reviewed in (4, 56)).  The dermonecrotic toxins that are the 
focus of this thesis are Type III toxins, otherwise known as AB toxins (reviewed in (44)).  
AB toxins have separate domains responsible for cell-binding and catalytic activity 
(Figure 1.1).  AB toxins can be single polypeptides composed of multiple domains or 
they can be multisubunit toxin complexes.  The binding domain (B) of the toxin is 
responsible for binding to a cell-surface receptor.  If the toxin translocates from an 
endosome, after internalization the translocation domain will facilitate transfer of the 
activity or catalytic domain (A) across the membrane into the cytosol where the A 
domain can then affect its intracellular target.  Alternatively, after binding by the B 
domain, the A domain can be trafficked in a retrograde fashion to the endoplasmic 
reticulum, where it escapes or is translocated into the cytosol. 
As previously mentioned, the dermonecrotic toxins PMT, CNF1, CNF2, CNF3, 
CNFY, and DNT are bacterial exotoxins that are responsible for a wide range of human 
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and zoonotic diseases.  PMT is associated with atrophic rhinitis in swine (36) and is also 
associated with respiratory diseases in both cattle and rabbits (5, 20).  In humans, PMT is 
responsible for dermonecrosis and bacteremia associated with animal bite wounds (43).  
CNF1, CNF2, and CNF3 are virulence factors of pathogenic E. coli.  Pathogenic E. coli 
are responsible for a wide range of diseases including intestinal infections, urinary tract 
infections, septicemia, neonatal meningitis, pneumonia, and hemolytic-uremic syndrome 
(23).  CNFY is an exotoxin produced by pathogenic Yersinia pseudotuberculosis.  DNT is 
an exotoxin produced by Bordetella species that induces a characteristic skin lesion when 
injected into rabbits, mice, and guinea pigs.  DNT has been shown to be lethal in mice 
(133) and is able to induce the lesions characteristic of atrophic rhinitis (111).  Some 
other commonly known examples of toxin-induced disease include the diarrheal disease 
cholera, which is caused by cholera toxin (CT) from Vibrio cholerae (reviewed in (79)), 
diphtheria, which is caused by diphtheria toxin from Corynebacterium diphtheriae 
(reviewed in (61)), botulism, which is caused by botulinum toxin from Clostridium 
botulinum (reviewed in (141)), and tetanus, which is caused by tetanus toxin from 
Clostridium tetani (reviewed in (106)). 
Although bacterial exotoxins can be harmful to cells it is also possible to exploit 
their unique properties for other applications.  Type III bacterial exotoxins have a wide 
variety of uses ranging from therapeutic treatments, to cosmetic purposes, to tools in 
basic science research.  The recombinant toxin containing domains of diphtheria toxin 
(DT) from Corynebacterium diphtheriae is used for treatment of cutaneous T-cell 
lymphoma, while recombinant toxins containing domains of pseudomonas exotoxin from 
Pseudomonas aeruginosa are used for treatment of hairy-cell leukemia (reviewed in 
(68)).  Currently efforts are underway to develop a recombinant toxins containing a 
domain of shiga toxin from Shigella dysenteriae that specifically targets and kills 
melanoma (109).   
Botulinum neurotoxin (BoNT) from Clostridium botulinum has a wide range of 
applications, which span both therapeutic uses as well as cosmetic purposes (reviewed in 
(131)).  BoNT has been used in treatment for a range of neurologic disorders, including 
cervical dystonia, hemifacial spasms, writer’s cramp, tardive dyskinesia, and Tourette’s 
syndrome.  The use of BoNT is also being explored in disorders such as hyperreflexive 
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bladder and benign prostatic hyperplasia.  BoNT is also commonly used for cosmetic 
purposes to treat wrinkles and hyperhidrosis. 
Bacterial protein toxins serve as important molecules for studying signaling 
pathways in basic science research.  Cholera toxin (CT) from Vibrio cholerae 
constitutively activates Gαs through ADP-ribosylation (40) and can therefore be used as a 
tool to study signal transduction through Gαs.  Similarly, pertussis toxin (PT) from 
Bordetella pertussis ADP-ribosylates Gαo, Gαi, and Gαt (55) and can therefore be used 
as a tool to study signal transduction through these pathways.  Furthermore, the 
mitogenic dermonecrotic toxin from P. multocida (PMT) has been used as a tool to study 
Gαq signal transduction (reviewed in (137)). 
There are many benefits to studying toxin trafficking and catalytic activity. 
Clearly, defining the catalytic activity of the toxins and the route by which these toxins 
enter the cell allows for the rational design of therapeutics to prevent their entry and 
therefore prevent the effects of the disease.  In this thesis, insights into the trafficking 
pathways exploited by PMT to gain entrance into the cell could lead to new ideas of how 
to prevent PMT entry and thus prevent the turbinate atrophy associated with atrophic 
rhinitis. 
In addition, because of the usefulness of toxins as both therapeutics and research 
tools, there is much to be gained by studying toxin action.  For instance, defining the cell 
type specificity, entry pathways, or translocation mechanism for a particular toxin can 
lead to the design of recombinant toxins with engineered cell-type specificity.  This 
knowledge could then be used to target therapeutic agents to specific cell types.  
Alternatively, identifying the particular signaling pathways activated by a toxin can allow 
for a better understanding of its activation of signaling pathways.  This allows specific 
toxins to be used as research tools in the study of cellular signaling pathways. 
 
1.2 Mechanisms to Elucidate Toxin Trafficking 
The main focus of this thesis is to further define the intracellular trafficking 
pathways of the dermonecrotic toxin family.  As previously mentioned, AB toxins have 
separate domains responsible for cell-binding and catalytic activity (Figure 1.1).  The 
binding domain (B) of the toxin is responsible for binding to a cell-surface receptor, 
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which triggers endocytosis of the toxin.  If the toxin translocates from an endosome, after 
internalization the translocation domain will facilitate transfer of the activity or catalytic 
domain (A) across the membrane into the cytosol, where the A domain can then affect its 
intracellular target.  Alternatively, after binding by the B domain the A domain can be 
trafficked in a retrograde fashion to the endoplasmic reticulum, where it escapes to the 
cytosol.   
 There are various ways of further defining the entry pathways used by AB toxins.  
Chemical inhibitors, small GTPase trafficking mutants, and markers of cellular organelles 
can all be used to map toxin entry and translocation.  Investigating the effect of chemical 
inhibitors and GTPase mutants on toxin activity lends insight as to whether the pathways 
these inhibitors and mutants block are involved in toxin trafficking.  Alternatively, one 
can visually map routes of toxin entry by using tagged endosomal markers with 
differently tagged toxins.  
 
1.2.1 Chemical inhibitors of intracellular trafficking 
 The trafficking pathways of a number of different toxins have been elucidated 
through the use of various chemical inhibitors (Figure 1.2).  Upon entering the cell some 
toxins, such as the single polypeptide AB toxin diphtheria toxin (DT), exhibit a 
dependence on intra-endosomal acidification for translocation (114), as inhibitors of 
endosomal acidification such as weak bases (NH4Cl) (94) or vacuolar proton pump 
inhibitors (bafilomycin A1 (BafA1)) (10) are able to block toxin activity (Figure 1.2).  
Toxin trafficking pathways through the endosomes can be further distinguished through 
the use of nocodazole, an inhibitor of microtubule polymerization.  Since transport from 
early to late endosomes is dependent on microtubule dynamics (7, 84) treatment with this 
agent blocks vectoral transport from early to late endosomes.  Treatment with nocodazole 
has no effect on DT activity (74), thus suggesting that transport to the late endosomes is 
not necessary for translocation of DT, instead it translocates from the early endosomes 
(Figure 1.2).  Alternatively, treatment with nocodazole was shown to block activity of 
PT, suggesting that PT translocates from the late endosome (Figure 1.2) (140).  
Trafficking pathways can be further defined through the use of cytochalasin D, an 
inhibitor of actin polymerization (Figure 1.2). 
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1.2.2  Endosomal acidification and the role of Arf6 
As previously mentioned, some toxins such as DT depend on intra-endosomal 
acidification for translocation.  It has recently been demonstrated that intra-endosomal 
acidification results in recruitment of a small GTPase, Arf6, along with its cognate 
GDP/GTP exchange factor (GEF), ADP-ribosylation factor nucleotide site opener 
(ARNO), to the endosomal membrane (80).  Once at the membrane Arf6 binds to the c-
subunit of the vacuolar ATPase, while ARNO binds to the a2-isoform (57).   Arf6 is 
involved in trafficking of ligands from the plasma membrane and localizes both to the 
plasma membrane and to internal punctate structures.  Internal structures that label for 
Arf6 are tubulovesicular in shape, and Arf6 can be visualized on tubule extensions, 
suggesting that Arf6 plays a role in recycling back to the plasma membrane (103). 
Alternatively, it has been demonstrated that Arf6-positive vesicles can recruit markers of 
the early endosome such as early endosomal antigen 1 (EEA1) to their surface and that 
they can fuse with early endosome vesicles positive for Rab5, another small GTPase 
involved in intracellular trafficking (discussed further below).  This fusion is mediated by 
the activity of PI-3 kinase, as specific inhibitors of PI-3 kinase such as LY294002 prevent 
this fusion from occurring (Figure 1.2) (89).  
 
1.2.3  Cholera toxin (CT) and Arf6 
Interestingly, CT, a multi-subunit AB5 toxin secreted by the bacterium Vibrio 
cholerae, has been shown to recruit Arf6 to endosomal membranes (Figure 1.2) (30).  
Arf6 (see 1.3 G-proteins and their Regulation for a further discussion of small 
GTPases) serves as an allosteric activator of the CT-catalyzed ADP-ribosylation of Gαs 
(62, 91) with crystal structures of an Arf6-CT complex lending insight into how this 
occurs (92).  Furthermore, CT has been shown to increase rates of intra-endosomal 
acidification (30), and while intra-endosomal acidification is not thought to be important 
for translocation of CT, the trafficking of CT through a low pH compartment is important 
for proteolytic activation of CT (86).  Therefore, it is possible to use CT as a marker for 
Arf6-positive acidified endosomes.  
Unlike DT which translocates from the endosome, CT has a KDEL signal and 
undergoes retrograde trafficking from the endosomes to the Golgi and from the Golgi to 
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the endoplasmic reticulum (ER), where the catalytic subunit of CT escapes to the cytosol 
(Figure 1.2) (75).  It has been demonstrated that treatment with brefeldin A (BFA), a 
fungal metabolite that interrupts trafficking between the Golgi apparatus and the ER(38), 
disrupts CT activity, implicating the Golgi in the trafficking role for CT (Figure 1.2) (96).   
 
1.2.4  Other markers of early endosomes 
Rab5 (see 1.3 G-proteins and their Regulation for a further discussion of small 
GTPases) and EEA1 are two other markers of early endosomes that have been 
demonstrated to colocalize with DT (Figure 1.2) (122). Studies have implicated the 
translocation domain of DT in the modulation of Rab5 activity (2). Vesicles taken up by 
clathrin-independent endocytosis with Arf6 have been shown to recruit EEA1 to their 
surfaces before fusion with endosomes from other pathways, such as the Rab5 Q79L 
(constitutively active Rab5) pathway. However, overexpression of Arf6 Q67L (discussed 
further below) inhibits recruitment of EEA1 and subsequent fusion with other endosomal 
pathways (89). This fusion of Arf6 and Rab5-positive vesicles was mediated by the 
activity of PI-3 kinase, as specific inhibitors of PI-3 kinase such as LY294002 prevent 
this fusion from occurring (Figure 1.2) (89).  
Transferrin (Tfn) and its cognate receptor are ubiquitous iron-uptake proteins that 
are well-characterized markers for Rab5-containing clathrin-coated vesicles and recycling 
endosomes (135). Tfn can thus be used as a marker for endosomal trafficking 
compartments (Figure 1.2). The trafficking of Tfn through Arf6 compartments seems to 
differ according to cell type. In HeLa cells Tfn localizes to a separate compartment from 
Arf6 (12), while in CHO cells and HEK 293T/17 cells transferrin localizes to the same 
compartment as Arf6 (18, 25). While overexpression of wildtype Arf6 does not affect the 
function of Arf6 or its distribution and localization in cells, specific mutations that 
interfere with GDP/GTP binding and/or hydrolysis do (103).  
Arf6 can also be used as a marker of the early endosomes.  The constitutively 
active, GTP-hydrolysis-defective mutant Arf6 (Q67L) localizes to the plasma membrane 
and causes a reduction in the formation of endosomes, whereas the dominant negative, 
GTP-binding-defective Arf6 mutant (T27N) localizes almost exclusively in endosomes 
(103). Overexpression of the Arf6 Q67L mutant results in an increase in cell surface 
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binding of Tfn, but also in a decrease in the rate of internalization of Tfn (24), suggesting 
that while the mutation in Arf6 results in an increase in binding of the ligand, it is unable 
to subsequently internalize it. Alternatively, overexpression of the Arf6 T27N mutant 
results in a decrease in the amount of cell surface-bound Tfn and prevents reappearance 
of cell surface Tfn receptors (24).  
 
1.3  G-proteins and their Regulation 
After binding and uptake the A domain of an AB toxin is translocated into the 
cytosol, where it comes into contact with its intracellular target.  Many A domains target 
G-proteins.  G-proteins function as molecular switches by binding and subsequently 
hydrolyzing GTP, i.e. converting between its active GTP-bound and inactive GDP-bound 
states (Figure 1.3).  G-proteins can be divided into two classes, the monomeric G-proteins 
and the heterotrimeric G-proteins.  The family of monomeric G-proteins is large and 
includes protein families such as Ras, Rho, and Rab.  Monomeric G-proteins range in 
size from 20-40 kDa and play a role in a variety of different processes in eukaryotic cells, 
including regulating cytoskeleton and vesicular trafficking.  The Rho subfamily is 
responsible for relaying signals from the cell surface to the actin cytoskeleton (reviewed 
in (121)), and the Rab subfamily functions to modulate the activity of transport vesicles 
within the cell (reviewed in (58)).  Monomeric G-proteins can be regulated by the activity 
of two types of signaling proteins:  GTPase-activating proteins (GAPs) and guanine 
nucleotide exchange factors (GEFs).  GAPs serve to increase the rate of GTP hydrolysis.  
This regulation of G-proteins along with the intrinsic GTP-ase activity of the monomeric 
G-proteins allows them to function as a tightly regulated molecular switch, in which GTP 
binding activates the protein, followed by the subsequent hydrolysis of GTP to GDP and 
inactivation of the protein.  GEFs increase the rate at which GTP is exchanged.  They 
promote the dissociation of GDP from the G-protein leaving the protein free to bind 
another GTP.   
The heterotrimeric G-proteins transduce signals from membrane-spanning G-
protein coupled receptors (GPCRs) (reviewed in (93)).  The action of heterotrimeric G-
proteins is depicted in Figure 1.3.  GPCRs are composed of a single polypeptide chain 
that crosses through the membrane seven times.  The cytoplasmic domains of the receptor 
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facilitate the interaction between the receptor and the G-protein.  Heterotrimeric G-
proteins are composed of three subunits: an α subunit ranging from 45-47 kD in size, a β 
subunit of 35 kD, and a γ subunit ranging from 7-9 kD in size.  When a ligand binds to 
the receptor, a conformational change in the receptor causes the G-protein α subunit to 
release GDP, which, in turn, allows GTP to bind in its place.  This binding of GTP 
induces a conformational change in the α subunit that results in the disassociation of the 
βγ complex from the α subunit, allowing them to interact with their effector proteins.  
Eventually, the intrinsic GTPase activity of the α subunit hydrolyzes the GTP to GDP, 
and the GDP-bound α subunit then reassociates with the βγ complex to form the inactive 
heterotrimeric G-protein.  
The physiological role of a particular heterotrimeric G-protein is dependent on the 
functions of the subunits of the G-protein.  There are four different families of G-protein 
α subunits: Gαs, Gαi/o, Gα12, and Gαq.   Members of the Gαs family are responsible for 
the stimulatory regulation of adenylyl cyclases thus leading to increases in intracellular 
cAMP levels, while members of the Gαi/o family are responsible for the inhibition of 
adenylyl cyclases (reviewed in (130)).  The Gαi/o family is the most widely expressed α 
subunit type and cellular levels of these proteins are relatively high. The Gα12 proteins 
are ubiquitously expressed and are thought to play a role in Rho-mediated activation of c-
Jun N-terminal kinase (JNK), activation of the Na+/H+ exchanger (48), activation of 
phospholipase D (105), and Rho-dependent formation of actin stress fibers (13).  
Stimulation of Gαq, and the subsequent activation of phospholipase C β1 (PLCβ1), 
activates the IP3 signaling pathway to cause increases in intracellular Ca2+ levels.  It has 
been difficult to elucidate the processes regulated by these proteins since Gα12-coupled 
GPCRs can also activate Gαq family proteins and vice versa.    
 
1.4  Toxins that affect G-proteins 
 Once inside the cell many toxins target G-proteins.  CT has been shown to ADP-
ribosylate and thereby activate Gαs (40), increasing adenylate cyclase activity.  In 
addition, CT interacts with another G-protein, Arf6, which then serves as an allosteric 
activator of the Gαs ADP-ribosylation reaction (64, 91).  PT also modifies G-proteins 
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through ADP-ribosylation of Gαo, Gαi, and Gαt (55).  Instead of ADP-ribosylation, the 
dermonecrotic toxins, which are the subject of this thesis, all constitutively activate G-
proteins through deamidate of a specific glutamine residue important for catalysis. PMT 
has been demonstrated to activate Gαq and Gαi2 by deamidation (98), while the CNFs 
and DNT deamidate members of the Rho family. 
 
1.5  Dermonecrotic Toxins 
 The dermonecrotic toxins are a family of related AB toxins, whose members 
induce dermonecrosis upon injection into animal skin. These toxins are related by 
sequence similarity (Figure 1.4 (42, 72) and Figure 1.5 (101)) and share similar 
intracellular GTPase-protein targets.    CNF1 and 2 share 85% identity and 96% 
similarity with one another while CNF1 shares 61% identity and 87% similarity with 
CNFY.  The binding domains of the dermonecrotic toxins are located at the N-terminus 
and PMT and CNF1 share 62% amino acid similarity and 26% identity in their N-termini 
(residues 4-552 of CNF1 and residues 38-607 of PMT).  The catalytic domains of the 
dermonecrotic toxins are located at the C-terminus. CNF1 and DNT share 58% similarity 
and 25% identity in their C-termini (residues 732-1007 of CNF1 and residues 1179-1452 
of DNT), while PMT shows no sequence similarity with CNFs or DNT.   
The CNFs modify and activate Rho proteins with CNF1 preferentially modifying 
RhoA and Cdc42, CNF2 preferentially deamidating RhoA and Rac1 (129), and CNFY 
acting as a selective activator of RhoA (47).  Similarly, PMT has been demonstrated to 
induce activation of Rho proteins indirectly through either stimulation of Gα12/13 (97) or 
through tyrosine kinases (113). 
 
1.6  Pasteurella multocida Toxin (PMT) 
 
1.6.1  PMT and disease 
PMT is a protein toxin produced by P. multocida serotype A and D strains.  PMT 
is the major virulence factor associated with atrophic rhinitis in swine (Figure 1.6) (36) 
and it has been demonstrated that PMT experimentally induces all of the major symptoms 
of the disease (73).  PMT has also been implicated in respiratory diseases in both cattle 
 10 
and rabbits (5, 20), and is responsible for dermonecrosis and bacteremia associated with 
animal bite wounds (43). 
 
1.6.2  Intracellular effects of PMT 
Once inside the cell, PMT activates a number of different intracellular signaling 
pathways (reviewed in (136, 138)).  PMT acts to enhance intracellular calcium signaling 
pathways resulting in increased inositolphospholipid hydrolysis (88), mobilization of 
intracellular calcium stores (124), increased protein kinase C (PKC)-dependent 
phosphorylation (125), and calcineurin-dependent nuclear factor of activated T cells 
(NFAT) activation (78).  PMT also initiates a multitude of mitogenic effects including 
initiation of DNA synthesis (112), increased tyrosine phosphorylation (69), and MAPK 
(Erk1/2) activation (120).  In addition, PMT has been observed to induce cytoskeletal 
rearrangement (29, 69). 
PMT exerts some of these effects through activation of the IP3 signaling pathway 
by stimulation of Gαq and the subsequent activation of phospholipase C β1 (PLCβ1).  
PMT activates Gαq and Gαi2 by deamidation (Figure 1.7) (98).  Stimulation of MAPK 
pathways occurs through Gαq/11-dependent transactivation of the epidermal growth factor 
receptor (120).  It has also been demonstrated that PMT-induced Rho activation occurs 
through stimulation of Gα12/13 (97) or through tyrosine kinases (113).  PMT-induced Rho 
activation by Gα12/13 may be due to deamidation, since it was previously demonstrated 
that PMT activates Gαq and Gαi2 by deamidation (98).  These pathways all activate 
serum response element (SRE) transcription through activation of serum response factor 
(SRF).  In the case of the ras-raf-MAPK-ERK cascade, phosphorylation of ternary 
complex factors (TCFs) and the binding of TCFs to SRF are necessary for activation of 
SRE (60).  Other pathways such as the Rho family pathways are independent of TCF 
(45).  Since the signaling pathways activated by PMT all activate transcription from the 
SRE promoter (37) (45) our lab has previously used an SRE-based luciferase reporter 
system to measure PMT’s activity (1). 
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1.6.3 PMT entry into the cell 
Little is known about the trafficking pathways that PMT exploits to gain access to 
the cytosol (Figure 1.8).  Evidence suggests that PMT binds to a ganglioside (29, 104), 
but a protein receptor has not been identified.  The lag time between toxin treatment and 
toxin activity supports the assertion that PMT is an intracellularly acting toxin (112).  In 
addition, it has been demonstrated that the addition of antibodies or the addition of weak 
bases only inhibit PMT activity if added during the early stages of intoxication (112). 
Furthermore, exposure of cells to PMT at 4oC results in no detectable PMT activity (112), 
suggesting that cellular uptake and endosomal trafficking is necessary for PMT 
intoxication.   
Studies have shown that BafA1, an inhibitor of the vacuolar ATPase H+ pump, 
inhibits PMT activity as measured by phosphorylation of FAK (3), implying that intra-
endosomal acidification is essential for PMT activity.  Furthermore, when PMT is bound 
to the cell surface and endocytosis is inhibited, there is an increase in PMT activity upon 
exposing the cells to an acidic pH suggesting that the drop in pH causes PMT to 
translocate directly across the membrane (3).  It has been demonstrated that PMT inserts 
into lipids in a pH-dependent manner (3) and that this lipid insertion occurs at the same 
pH at which PMT unfolds (123).  Together these data support a model, in which PMT is 
endocytosed and trafficked through a low pH compartment where PMT unfolds, inserts 
into the membrane, and translocates to the cytosol.  
 
1.7  Cytotoxic Necrotizing Factor 1 (CNF1) 
 
1.7.1  CNF1 and disease 
 Pathogenic E. coli are responsible for a wide range of diseases, including not only 
intestinal infections but also extra-intestinal infections, such as urinary tract infections, 
septicemia, neonatal meningitis, pneumonia, and hemolytic-uremic syndrome (23). CNF1 
is a virulence factor of uropathogenic E. coli and is commonly found in E. coli strains 
producing extra-intestinal infections (16).  CNF1 has been found in E. coli strains 
isolated from cases of neonatal meningitis (8), and it has been demonstrated that CNF1 
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causes the RhoA activation in brain microvascular endothelial cells thereby allowing the 
pathogen to enter the central nervous system (64). 
 
1.7.2  Intracellular effects of CNF1 
CNF1 induces morphological changes in cells including multinucleation (Figure 
1.9C) (14) and the formation of actin stress fibers along with an increase in cellular F-
actin (Figure 1.9D) (33, 35, 116). CNF1 has also been shown to increase DNA synthesis 
(70).  These morphological changes are the result of the molecular action of CNF1, which 
is the activation of RhoA through the deamidation of the glutamine at position 63 to 
glutamic acid (Figure 1.10) (35, 116).  Gln 63 is thought to be important for GAP-
mediated GTP hydrolysis (110), thus modifying this residue impairs GTP hydrolysis, 
causing a constitutive activation of the protein.  CNF1 also acts on Rac1 and Cdc42, two 
other members of the Rho GTPase family, in a similar manner by causing the 
deamidation of the glutamine at position 61 into glutamic acid (Figure 1.10) (76).  In 
addition, it has been demonstrated that CNF1 can function as a transglutaminase (117); 
however, unlike DNT which functions preferentially as a transglutaminase (115), CNF1 
functions preferentially as a deamidase (117). 
Current evidence suggests that the deamidation modification subjects Rac1 to 
ubiquitin/proteasome-mediated degradation (28), resulting in a subsequent decrease in 
Rac1 activation.  Additionally, CNF1-mediated activation of RhoA is thought to be 
transient, but this transient activation is likely to be proteasome-independent (46).  
 It was previously demonstrated that Rho activates phosphoinositide 5-kinase (19), 
thereby causing elevated levels of PIP2.  This has been suggested as a mechanism of how 
Rho can regulate the actin cytoskeleton, and accordingly treatment with CNF1 activates 
phosphoinositide 5-kinase in a time- and dose-dependent manner (34).  However, the 
authors observed that LY294002, an inhibitor of PI3-kinase (132), did not block CNF1 
activity suggesting that CNF1 activity is not dependent on PI3-kinase activity. 
 
1.7.3  CNF1 entry into the cell 
 The N-terminus of CNF1 contains the binding and translocation domains (9). 
Evidence shows that the N-terminal 299 residues of CNF1 bind to a 37-kDa laminin 
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receptor precursor protein present in human brain microvascular endothelial cells (21).  
This 37-kDa protein is a precursor to the 67-kDa laminin receptor protein, as the 37-kDa 
protein dimerizes to form the 67-kDa laminin receptor protein (71).  It was subsequently 
demonstrated that entry of CNF1 is mediated by the 67-kDa receptor (Figure 1.11)(65).  
It has also been demonstrated that a C-terminal fragment of CNF1, comprising residues 
683-730, is able to bind to cells and that CNF1 can bind to another receptor on HEp-2 
cells, suggesting that there may be another CNF1 receptor in addition to the 67-kDa 
laminin receptor (85).  Once bound to the cells, CNF1 enters via a clathrin-independent 
mechanism, as proteins inhibiting the clathrin-coated pathway, such as dynamin K44A, 
or chemical inhibitors of the clathrin-mediated pathway, such as chlorpromazine, were 
unable to inhibit CNF1 endocytosis (22).  Furthermore, drugs such as amiloride, which 
inhibits macropinocytosis (134), or filipin, which sequesters cholesterol thereby 
inhibiting endocytic pathways dependent on caveolae (118), were unable to inhibit 
CNF1-induced multinucleation (22).   
 After internalization, CNF1 must pass through an acidified endosome before 
translocation to the cytosol (Figure 1.11).  Weak bases such as methylamine inhibit the 
CNF1-mediated phosphorylation of p125fak (70).  Other agents, such as BafA1 that 
inhibits the endosomal proton pump (10) or the weak base NH4Cl, have also been shown 
to inhibit multinucleation induced by CNF1 (22).  Furthermore, CNF1 can be 
translocated across the membrane with an acidic pulse (22).  Entry of CNF1 is also 
dependent upon the toxin entering a late endosome (Figure 1.11).  It has been 
demonstrated that communication between early and late endosomes requires 
microtubules.  CNF1-induced multinucleation of HeLa and MDCK cells can be blocked 
with the use of the microtubule inhibitor nocodazole (84), suggesting that translocation of 
CNF1 must occur from a late endosome (22).  Treatment with BFA, which interrupts 
trafficking between the Golgi apparatus and the ER (38, 87), did not affect CNF1-
induced multinucleation, indicating that the toxin is not trafficked through the Golgi 
apparatus (Figure 1.11) (22). 
 It has been suggested that a hydrophobic region encompassing residues 331-414 
comprises the translocation domain (31).  Hydrophobicity plots of CNF1 indicate a 
hydrophilic loop spanning residues 373-386, therefore suggesting that the translocation 
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domain has a helix-loop-helix structure similar to that of diphtheria toxin (reviewed in 
(32)).  Furthermore, mutation of acidic residues within this hydrophilic loop abolishes 
CNF1-induced multinucleation without altering cell binding, enzymatic activity (as 
measured by in vitro deamidation), or endocytic activity (102).  This study suggested an 
important role for the acidic residues of the translocation domain in translocation of 
CNF1 to the cytosol.  During the process of endocytosis and translocation, CNF1 
undergoes a cleavage event that results in the presence of a 55-kDa fragment in the 
cytosol (66).  The region where cleavage occurs is located between residues 532 and 544, 
and its processing requires an acidic pH, as treatment of cells with BafA1 prevents the 
appearance of the fragment (66).  Furthermore, CNF1 mutants that do not insert into the 
membrane prevent the appearance of the fragment, suggesting that insertion into the 
membrane is also required for processing (66). 
 
1.7.4 Assays used to measure CNF1 activity 
 Previous studies have used visual indicators of Rho activation, such as 
multinucleation (22) and formation of actin stress fibers to measure activity of CNF1 (34, 
70).  While examining cells for mutlinucleation or the formation of actin stress fibers 
allows one to determine the percentage of the cell population affected by CNF1, it does 
not give a quantifiable measure of signaling pathway activation by CNF1.  Other studies 
have used electrophoretic mobility assays to detect a shift in Rho GTPases that occurs 
after toxin-mediated deamidation (34, 70) or have used tyrosine phosphorylation of 
p125fak and paxillin, as an indicators of CNF1 activity (70). 
 
1.8  Cytotoxic Necrotizing Factor 2 (CNF2) 
 Cytotoxic necrotizing factor 2 (CNF2) elicits different cellular effects than CNF1, 
which could be due to differences in their substrate preference or levels of substrate 
activation.  Whereas CNF1 has been shown to induce multinucleation and rounding of 
HeLa cells, moderate necrosis of rabbit skin, and no necrosis in the mouse footpad test, 
CNF2 has been shown to only induce moderate nucleation of HeLa cells, elongation of 
HeLa cells, and a markedly intense necrotic response in both the rabbit skin test and 
mouse footpad test (26).  Like CNF1, CNF2 also binds to the laminin receptor protein 
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(Figure 1.11) (85).  Analysis of the protein sequence of CNF2 has revealed two 
hydrophobic helices that are thought to be part of the translocation domain.  Acidification 
of the endosome is thought to be an important step in CNF2 translocation as the weak 
base methylamine was seen to inhibit CNF2 activity on cells when added before exposure 
to CNF2 (Figure 1.11) (100).  The cytoskeletal effects of CNF2 are due to its 
modification of the Rho proteins, as these Rho proteins are modified in CNF2-treated 
cells (Figure 1.10) (100).  In contrast to CNF1, which preferentially deamidates RhoA 
and Cdc42, CNF2 has been shown to preferentially deamidate RhoA and Rac1 (129).  
This CNF2-induced deamidation occurs at glutamine 63 of RhoA and glutamine 61 of 
Rac1 (Figure 1.10) (129). 
 
1.9 Cytotoxic Necrotizing Factor 3 (CNF3)  
 Cytotoxic necrotizing factor 3 (CNF3) was first identified in fecal samples from 
sheep and goats and shares about 70% sequence identity with CNF1 and CNF2 and 68% 
sequence identity with CNFY (95).  CNF3 is a stronger activator of RhoA than CNF1 and 
is also able to activate Rac1 and Cdc42, although RhoA is the preferred substrate (126).  
Furthermore, CNF3 and CNFY may bind to a similar receptor as they are able to enter 
the same cell lines (Figure 1.11) (126). 
 
1.10 Cytotoxic Necrotizing Factor Y (CNFY)  
 Cell extracts from certain strains of Yersinia pseudotuberculosis also induce the 
multinucleation, similar to that characteristic of E. coli CNFs in HEp-2 cells (77).  The 
cnfY gene, which is associated with this activity, is located on the chromosome and shares 
65.1% gene identity with the E. coli cnf1 gene (77).  CNFY activates Rho A through a 
deamidation of glutamine 63 (47).  Although both Rac1 and Cdc42 can serve as 
substrates of CNFY in vitro, CNFY is a strong, selective activator of RhoA in vivo (47).  
Accordingly, while treatment with CNFY leads to stress fiber formation, it does not lead 
to formation of filopodia or lamellipodia.  The substrate specificity of CNFY that leads to 
selective activation of RhoA is due to differences in the catalytic domain of the toxin and 
can specifically be attributed to differences in a loop region (L8) on the surface of the 
catalytic domain (46). 
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While Caco-2 and CHO-K1 cells are unresponsive to CNFY, HeLa, HEp-2, and 
HEK 293T/17 cells are sensitive to CNFY (6).  Although the binding of CNF1 does not 
influence the uptake of CNFY, conversely the binding of CNFY can affect the uptake of 
CNF1, suggesting that there may be overlap between the receptors (6).  Furthermore, 
uptake of CNFY is dependent upon acidified endosomes, but uptake and internalization of 
CNFY appears to be independent of clathrin or lipid rafts (Figure 1.11) (6). 
 
1.11  Bordetella Dermonecrotic Toxin (DNT) 
 
1.11.1  DNT and disease 
 Bordetella species are associated with upper respiratory diseases such as 
whooping cough in humans, atrophic rhinitis and pneumonia in swine, kennel cough, and 
turkey coryza (reviewed in (41, 108, 139)).  Bordetella species produce a 160 kDa 
dermonecrotic toxin (DNT), composed of a single polypeptide chain (51).  DNT is named 
for the characteristic skin lesion that occurs when the toxin is injected into rabbits, mice, 
and guinea pigs.  In addition to being dermonecrotic, the toxin has been demonstrated to 
be lethal in mice (133) and to cause splenic atrophy in mice (59).  DNT is able to induce 
lesions characteristic of atrophic rhinitis and the production of these lesions as well as 
lung lesions can be correlated to the production level of DNT (111).  Furthermore, pigs 
inoculated with strains of B. bronchiseptica that are not producing DNT do not show the 
turbinate atrophy found in pigs inoculated with DNT-producing strains of B. 
bronchiseptica (11). 
DNT’s from Bordetella pertussis, Bordetella parapertussis, and Bordetella 
bronchiseptica are able to produce similar lesions with lesion formation occurring at 
similar doses and time courses, suggesting that the DNT’s from these different species 
are similar (133).  The DNT from B. avium required a higher dose and longer time for 
production of lesions (133).  This observation was further verified by southern blot 
analysis with a B. pertussis probe, which demonstrated that the restriction maps of B. 
pertussis, B. parapertussis, and B. bronchiseptica are the same, while failing to hybridize 
in the B. avium and P. multocida strains (133).  After complete sequencing it was 
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determined that the DNT of B. bronchiseptica is 99% homologous to the DNT of B. 
pertussis (107). 
 
1.11.2  Intracellular effects of DNT 
 DNT acts to increase both the rate of protein synthesis (53) as well as the rate of 
DNA synthesis (54).  Although cell number does not increase in DNT-treated cells there 
is an increase in the number of polynucleated cells (Figure 1.12F) (54).  DNT has also 
been demonstrated to inhibit the elevation of alkaline phosphatase and to reduce the 
accumulation of type I collagen in an osteoblastic cell line (50).  High levels of alkaline 
phosphatase and accumulation of type I collagen are associated with osteoblastic 
differentiation (128), thus these results suggest that DNT can impair osteoblastic 
differentiation (50).  In fact, DNT impairs bone formation in vivo as DNT injected into 
the tissue overlying the calvariae of neonatal rats results in degenerated and necrotized 
periosteal cells and osteoblasts, a loss of osteoclasts, fragmentation of bone matrix, and 
multinuclear cells (52).  DNT has other cellular effects, including an increase in 
membrane organelles such as the Golgi apparatus, smooth and rough ER, and 
mitochondria as well as the formation of caveolae (119). 
 When cells are treated with DNT doses that are known to elicit the cellular effects 
of DNT (inhibition of osteoblastic differentiation (50), stimulation of DNA (54) and 
protein (53) synthesis), the normally flat cells become rounded and refractive (Figure 
1.12D) (52).  In addition, the cells treated with DNT form dense, thick actin fibers and 
show an increase in vinculin-stained focal adhesions (52).  DNT-treated cells appear to 
have more densely distributed microtubules (52).  It was discovered that treatment with 
DNT can rescue cells from the phenotype induced by Clostridium botulinum C3 
exoenzyme (C3) (52), which ADP-ribosylates and inactivates Rho (17, 90).   
Incubation of RhoA with DNT changes the electrophoretic mobility of RhoA 
(52), which was attributed to DNT’s ability to deamidate glutamine at position 63 to 
glutamic acid (49), causing constitutive activation of RhoA.  This constitutive activation 
of RhoA is due to a 10-fold decrease in intrinsic GTP hydrolysis (49).  Furthermore, cells 
transfected with a RhoAGlu-63 mutant exhibit an increase in the formation of actin stress 
fibers, suggesting that this modification is directly responsible for the morphological 
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effects of DNT (49).  DNT catalyzes the deamidation of Rac1 and Cdc42 in vitro (49) as 
well as in vivo (81) and causes a decrease in their GTP hydrolysis (81).  A C-terminal 
fragment of DNT, encompassing residues 1136-1451, retains full deamidating activity 
with cysteine-1292 (Cys) , histidine-1307 (His), and lysine-1310 (Lys) being essential for 
enzymatic activity (115).  Other groups have demonstrated that a shorter C-terminal 
fragment (1176-1451) retains enzymatic activity and that this activity is abolished with a 
mutation at Cys-1305, implicating this position as important for DNT activity (63).  
Further evidence suggests that unlike CNF1, which shows a preferential deamidase 
activity (117), DNT has a higher transglutaminase activity than deamidase activity, 
suggesting that DNT acts preferentially as a transglutaminase (115). 
 
1.11.3  DNT entry into the cell 
The binding domain of DNT is located at the N-terminus as fragment 1-531 
competes with full-length DNT for binding and entry into cells and thus this fragment 
was able to reduce DNT-induced polynucleation in cells (63). This is further supported 
by the observation that antibodies directed against the N-terminus are able to inhibit DNT 
activity when added to the outside of cells, but are unable to do so when microinjected 
(83).  The minimal N-terminal fragment that will compete for binding with full-length 
DNT, thus preventing Rho modification, was the N-terminal 54 residues of DNT (83) and 
it was demonstrated that this fragment is able to bind to cells (83).  DNT 1-54 only binds 
to cells which are sensitive to DNT, suggesting that it recognizes a receptor present on 
DNT-sensitive cells (83).  
While microinjection of full-length DNT does not promote formation of actin 
stress fibers, microinjection of DNT pre-treated with furin does result in formation of 
actin stress fibers (82), suggesting that proteolytic cleavage of DNT is essential for 
intracellular activity (Figure 1.10).  Further analysis revealed that DNT is cleaved at the 
C-terminal side of the arginine located at residue 44 (82) and that the two fragments 
remain covalently linked after cleavage (82).  Residues 45-166 are thought to play a role 
in translocation of DNT across the membrane (82).  It is believed that endocytosis of 
DNT is dependent upon dynamin, as expression of dominant-negative mutants of 
dynamin reduce the sensitivity of cells to DNT (82).  DNT activity is insensitive to 
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treatment with agents that lower the pH of endosomes such as BafA1 (10) and NH4Cl 
(94), suggesting that DNT does not require translocation from an acidified endosome 
(Figure 1.11) (82).  Furthermore, DNT activity is unaffected by treatment with 
cytochalasin D or nocodazole, inhibitors of actin and microtubules, respectively (Figure 
1.11) (82).  DNT activity is also not affected by treatment with BFA (Figure 1.11) (82), 
suggesting that DNT is not trafficked from the Golgi apparatus to the ER (82).  
 
1.11.4  Assays used to measure DNT activity 
Since DNT modifies Rho GTPases, many assays to measure DNT activity are 
similar to those used to measure CNF1 activity.  Thus, DNT activity can be measured by 
the accumulation of actin stress fibers (52) or multinucleation of cells (54), or by 
assessment of the extent of Rho protein modification (52). While these methods provide 
information on the percentage of a cell population affected by DNT, they do not give a 
quantifiable measure of intracellular signaling. Since DNT increases DNA synthesis, it is 
possible to quantitatively measure increases in DNT activity by measuring incorporation 
of a radiolabeled thymidine (54). However, this method requires the use of radioactivity. 
DNT activity assays can also be performed in the specialized MC3T3-E1 osteoblastic cell 
line, where DNT inhibits both alkaline phosphatase activity and type I collagen 
accumulation (50), but this assay is not generally applicable to other cells.   
 
1.12  SRE-Luciferase Assay 
The SRE-luciferase assay provides a quantitative measure of the activation of 
signaling pathways that result in transcriptional activation of genes regulated by the 
serum response element (SRE) which is a DNA sequence located in the promoter region 
of certain genes.  Serum response factor (SRF) and ternary complex factor (TCF), 
stimulated through a variety of different signaling pathways, as displayed in Figure 1.13, 
form a complex with SRE. Activation of Gα12 causes the activation of SRE through 
activation of RhoA (37).  Several members of the Rho family, including RhoA, Rac1 and 
CDC42, activate SRE transcription through SRF and act synergistically with activated 
TCF, suggesting that the Rho family is able to induce SRE transcription through SRF 
(45).  Furthermore, while activation of Gα12 occurs through Rho, functional Rho is not 
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required for SRE signaling through CDC42 or Rac1 (45). Activation of this SRF 
signaling pathway does not correlate with activation of the MAP kinase signaling 
pathways such as ERK, as activation of ERK is neither necessary nor sufficient for 
activation of SRF (45).  Activation of Gαq can also lead to SRE signaling through Rho 
proteins (113). Gαq interacts with the Rho GEF Lbc, suggesting that Gαq enhancement of 
Rho-mediated SRE signaling occurs downstream of Rho activation (113). 
As previously mentioned, the CNFs activate Rho proteins.  CNF1 preferentially 
activates RhoA and CDC42, CNF2 preferentially activates RhoA and Rac1(129), and 
CNFY preferentially activates RhoA (47).  PMT not only induces activation of Rho 
proteins through stimulation of Gα12/13 (97), but also activates Gαq.  Since these 
dermonecrotic toxins all activate pathways that lead to downstream activation of SRE, it 
is possible to use an SRE reporter gene, such as the firefly luciferase gene luc, to measure 
their intracellular activity.  Use of an SRE-luciferase reporter gives a quantitative readout 
of toxin activity providing a valuable tool with which to study toxin trafficking, 
translocation, and activity. 
 
1.13  Aims 
Unanswered questions concerning the intracellular trafficking pathways of PMT 
include: does PMT translocate from the late endosome? Are the small GTPases Arf6 or 
Rab5 involved in PMT trafficking? Is PMT internalized via a similar pathway as CT?  Is 
PMT trafficking affected by treatment with brefeldin A?  What is the role of actin in the 
entry and trafficking of PMT?  Questions concerning CNF1, CNF2, CNFY, and DNT 
include:  What are the dose and time course responses of treatment of these toxins in the 
SRE-luciferase assay?  How is CNF activity affected by inhibitors of endosomal 
acidification?  Does CNF2 translocate from the late endosome?  
These questions are important because, as previously stated, toxins are useful both 
as therapeutics and as research tools.  By further defining the trafficking pathways used 
by PMT to enter the cell, one will be able to rationally design inhibitors to prevent its 
entry into cells, thereby preventing the effects of atrophic rhinitis.  Furthermore, defining 
the entry pathways of the CNFs will allow for better methods of preventing their entry 
and hopefully preventing the effects of E. coli-induced diseases like urinary tract 
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infections and meningitis.  Alternatively, further defining the trafficking pathways of 
these toxins may some day allow for their use as recombinant toxins to deliver 
therapeutic molecules to specific cell types or specific cellular compartments.  In 
addition, toxins are also often used as research tools.  CT has been used as a marker of 
the endosomes and Golgi.  Further defining the trafficking pathways of the dermonecrotic 
toxin family will allow for their use as markers of trafficking pathways. 
My overall objectives/goals are to further define the PMT trafficking pathway by 
determining whether PMT translocates from the late endosome and whether entry is 
mediated by small GTPases such as Arf6 or Rab5.  I also hope to demonstrate the 
usefulness of the SRE-luciferase assay in quantitatively measuring the signaling activity 
of the dermonecrotic toxin family.  By demonstrating the usefulness of the SRE-
luciferase assay in quantitatively measuring toxin activity, I will further be able to 
investigate the effects of various inhibitors of endosomal acidification on dermonecrotic 
toxin activity.   
To achieve these goals my specific aim in chapter 2 is to further characterize the 
entry pathway of PMT using the SRE-luciferase assay as a measure of PMT activity.  As 
previously stated, not much is currently known about trafficking of PMT inside the cell.  
While it has been shown that endosomal acidification is important for PMT-mediated 
phosphorylation of FAK (3), and that weak bases inhibit PMT activity (112), it is not 
known whether PMT translocates from an early or late endosome.  My aim is to confirm 
that inhibitors of endosomal acidification inhibit the activity of PMT in the SRE assay.  I 
also hope to determine whether PMT translocates from an early or late endosome through 
the use of nocodazole, an inhibitor that blocks transport from early to late endosomes (7, 
84).  I specifically plan to do this by observing whether treatment with nocodazole blocks 
PMT-induced SRE activity.  Furthermore, I plan to further define this trafficking pathway 
by determining the involvement of actin dynamics in the pathway by determining the 
effect of cytochalasin D on PMT activity. 
   I aim to determine whether the small GTPase Arf6 is involved in the uptake of 
PMT in a manner similar to that described for CT, which localizes to Ar6-positive 
endosomes by observing whether PMT and CT colocalize in endosomes.  If PMT and CT 
use the same initial pathway for entry into the cell, I aim to further define the downstream 
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trafficking pathway.  One possibility I propose to explore is whether the Arf6-positive 
PMT-containing vesicle fuses with Rab5-positive vesicles in a manner dependent upon 
PI-3 kinase.  I will specifically test this by observing the effect of LY294002 on PMT-
induced SRE activity.  A second possibility investigated is whether there is any 
involvement of Golgi trafficking in internalization of PMT through the use of Golgi 
disruptors such as BFA. 
My specific aim in chapter 3 is to use the SRE-luciferase assay to measure the 
activity of other dermonecrotic toxins, such as CNF1, CNF2, CNFY, and DNT.  I plan to 
do this by treating HEK 293T/17 cells with each toxin and observing the subsequent 
changes in SRE-luciferase activity.  By establishing their use in the SRE-luciferase assay, 
I hope to determine the time course and dose response of the SRE-luciferase reporter 
assay to cells treated with these toxins.  Furthermore, I aim to demonstrate that the SRE-
luciferase assay is a useful assay for the measurement of CNF1, CNF2, CNFY, and DNT 
activity because it provides a quantitative measurement of toxin activity. 
I aim to further define the trafficking of these toxins using the SRE-luciferase 
assay.  As the SRE-luciferase assay provides a quantitative measure of toxin activity, I 
want to investigate the dose response of the weak base NH4Cl and the proton pump 
inhibitor BafA1 on toxin-induced SRE-luciferase activity.  This information will yield 
insight into from what endosomal compartment the toxins translocate, as well as 
information about how endosomal pH affects translocation.  I also aim to further define 
the translocation compartment of CNF2 by observing the effect of nocodazole on CNF2-
induced SRE-luciferase activity. 
Results from these studies not only provide insight into the trafficking pathways 
of the dermonecrotic toxin family, but also provide a novel way of measuring toxin 
activity.  Defining the trafficking pathways the dermonecrotic toxins use to gain entry 
into the cell can be used to design specific inhibitors to inhibit their entry and therefore 
inhibit their toxic effects.  In addition, further defining the trafficking pathways of these 
toxins will allow for the use of their binding domains as cargo-carrying delivery 
molecules to target therapeutics to specific cell types and compartments.   
In addition, knowledge gained from this thesis provides a novel way to measure 
activity of the CNF family. Development of the SRE-luciferase assay as a method of 
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measuring toxin activity has allowed for further insight into the trafficking pathways of 
these toxins and their translocation. It can also be used to compare the quantitative 
activity among a family of toxins or the quantitative activity of a single toxin across 
different cell lines.  Overall, the SRE-luciferase assay is a useful tool that has broad 
applications in measuring the activity of toxins in the dermonecrotic toxin family. 
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1.14 Figures 
 
 
Figure 1.1 Type III AB Toxins 
AB toxins have separate domains responsible for cell-binding and catalytic activity.  AB toxins can be 
single polypeptides composed of multiple domains or they can be multisubunit toxin complexes.  The 
binding domain (B) of the toxin is responsible for binding to a cell-surface receptor.  If the toxin 
translocates from an endosome, after internalization the translocation domain (T) will facilitate transfer of 
the activity domain (A) across the membrane into the cytosol where the catalytic domain can then affect its 
intracellular target.  Alternatively, after binding by the B domain the A domain can be trafficked in a 
retrograde fashion to the endoplasmic reticulum, where it escapes to the cytosol. 
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Figure 1.2 Intracellular Trafficking 
This figure depicts the various intracellular trafficking pathways and the effects of various chemical 
inhibitors and G-protein mutants on trafficking activity.  Mutants of Arf6 impair the GTP cycling abilities 
of Arf6 and therefore prevent internalization via Arf6 endosomes.  Cytochalasin D is an inhibitor of actin 
polymerization that prevents endocytosis via mechanisms dependent on actin polymerization.  NH4Cl and 
bafilomycinA1 are inhibitors of endosomal acidification while nocodazole has been shown to inhibit the 
progression from early to late endosomes.  Brefeldin A blocks trafficking from the Golgi to the ER, while 
the PI3-kinase inhibitor LY294002 has been shown to block the fusion of Arf6 positive endosome with 
Rab5-positive endosomes. 
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Figure 1.3 Heterotrimeric G-Protein Cycle 
By converting between its active GTP-bound and inactive GDP-bound states the heterotrimeric G-protein 
serves as a molecular regulatory switch.  The activation of the G-protein involves a complex consisting of 
the ligand, the receptor, and the heterotrimeric G-protein.  In the inactive state, the α subunit of the G-
protein has a GDP bound and is associated with the βγ complex.  When a protein ligand binds to the 
receptor, a conformational change in the receptor causes the α subunit to release GDP, which allows GTP 
to bind in its place. This binding of GTP induces a conformational change in the α subunit that results in 
the disassociation of the βγ complex from the α subunit.  The conformational change in the α subunit 
allows the active GTP-bound α subunit to interact with its effector proteins.  Although the βγ complex does 
not undergo any conformational changes, disassociation from the α subunit exposes a surface of the βγ 
complex that was previously blocked by the α subunit, thereby allowing the surface of the βγ complex to 
interact with another set of effector proteins.  Eventually, the intrinsic GTPase activity of the α subunit is 
responsible for hydrolyzing GTP to GDP.  The GDP bound α subunit then reassociates with the βγ 
complex to form the inactive heterotrimeric G-protein.  Several different molecules can regulate 
heterotrimeric G-protein activity.  GTPase-activating proteins (GAPs) bind to the activated Gα subunit 
altering the conformation of the subunit, so that there is an increase in the rate at which GTP is hydrolyzed.  
Several members of the RGS protein family act as GAPs.   
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Figure 1.4 Sequence Alignment of the Dermonecrotic Toxin Family 
CNF2            ------------------------------------------------------------ 
CNF1            ------------------------------------------------------------ 
CNF3            ------------------------------------------------------------ 
CNFY            ------------------------------------------------------------ 
PMT             ------------------------------------------------------------ 
DNT             MDKDESALRQLVDMALVGYDGVVEELLALPSEESGDLAGGRAKREKAEFALFSEAPNGDE 60 
                                                                             
 
CNF2            ------------------------------------------------------------ 
CNF1            ------------------------------------------------------------ 
CNF3            ------------------------------------------------------------ 
CNFY            ------------------------------------------------------------ 
PMT             ------------------------------------------------------------ 
DNT             PIGQDARTWFYFPKYRPVAVSNLKKMQVAIRARLEPESLILQWLIALDVYLGVLIAALSR 120 
                                                                             
 
CNF2            ----------------------------------------------MNVQWQQKYLLEYN 14 
CNF1            ----------------------------------------------MGNQWQQKYLLEYN 14 
CNF3            ----------------------------------------------MNTQWQQKYLLEYN 14 
CNFY            ----------------------------------------------MKNQWQHQYFLSYS 14 
PMT             ------------MKTKHFFNSDFTVKGKSADEIFRRLCTDHPDKQLNNVKWKEVFINRFG 48 
DNT             TVISDLVFEYVKARYEIYYLLNRVPHPLATAYLKRRRQRPVDRSGRLGSVFEHPLWFAYD 180 
                                                                  ::.     :. 
 
CNF2            ELVSNFPSPERVVSDYIRRCFKTDLPW---FSQVDPDNTYFIRFSQSRSNSRSYTGWDHL 71 
CNF1            ELVSNFPSPERVVSDYIKNCFKTDLPW---FSRIDPDNAYFICFSQNRSNSRSYTGWDHL 71 
CNF3            DLVSKFPSPEKVTSDYIKHKFKTDLPW---FSRVDPDKTYFIQFSQNRSNSRSYTGWDHL 71 
CNFY            ELVANFPSPEKVVSDYIKHKFSTTLPW---FGWADPDNLYFIRFTQSRSNNKSYTGWDHL 71 
PMT             QMMLDTPNPRKIVEKIINEGLEKQG-----LKNIDPENTYFNIFSSSDSSDGNVFHYNSL 103 
DNT             ELAGTVDLDADIYEQALAESIERRMDGEPDDGSLDTAEHDVWRLCRDGINRGEQAIFQAS 240 
                ::         : .. : . :.            *. :  .  :  .  .  .   ::   
 
CNF2            GKYKTGVLTLTQAALINIGYHFDVFDDANASAGIYKTSSADMFN-------------EKN 118 
CNF1            GKYKTEVLTLTQAALINIGYRFDVFDDANSRTGIYKTKSADVFN-------------EEN 118 
CNF3            GKYKTDALTLTQAAIINIGYRFEVFDEANATAGIYTTNNADLFD-------------ETN 118 
CNFY            GKYAIETLTLTQAAIVNIGSRFDIFDEANSTAGIYKTNNADSFD-------------ETN 118 
PMT             SESYRVTDACLMNIFVERYFDDWDLLNSLASNGIYSVGKEGAYYPDHDYGPEYNPVWGPN 163 
DNT             GPYGVVADAGYMRTVADLAYADALADCLHAQLRIRAQGSVDSPG-------------DEM 287 
                .     . :     . :            :   *    . .                    
 
CNF2            EEKMLPSEYLYFLKGCDFSGIYGRFLSDYWSKYYDKFKLLLKNYYISSALYLYKN----- 173 
CNF1            EEKMLPSEYLHLLQKCDFAGVYGKTLSDYWSKYYDKFKLLLKNYYISSALYLYKN----- 173 
CNF3            EAKMLPSEYLYFLKNCDFAGLYNKALSDYWSKNHEKFKLLLKNYYISSSLYLYKN----- 173 
CNFY            EAKMLPSEYLYFLRDCDFSNLYNKALSDYWAENYEKFSTLLQNYYISSAYYLYKD----- 173 
PMT             EQIYHSRVIADILYARSVWDEFKKYFMEYWQKYAQLYTEMLSDTFLAMAIQQYTR----- 218 
DNT             PRKLDAWEIAKFHLAATQQARVDLLEAAFALDYAALRDVRVYGDYRNALALRFIKREALR 347 
                     .     :                :  .        : . :       :        
 
CNF2            ------------GEIDEYEYNFSISALNRRDN-ISLFFFDIYGYYSSDMFVAKNN----- 215 
CNF1            ------------GELDEREYNFSMNALNRSDN-ISLLFFDIYGYYASDIFVAKNN----- 215 
CNF3            ------------NVISKDEHEFTMKALNRDDN-IELFSFDIYGYYSSDIFGAKND----- 215 
CNFY            ------------SAISKDEYEFSIDAIFNKKNKILRYYFDVYGYYSSDMFVAMND----- 216 
PMT             ------------QTLTDEGFLMVCNTYYGNKEEVQITLLDIYGYPSTDIICIEQKG---- 262 
DNT             LLGARRGNASTMPAVAAGEYDEIVASGAANDAAYVSMAAALIAGVLCDLESAQRTLPVVL 407 
                              :    .     :    .         : .    *:    .       
 
CNF2            ----------------ERVMLFIPGAKKP-------FLFEKNIADLRISLKNLIKENDNK 252 
CNF1            ----------------DKVMLFIPGAKKP-------FLFKKNIADLRLTLKELIKDSDNK 252 
CNF3            ----------------DRIMLFIPGATNP-------FLFSENISHLRTHLKELIKENDNR 252 
CNFY            ----------------NKTMLFIPGATNP-------FIFADNITDLRDKIKALISDKNTR 253 
PMT             -------------LPTPKVILYIPGGTQP-------FVEFLNTDDLKQWIAWHLKDNKHM 302 
DNT             ARFRPLGVLARFRRLEQETAGMLLGDQEPEPRGFISFTDFRDSDAFASYAEYAAQFNDYI 467 
                                 .    : *  :*       *    :   :        . ..   
 
CNF2            QLLS-----------------------------QHFSLYSRQDGITYAGVNSVLNAIEND 283 
CNF1            QLLS-----------------------------QHFSLYSRQDGVSYAGVNSVLHAIEND 283 
CNF3            ELLS-----------------------------RHFSLYDCQDGSTFYGVDSVLKEIVN- 282 
CNFY            ELFS-----------------------------KHFSLYDRQDGNTYLGVNSMLEQIVS- 283 
PMT             VRFR-----------------------------KHFSLKQRQEGETFTGIDKALQYIAEE 333 
DNT             DQYSILEAQRLARILALGSRMTVDQWCLPLQKVRHYKVLTSQPGLIARGIENHNRGIEYC 527 
                                                 :*:.:   * *    *::.  . *    
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Figure 1.4 (cont.) 
CNF2            ----------------GVFNESYFLYSNKR-------INNKDVFDAVAFSVKKR------ 314 
CNF1            ----------------GNFNESYFLYSNKT-------LSNKDVFDAIAISVKKR------ 314 
CNF3            ----------------GNFNESYFMYTYKK-------FNERDVFDAISFSVQKR------ 313 
CNFY            ----------------GVVDTNYIMYSNKN-------IRERNVFESMAFSTRER------ 314 
PMT             SP--------------EWPANKYILYNPTH-------LETENLFNIMMKRTEQR------ 366 
DNT             LGRPPLTDLPGLFTMFQLHDSSWLLVSNINGELWSDVLANAEVMQNPTLAALAEPQGRFR 587 
                                     .::: .          :   ::::     .  .       
 
CNF2            ------------------SFSDGDIVIKSNSE-------------------AQRDYALTI 337 
CNF1            ------------------SFSDGDIVIKSNSE-------------------AQRDYALTI 337 
CNF3            ------------------SFSDGDTIIKSNSE-------------------AQRDYALTI 336 
CNFY            ------------------SFNDGDVIIKSNAE-------------------VQRDYALNV 337 
PMT             ------------------MLEDSDVQIRSNSE-------------------ATRDYALSL 389 
DNT             TGRRTGGWFLGGPATEGPSLRDNYLLKLRQSNPGLDVKKCWYFGYRQEYRLPAGALGVPL 647 
                                   : *.      :::                        .: : 
 
CNF2            LQTILSMTPIFDVAIPEVS----------------VTLGLGIIASSMGISFDQLINGDTY 381 
CNF1            LQTILSMTPIFDIVVPEVS----------------VPLGLGIITSSMGISFDQLINGDTY 381 
CNF3            IQAIVSMIPVFDIILPEVS----------------VPLSMGIIASSMGISFDQLINGDTY 380 
CNFY            LQTILSLSPIFDIVLPEVS----------------IPISLGITASSVGISFDELINGDTY 381 
PMT             LETFISQLSAIDMLVPAVG----------------IPINFALSATALGLSSDIVVNGDSY 433 
DNT             FAVSVALRHSLDDLAAHAKSALYKPSEWQKFAFWIVPFYREIFFSTQDRSYRVDVGSIVF 707 
                : . ::    :*   . .                 :.:   :  :: . *    :..  : 
 
CNF2            EER-----------------------------RSAIPGLATNAALLGLSFAIPFLISKAG 412 
CNF1            EER-----------------------------RSAIPGLATNAVLLGLSFAIPLLISKAG 412 
CNF3            EER-----------------------------RSAIPGVATNAVLLGISFALPYLISKAS 411 
CNFY            EER-----------------------------RSAIPGLATNAVLLGISFAIPFLISKAE 412 
PMT             EKR-----------------------------KYGIGSLVQSALFTGIN-LIPVISETAE 463 
DNT             DSISLLASVFSIGGKLGSFTRTQYGNLRNFVVRQRIAGLSGQRLWRSVLKELPALIGASG 767 
                :.                              :  * .:  .    .:   :* :   :  
 
CNF2            T--NQKILSRYTKHEIRTLNETNIDMFLEEYGIN-------KNSISETKVLEVELKGSGQ 463 
CNF1            I--NQEVLSSVINNEGRTLNETNIDIFLKEYGIA-------EDSISSTNLLDVKLKSSGQ 463 
CNF3            E--NKVILSQTVSNEDSILNETNIDNFLAENGIN-------KDDIPANGILEVDIKKSGI 462 
CNFY            E--NKLIINNLVGSDENILNKNNLGDFLEKYNIS-------ESDIPENGSLVINLKNTNV 463 
PMT             I--LSSFSRTEEDIPAFFTEEQALAQRFEIVEEE-------LHSISPDDPPREITDENLH 514 
DNT             LRLSRSLLVDLYEIFEPVPIRRLVAGFVSATTVGGRNQAFLRQAFSAASSSAGRTGGQLA 827 
                      .             .  :   .                :.               
 
CNF2            HVNIVKLSDEDSKIVAVKGNSLSGIY-----YEVDIETGYEISSRRIYRTEYN---DKIF 515 
CNF1            HVNIVKLSDEDNQIVAVKGSSLSGIY-----YEVDIETGYEILSRRIYRTEYN---NEIL 515 
CNF3            PVNLVKISDEDNQIVAVRGSSQSGIY-----YEVDIETGYEILSRRVYRTEYN---NEIF 514 
CNFY            PVRLVKLNDEEGEIVAIKGSTLSGIY-----YEVDTETGYEILSRRVFRTEYN---EKIY 515 
PMT             KIRLVRLNNENQPLVVLR--RLGGNK-----FIRIEPITFQEIKGSLVSEVINPVTNKTY 567 
DNT             SEWRMAGVDATGLVESTSGGRFEGIYTRGLGPLSECTEHFIVESGNAYRVIWD-AYTHGW 886 
                    :   :    :         *               :   .        :    .   
 
CNF2            WTRGGGLKGGQSFD-----FESLKLPIFFKDEP--------------YSAVPGSS-LSFI 555 
CNF1            WTRGGGLKGGQPFD-----FESLNIPVFFKDEP--------------YSAVTGSP-LSFI 555 
CNF3            WIRNGGLKGGQPFD-----FENLDIPTFFVDKP--------------YSELASSPELSFI 555 
CNFY            WTRGGGLKGGQPFN-----FEGLDIPVYFIDKP--------------YSELASSVELSFV 556 
PMT             YVSNAKLLGGSPYSPFRIGLEGVWTPEVLKARASVIGKPIGESYKRILAKLQRIHNSNIL 627 
DNT             RVVNGRLPPRLTYTVP-VRLNGQGHWETHLDVPGRGG------APEIFGRIRTRNLVALA 939 
                   .. *    .:      ::.          .               . :       :  
 
CNF2            NDDSSLLYPNST---------------PKLPQPTPEMEIVNYVKRAGDFGERLVTLMR-G 599 
CNF1            NDDSSLLYPDTN---------------PKLPQPTSEMDIVNYVKGSGSFGDRFVTLMR-G 599 
CNF3            NDDSPLLFPYVD---------------SRLPKPTSEMDISYYSSNFSSFAENTVTLMR-G 599 
CNFY            NDDSPLLFPEMD---------------SRLPKPTPELDIKYYSSNLSSFKEDTVILMR-G 600 
PMT             DERQGLMHELMELIDLYEESQPSSERLNAFRELRTQLEKALYLPEMEALKKQILQIPNKG 687 
DNT             AEQAAPMRRLLN--------QARRVALRHIDTCRSRLALPRAESDMDAAIRIFFGEPDAG 991 
                 :    :                      :    ..:                .     * 
 
CNF2            TTEEEAWNIARYHTAGGSTEELHEILLGQGPQSSLG---FTEYTSNINSADAASRRHFLV 656 
CNF1            ATEEEAWNIASYHTAGGSTEELHEILLGQGPQSSLG---FTEYTSNVNSADAASRRHFLV 656 
CNF3            ATEEEAWNIAYYKTAGGSNKELEEIFIGGGPQANLS---FTEYTSNIRSADAASRRHFLV 656 
CNFY            TTEEEAWNIANYKTAGGSNKDLEENFIEAGPQFNLS---FSEYTSSINSADTASRKHFLV 657 
PMT             SGAARFLLRTAMNEMAGKTSESTADLIRFALQDTVISAPFRGYAGAIPEAIDFPVKYVIE 747 
DNT             LRQRIGRRLQEVRAYIGDLSPVNDVLYRAGYDLDDVATLFNAVDRNTSLGRQARMELYLD 1051 
                            .   *. .     :   . :       *         .     .  :  
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Figure 1.4 (cont.) 
CNF2            VIKVQVKYINNNNVS-----------------------HVNHWAIPDEAPVEVLAVVDRR 693 
CNF1            VIKVHVKYITNNNVS-----------------------YVNHWAIPDEAPVEVLAVVDRR 693 
CNF3            VINVKIKYISNDNVL-----------------------YANHWAIPDEAPVEVLAVVDRR 693 
CNFY            IIKVQVKYISNDNVL-----------------------YANHWAIPDEAPVEVLAVVDRR 694 
PMT             DISVFDKIQTNYWELPA---------------YESWNEGSNSRLLPGLLRESQSKGMLSK 792 
DNT             AIVDLHARLGYENARFVDLMAFHLLSLGHAATASEVVEAVSPRLLGNVFDISNVAQLERG 1111 
                 *                                      .   : .    .    :    
 
CNF2            FNFPEPSTPPNISIIHKLLSLRYFKENIESTSRLNLQKLNRGNIDIFKGRGSISSTRQRA 753 
CNF1            FNFPEPSTPPDISTIRKLLSLRYFKESIESTSKSNFQKLSRGNIDVLKGRGSISSTRQRA 753 
CNF3            FIFPEPPTPPKLSLIQK-ISQRFFTEDIDETSRINFQRLNSGNINVLKGRGSLSSKNQRS 752 
CNFY            FIFPEPPVKPKLSFIQK-IANRFLTENVAEISSINFRRLNSGNINVLKGRGVFSSRRLRE 753 
PMT             CRIIENSLYIGHSYEEMFYSISPYSNQVGGPYELYPFTFFSMLQEVQGDLGFEQAFATRN 852 
DNT             IGNPASTGLFVMLGAYSESSPAIFQSFVNDIFPAWRQASGGGPLVWNFGPAAISPTRLDY 1171 
                      .            :     . :                    . .  ..      
 
CNF2            IYPYFESANADEQQPVFFYIK-------KNRFDDFGYDQYFYNSTVGLNGIPTLNTYTGE 806 
CNF1            IYPYFEAANADEQQPLFFYIK-------KDRFDNHGYDQYFYDNTVGLNGIPTLNTYTGE 806 
CNF3            IYLRFDAVNADDLRPDEIYVK-------KDQFDDLGYDRYFYNNAVGLDGSPTLNTYTGE 805 
CNFY            IYLRFDAANADELRPGDVYVK-------KTKFDSMGYDSHFYNEGIGINGAPTLNTYTGE 806 
PMT             FFNTLVSDRLSLMENTMLLTESFDYTPWDAIYGDINYDEQFAAMSINERIEKCMNTYRGV 912 
DNT             ANTDIGLLNHGDISPLRARPPLGGRRD-IDLPPGLDISFVRYDRPVRMSAPRALDASVFR 1230 
                    :   . .                      . . .       :       :::     
 
CNF2            ILSDASS---------------LGSTYWKKYNLTNETSIIRVSNSARGAN---------- 841 
CNF1            IPSDSSS---------------LGSTYWKKYNLTNETSIIRVSNSARGAN---------- 841 
CNF3            FLTDPSL---------------FGSLYWSKYNLTNKTSIIRVANSARGAN---------- 840 
CNFY            YVADSSS---------------QGATYWLKYNLTNETSIIKVSNSARGAN---------- 841 
PMT             AFQNSSKSIDFFLN-NLTTFIDNGLTEIAISDLPYDIVQQEISQFLQGSNEWKTLDAMLF 971 
DNT             PVDGPVHGYIQSWTGAEIEYAYGAPAAAREVMLTDNVRIISIENGDEGAIG--------- 1281 
                   ..                  .        *. .     : :  .*:            
 
CNF2            ---------GIKIALEEVQEG---------------------KPVIITSGNLSGCTTIVA 871 
CNF1            ---------GIKIALEEVQEG---------------------KPVIITSGNLSGCTTIVA 871 
CNF3            ---------GIRIALKEVQEN---------------------KPVIITNGNLSGCTTIVA 870 
CNFY            ---------GIKIALEEIEEN---------------------KPVVITSGTLTGCTVVFA 871 
PMT             NLDKGDINGAFRKLLQSAKDNNIKFRAIGHSDNSVPPFNNPYKSLYYKGNIIAEAIEKLD 1031 
DNT             ----------VRVRLDTVPVA---------------------TPLILTGGSLSGCTTMVG 1310 
                          .:  *.                          ..:  ... :: .   .  
 
CNF2            RKGG--------YLYKVHTGTTIPLAGFTS--------------------TTGVKKAVEV 903 
CNF1            RKEG--------YIYKVHTGTTKSLAGFTS--------------------TTGVKKAVEV 903 
CNF3            RKGE--------YLYEVHTGTLEPLLGFTS--------------------TTGVKKAVEV 902 
CNFY            RKGE--------YFYAVHTGNSESLIGFTS--------------------TSGVAKAIEV 903 
PMT             REGQKFVVFADSSLLNSTPGTGRPMPGLVQYLKIPATVVDSDGAWQFLPDVASSRVPIEV 1091 
DNT             VKEG--------YLAFYHTGKSTELGDWAT-------------------AREGVQALYQA 1343 
                 :           :    .*.   : . .                       .     :. 
 
CNF2            FELLTNNPMPRVEGVMN-----------------NDFLVNYLAESFDESLITYSSSEQ-- 944 
CNF1            LELLTKEPIPRVEGIMS-----------------NDFLVDYLSENFEDSLITYSSSEK-- 944 
CNF3            LSTLAEQEIPSLAGTIN-----------------NDFLVDFLAENFDKSLVTYSSSTL-- 943 
CNFY            LSSLSELEVPALPDVIN-----------------NNTLVEYLSDNFDSALISYSSSSL-- 944 
PMT             TELENWQVLTPPQGKILGLKQFKLTAGFPTEQSRLPLLENSVSEDLREELMQKIDAIKND 1151 
DNT             HLAMGYAPISIPAPMRN-------------------DDLVSIAATYDRAVIAYLGKDVPG 1384 
                        :.                               ::      ::   .      
 
CNF2            -KIGSKITISRDNVSTFP-----YFLDNIPEKGFGTSVTILVRVDGNVIVKSLSESYSLN 998 
CNF1            -KPDSQITIIRDNVSVFP-----YFLDNIPEHGFGTSATVLVRVDGNVVVRSLSESYSLN 998 
CNF3            -KPDSIITISRDNVSTFP-----YYTDDIIHPGFGTSVTILVRIDDNTVVKSLSESYVTN 997 
CNFY            -KPNSMINISRENVSTFS-----YYTDDIQLPSFGTSVTILVRTNDNTVVRSLSESYTMN 998 
PMT             VKMNSLVCMEAGSCDSVSPKVAARLKDMGLEAGMGASITWWRREGGMEFSHQMHTTASFK 1211 
DNT             -GGSTRITRHDEGAGSVVSFDYNAAVQASAVPRLGQVYVLISNDGQGARAVLLAEDLAWA 1443 
                   .: :     . . .         :      :*   .   . .       :        
 
CNF2            VENSNISVLHVFSKDF-------------------------------------------- 1014 
CNF1            ADASEISVLKVFSKKF-------------------------------------------- 1014 
CNF3            ADGSRISVFKVLSKDF-------------------------------------------- 1013 
CNFY            SNSSKMVVFNVLQKDF-------------------------------------------- 1014 
PMT             FAGKEFAVDASHLQFVHDQLDTTILILPVDDWALEIAQRNRAINPFVEYVSKTGNMLALF 1271 
DNT             GSGSALDVLNERLVTLFPAPV--------------------------------------- 1464 
                   . : *       .                                             
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Figure 1.4 (cont.) 
CNF2            -------------- 
CNF1            -------------- 
CNF3            -------------- 
CNFY            -------------- 
PMT             MPPLFTKPRLTRAL 1285 
DNT             -------------- 
 
 
Figure 1.4 Sequence Alignment of the Dermonecrotic Toxin Family 
 
ClustalW was used to align the sequences of PMT, CNF1, CNF2, CNF3, CNFY, and DNT (42, 72).  An 
asterisk (*) is used to denote positions with a single, fully conserved residue, a colon (:) denotes 
conservation between groups with strongly similar properties, and a period (.) denotes conservation 
between groups with weakly similar properties.  Red indicates small, hydrophobic, or aromatic residues 
(AVFPMILW).  Blue indicates acidic residues (DE).  Magenta indicates basic residues (RK).  Green 
indicates hyroxyl, sulfhydryl, or amine (STYHCNGQ).  Grey is used to indicate any other amino acids not 
described above. 
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Figure 1.5 Sequence Similarity among the Dermonecrotic Toxin Family 
This figure depicts the sequence similarity and identity among members of the dermonecrotic toxin family 
(101).  The binding domains of the dermonecrotic toxins are located at the N-terminus. PMT and CNF1 
share 62% amino acid similarity and 26% identity in their N-termini (residues 4-552 of CNF1 and residues 
38-607 of PMT).  The catalytic domains of the dermonecrotic toxins are located at the C-terminus. CNF1 
and DNT share 58% similarity and 25% identity in their C-termini (residues 732-1007 of CNF1 and 
residues 1179-1452 of DNT).  
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Figure 1.6 Effect of PMT 
PMT is the major etiological agent of atrophic rhinitis.  This figure depicts the various pathological changes 
in nasal turbinate bones and the snout as a consequence of atrophic rhinitis.  Infection with PMT results in 
an imbalance between osteoblasts and osteoclasts and the subsequent resorption of bone.  A depicts 
uninfected nasal turbinates.  B-D depicts the progression of bone destruction associated with atrophic 
rhinitis from least severe to most severe.  As the disease progresses you get complete destruction of the 
nasal turbinates (D) and as resorption proceeds, the nasal septum is eroded as well. This destruction of bone 
with the nasal turbinates results in a characteristic twisting of the snout (E). A, E - Copyright © 
www.ThePigSite.com - Reproduced with Permission. B, C, D - taken with permission from Wilson & Ho 
2006. 
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Figure 1.7 PMT Mode of Action 
In this model of PMT action, PMT deamidates the Gαq subunit thereby helping the subunit to exchange 
GDP for GTP and activating the Gαq subunit.  The activated Gαq subunit then functions to activate its 
effector proteins. After the initial activation, the pathway subsequently shuts off. 
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Figure 1.8 Intracellular Trafficking of PMT 
Not much is known about intracellular trafficking of PMT.  The binding and translocation domains of PMT 
are located at the N-terminus while the activity domain is located at the C-terminus.  It is thought that PMT 
binds to a cell surface receptor and subsequently enters the cell via receptor-mediated endocytosis.  After 
endocytosis PMT passes through an acidified endosome before translocation to the cytosol. 
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Figure 1.9 Cellular Effects of CNF1 
NIH 3T3 cells were either left untreated (A) and (B) or treated with 300 ng/mL CNF1 for 16 hours (C) and 
(D).  Cells were then visualized using phase-contrast microscopy (A) and (C) or stained with rhodamine 
phalloidin to visualize the actin cytoskeleton by fluorescence microscopy (A) and (D).   
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Figure 1.10 CNF Activity on RhoA, Rac, and Cdc42 
The small GTP-proteins RhoA, Rac, and Cdc42 cycle between active (GTP-bound) and inactive (GDP-
bound) states through the binding and subsequent hydrolysis of GTP.  GAPs serve to accelerate the 
hydrolysis of GTP, thereby inactivating the proteins, while GEFs serve to accelerate the exchange of GTP 
for GDP, thereby activating the proteins.  The CNFs constitutively activate these small G-proteins through 
deamidation of Gln-63 in RhoA to Glu-63 and/or deamidation of Gln-61 to Glu-61 in Rac and Cdc42.  
Constitutively activated RhoA, Rac, and Cdc42 then activate their downstream effectors to ultimately cause 
activation of SRF and transcription of SRE-responsive genes. 
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Figure 1.11  Trafficking and Entry Pathways of CNF1, CNF2, CNFY, and DNT 
The receptor-binding domain of the CNFs is located at the N-terminus. CNF1 and CNF2 bind to the 67-
kDa laminin-receptor protein (LR), which mediates cellular entry.  Although the binding of CNF1 does not 
influence the uptake of CNFY, conversely the binding of CNFY can affect the uptake of CNF1, suggesting 
that there may be overlap between the receptors; however, the exact receptors are unknown (UR).  Once 
bound to cells, CNF1 enters via a clathrin-, dynamin-, and caveolae-independent pathway. Similarly, 
uptake and internalization of CNFY appears to be independent of clathrin and lipid rafts.  CNF1, CNF2, and 
CNFY are all dependent on endosomal acidification for entry and translocation. CNF1 and CNFY are 
thought to translocate from the late endosome.  In contrast, DNT does not require an acidified endosome 
for translocation, nor is it affected by cytochalasin D, nocodazole, or brefeldin A.  The translocation 
domain of DNT is thought to be located in the region of residues 45-166 and proteolytic cleavage of DNT 
by furin (F) is necessary for its intracellular activity.  The entry receptor for DNT is unknown (UR). 
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Figure 1.12 Morphological and Cellular Effects of DNT 
Infection with DNT causes the turbinate atrophy associated with atrophic rhinitis.  Pigs were inoculated 
with either a strain of B. bronchiseptica that produces DNT (A) or a strain of B. bronchiseptica in which 
dnt was mutated (B).  Cross-sections of the snouts were prepared 28 days after inoculation. Subconfluent 
osteoblastic MC3T3-E1 cells were treated with 50 ng/mL DNT for 24 hours (D) or 3 days (F) or left 
untreated (C and E) (Bars 50 µM).  
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Figure 1.13 SRE-luciferase Reporter Assay 
This figure shows the various signaling pathways that lead to activation of serum response element.  These 
pathways all activate serum response element (SRE) transcription through activation of serum response 
factor (SRF).  In the case of the ras-raf-MAPK-ERK cascade phosphorylation of ternary complex factors 
(TCFs) and the binding of TCFs to SRF are necessary for activation of SRE.  Other pathways such as the 
Rho family pathways are independent of TCF.  Activation of SRE drives expression of the reporter 
luciferase, which can be assayed and used as a measure of activation of these pathways. 
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Chapter 2:  Arf6-Dependent Intracellular Trafficking of 
Pasteurella multocida Toxin and pH-Dependent Translocation 
from Late Endosomes 
 
 
2.1 Introduction  
Although the intracellular action of PMT is becoming more defined (48), little is 
known about the trafficking pathways the toxin exploits to gain access to its cytosolic 
targets.  The lag time between toxin treatment and toxin activity supports the assertion 
that PMT is an intracellularly-acting toxin (39).  In addition, it has been demonstrated 
that the addition of PMT-specific antibodies or the addition of weak bases, such as 
methylamine, only inhibit PMT activity if added during the early stages of intoxication 
(39).  Furthermore, exposure of cells to PMT at 4°C results in no detectable PMT activity 
(39), suggesting that endocytic trafficking involving a pH-dependent step is necessary for 
PMT intoxication.  This was confirmed by use of bafilomycin A1 (BafA1), an inhibitor 
of the vacuolar ATPase proton pump (V-ATPase) (6), as measured by its inhibition of 
PMT-mediated phosphorylation of focal adhesion kinase (FAK) (4).  Furthermore, when 
PMT was bound to the cell surface and endocytosis was inhibited, there was an increase 
in PMT activity upon exposing the cells to an acidic pH, suggesting that the drop in pH 
caused PMT to translocate directly across the plasma membrane (4).  In this same study, 
PMT was found to insert into lipids in a pH-dependent manner and at a pH similar to that 
at which the protein is reported to unfold (43).  Together, these data support a model in 
which PMT is endocytosed and trafficked through a low pH compartment where PMT 
unfolds, then inserts into and translocates across the vesicle membrane to presumably 
deliver the catalytic domain into the cytosol.  This thesis aims to characterize how 
inhibitors of endosomal acidification such as NH4Cl and BafA1 affect PMT activity 
through use of the SRE assay.  
The small GTPase Arf6 is involved in trafficking of ligands from the plasma 
membrane and localizes both to the plasma membrane and to internal punctate structures.  
Intra-endosomal acidification has been shown to result in recruitment of Arf6, along with 
its cognate GDP/GTP exchange factor (GEF) and an ADP-ribosylation factor nucleotide 
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site opener (ARNO), to the endosomal membrane (27).  Once at the endosomal 
membrane, Arf6 binds to the c-subunit of the V-ATPase, while ARNO binds to the a2-
isoform (19).  Internal structures that label for Arf6 are tubulovesicular in shape, and 
Arf6 can be visualized on tubule extensions, suggesting that Arf6 also plays a role in 
recycling back to the plasma membrane (37).  It has been demonstrated that Arf6-positive 
vesicles can recruit markers of the early endosome, such as early endosome antigen 1 
(EEA1), to their surface (9).  Alternatively, the fusion of primary endocytic vesicles with 
early endosomes is regulated by Rab5, another small regulatory GTPase involved in 
intracellular trafficking of recycling endosomes (51), and EEA1(29).  This fusion is 
mediated by the activity of PI-3 kinase, as specific inhibitors of PI-3 kinase such as 
LY294002 prevent this fusion from occurring (32).  Since previous evidence supports the 
assertion that PMT is trafficked through acidified endosomes this thesis aims to 
determine the role of Arf6 in the trafficking of PMT.  We aim to determine whether an 
Arf6/Rab5 vesicle fusion event is important for PMT trafficking.  
Transferrin (Tfn) and its cognate receptor are ubiquitous iron-uptake proteins that 
are well-characterized markers for Rab5-containing clathrin-coated vesicles and recycling 
endosomes (47).  The trafficking of Tfn through Arf6 compartments seems to differ 
according to cell type.  In HeLa cells Tfn localizes to a separate compartment from Arf6 
(7), while in CHO cells and HEK 293T/17 cells Tfn localizes to the same compartment as 
Arf6 (8, 13).  While overexpression of wildtype Arf6 does not affect the function of Arf6 
or its distribution and localization in cells, specific mutations that interfere with 
GDP/GTP binding and/or hydrolysis do (37).  The constitutively active, GTP-hydrolysis-
defective mutant of Arf6 (Q67L) localizes to the plasma membrane and causes a 
reduction in the formation of endosomes, whereas the dominant negative, GTP-binding-
defective Arf6 mutant (T27N) localizes almost exclusively in endosomes (37).  
Overexpression of the Arf6 Q67L mutant results in an increase in cell surface binding of 
Tfn, but also in a decrease in the rate of internalization of Tfn (11), suggesting that while 
the mutant results in an increase in binding of the ligand, it is unable to subsequently 
internalize it.  Alternatively, overexpression of the Arf6 T27N mutant results in a 
decrease in the amount of cell surface-bound Tfn and prevents reappearance of cell 
surface Tfn receptors (11).  Since Tfn is present in vesicles containing Arf6 this thesis 
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aims to determine whether PMT uses the same route as Tfn, and therefore Arf6, to gain 
entry to the cell.  
Cholera toxin (CT), a multi-subunit protein toxin secreted by Vibrio cholerae, has 
been shown to recruit Arf6 to endosomal membranes during its cellular intoxication 
process (16).  Arf6 also serves as an allosteric activator of the CT-catalyzed ADP-
ribosylation of Gαs (20, 33), with crystal structures of an Arf6-CT complex lending 
insight into how this occurs through changes in the active site loop structure that 
facilitates NAD binding (34).  Furthermore, CT has been shown to increase rates of intra-
endosomal acidification (16), and while intra-endosomal acidification is not thought to be 
important for translocation of CT, the trafficking of CT through a low pH compartment 
has been demonstrated to be important for proteolytic activation of the catalytic subunit 
(30).  These observations suggest the possibility that PMT may use the same initial 
trafficking pathway as Tfn and/or CT, and may be trafficked to an acidified Arf6-positive 
endosome, from where it may translocate.  
Although we hypothesize that PMT shares a common initial entry pathway with 
CT, CT has a KDEL signal and undergoes further retrograde trafficking through the 
Golgi to the endoplasmic reticulum (ER), where the catalytic subunit of CT escapes to 
the cytosol (22).  It has been demonstrated that treatment with brefeldin A (BFA), a 
fungal metabolite that interrupts trafficking between the Golgi apparatus and the ER (17), 
disrupts CT activity implicating the importance of Golgi-ER trafficking for CT (36).  
Since we propose that PMT translocates from the acidified endosome, treatment with 
BFA should have no effect on PMT activity and would provide a useful tool for 
discerning where the entry pathways of PMT and CT diverge.  On the other hand, 
although PMT translocation is pH dependent, it is not clear whether translocation occurs 
from early endosomes or late endosomes.  Since it has been shown that vectoral transport 
from early to late endosomes is dependent on microtubule and actin dynamics (5, 29), 
disruption of the microtubule network with nocodazole or actin polymerization with 
cytochalasin D should inhibit PMT translocation and cytotoxicity. 
Our studies reported herein aim to elucidate the trafficking events involved in 
PMT intoxication. In particular, we describe the role of the small GTPase Arf6 in the 
uptake and trafficking of PMT.  Furthermore, we show that PMT shares the same initial 
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pathway for entry into the cell as Tfn and CT, but then the PMT trafficking pathway 
diverges from the others to a late-endosomal compartment, from which PMT then 
translocates in a pH-dependent manner.  We propose to investigate the role of Arf6 and 
the various chemical inhibitors on PMT activity through use of the SRE-luciferase assay.  
The SRE-luciferase assay provides a convenient method for quantitatively measuring 
PMT signaling activity.  Any change in SRE signaling induced by the overexpression of 
Arf6 WT or mutant toxins or by treatment with various inhibitors can be attributed to 
modification of the trafficking and entry of the toxin.  Use of this assay will provide a 
sensitive, quantitative measure of PMT signaling activity. 
 
2.2 Materials and Methods  
 
2.2.1 Materials 
HEK 293T/17 cells (# CRL-11268) and Swiss 3T3 cells (# CCL-92) were 
obtained from the ATCC.  The pcDNA3.1 vector encoding the wild-type Arf6 protein 
was obtained from the Missouri S&T cDNA Resource Center.  The pSRE-luc plasmid 
was purchased from Stratagene.  The p-Renilla-TK (pGL 7.4 hRluc/TK) plasmid, 1 x 
Passive Lysis Buffer, and Dual Luciferase Assay System were purchased from Promega.  
Bafilomycin A1 (BafA1), brefeldin A (BFA), and LY294002 were purchased from 
Alexis Biochemicals.  Cytochalasin D, nocodazole, monensin, and nigericin were 
purchased from Sigma.  NH4Cl was purchased from J.T. Baker.  Escherichia coli TOP10 
cells were purchased from Invitrogen.  Escherichia coli BL21 cells, pET21b vector, and 
Thrombin Cleavage Capture Kit were purchased from Novagen.  The CT subunit B 
Alexa Fluor®-594 conjugate (CTxB-594) was purchased from Molecular Probes.  
Transferrin-Texas Red (Tfn-TR) was purchased from Invitrogen. Coverslips were 
purchased from Corning and ProLong Gold mounting media was purchased from 
Invitrogen. Ni2+-NTA-agarose was obtained from Qiagen. HiTrapQ anion exchange 
columns and PD-10 desalting columns were obtained from Amersham. Superdex 200 
sizing column was obtained from GE Health.  Centricon filter units were obtained from 
Millipore. Pierce GelCode Blue protein gel stain and Pierce® ECL Western Blotting 
Substrate were purchased from Thermo Scientific.  HyBlot CL autoradiography film was 
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obtained from Denville Scientific Inc. Dulbecco’s Modified Eagle Medium (DMEM) was 
obtained from Gibco. Bovine growth serum (BGS) was purchased from HyClone.  
Penicillin and streptomycin were obtained from Cellgro.  Mouse anti-phospho-Akt 
(Ser473) 587F11 (cat#4051) and mouse anti-Akt (cat#9272) were obtained from Cell 
Signaling. HRP-conjugated goat anti-mouse IgG antibodies (115-036-003) were obtained 
from Jackson ImmunoResearch Laboratories, Inc. HRP-conjugated goat anti-rabbit 
antibodies (sc-2004) were obtained from Santa Cruz Biotechnology.  Polyvinyl alcohol 
(PVA) and DABCO (1, 4-diazabicyclo-[2.2.2]octane) anti-fade reagent were obtained 
from Fluka. 
 
2.2.2 Plasmid constructs 
The pcDNA3.1 vector encoding the wild-type Arf6 protein was obtained from the 
Missouri S&T cDNA Resource Center. pcDNA3.1-Arf6 T27N, pcDNA3.1-Arf6 T44N, 
pcDNA3.1-Arf6 Q67L, pcDNA3.1-Arf6 T157A, pcDNA3.1-Arf6 G2A/Q67L, and 
pcDNA3.1-Arf6 G2A/T157A mutants were created by a two step PCR with the first step 
introducing the mutation and a second step amplifying the entire cDNA using the primers 
listed in Table 1.  The cDNA was then digested with XhoI and EcoRI and inserted into 
the pcDNA3.1 vector. Constructs were verified by sequencing. 
 
2.2.3 Expression, purification, and quantification of PMT and PMTb-GFP 
 Recombinant PMT (rPMT) was expressed and purified as previously described 
(1).  rPMT was expressed in Escherichia coli TOP10 cells harboring the pTHC-ToxA 
vector under the induction of IPTG.  The cell extract was purified by Ni2+-NTA-agarose 
chromatography.  Fractions containing rPMT were further purified by FPLC using 
HiTrapQ anion exchange chromatography and desalted with a PD-10 column.  Removal 
of the His6-tag was accomplished, according to manufacturer’s protocol using a 
Thrombin Cleavage Capture Kit. rPMT was further purified by FPLC using a HiTrapQ 
anion exchange column and a Superdex 200 sizing column.  Fractions containing rPMT 
were concentrated using Centricon filter units and desalted using a PD-10 column with 
phosphate-buffered saline (PBS) containing 10% glycerol.  The concentration of rPMT 
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was determined by NIH Image J digital image analysis of GelCode Blue-stained SDS-
PAGE gels using BSA as the standard.  Toxin samples were stored at −80 °C until use. 
An N-terminal fragment of PMT (residues 1–568) with GFP at the C-terminus in 
the pET21b vector (denoted as PMTb-GFP) was expressed in E. coli BL21 cells and 
purified as described above. 
 
2.2.4 Cell culture 
HEK 293T/17 cells and Swiss 3T3 cells were cultured and maintained at 37 °C 
and 5% CO2 in DMEM with 10% BGS, 100 U/mL penicillin G, and 100 µg/mL 
streptomycin.  Cells were replated every other day while media was changed everyday.  
Cells were split for experiments when they reached 80% confluency and replated in a 1:7 
dilution. 
 
2.2.5 SRE-luciferase assay 
HEK 293T/17 cells at 80% confluency were replated at a 1:7 ratio in 24 well 
plates.  The next day the medium was changed to DMEM with 2% BGS, 100 U/mL 
penicillin and 100 µg/mL streptomycin, and cells were transfected using the CaCl2 
method, as previously described (21).  The plasmid DNA (0.25 µg/mL of pSRE-luc, 
0.025 µg/mL p-Renilla-TK (pGL 7.4 hRluc/TK), 0.025 µg/mL pcDNA3-Gαq and 0.1 
µg/mL of a vector encoding the protein of interest) in a solution of 250 mM CaCl2 was 
added dropwise to a solution of 2× HEPES-buffered saline (280 mM NaCl, 50 mM 
HEPES, pH 7.0) while vortexing.  The solution was incubated at room temperature for 20 
min and then added dropwise to each well.  Cells were incubated for 7 h at 37°C, after 
which the medium was changed without or with rPMT (at a final concentration of 100 
ng/mL).  
 
2.2.6 Treatment of cells with toxins and inhibitors 
HEK 293T/17 cells were plated and transfected as described above.  Cells were 
incubated for 7 h at 37 °C, after which medium containing the indicated inhibitor was 
added to the wells. Stock solutions of 700 nM BafA1, 200 µM cytochalasin D, 100 µM 
nocodazole, and 700 µM LY294002 were created by dissolving the inhibitor in dimethyl 
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sulfoxide DMSO. A stock solution of 140 mM NH4Cl was created by dissolving NH4Cl 
in water.  The stock solution of 70 µM BFA was created by dissolving the inhibitor in 
methanol.  After 15 min incubation with the inhibitor, rPMT was added to the wells at a 
final concentration of 100 ng/mL.  After 16 h of rPMT treatment the media was removed 
and the cells were lysed by adding 150 µL of 1× Passive Lysis Buffer and incubating for 
15 min on a rotary shaker.  Cell lysates were analyzed using the Dual Luciferase Assay 
System, according to the manufacturer’s protocol.  Luminescence was measured using a 
Synergy-HT multi-detection microplate reader (BioTek).  SRE activity was determined 
as described above, and the data were expressed as the mean ± S.D. of results from three 
independent experiments repeated in triplicate. 
 
2.2.7 Measurement of luciferase activity 
After 16 h of rPMT treatment the medium was removed, and cells were lysed by 
adding 150 µL of 1× Passive Lysis Buffer and incubating for 15 min on a rotary shaker.  
Cell lysates were analyzed using the Dual Luciferase Assay System, according to 
manufacturer’s protocol.  Briefly, 10 µL of a 150 µL cell extract was added to a 
microplate and 50 µL of Luciferase Assay Reagent II was added, followed by addition of 
50 µL of Stop & Glo® Reagent, and Renilla luciferase luminescence was measured using 
a Synergy-HT multi-detection microplate reader (BioTek). Results were reported as 
relative light units (sensitivity = 100, integration time = 1 s). 
 
2.2.8 Western blot analysis 
HEK 293T/17 cell lysates were separated on a 10% SDS-PAGE acrylamide gel 
and subsequently transferred to a nitrocellulose membrane and subjected to western blot 
analysis. Membranes were blocked for 30 min at room temperature in 5% powdered milk 
in 10 mM Tris-blocking buffer (10 mM Tris-HCl, pH 8.0, 2 mM EDTA, 50 mM NaCl, 
0.1% NaI).  Membranes were then incubated overnight at 4°C with the indicated primary 
antibody in 5% milk in 10 mM Tris-blocking buffer.  Membranes were then washed 5 
times for 3 min in 1% Tween in 100 mM Tris-washing buffer (100 mM Tris-HCl, pH 8.0, 
200 mM NaCl) before incubation at room temperature with the appropriate secondary 
antibody.  The following primary antibodies were used: mouse anti-phospho-Akt 
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(Ser473) 587F11 and mouse anti-Akt.  HRP-conjugated secondary antibodies used 
included: goat anti-mouse IgG and goat anti-rabbit.  After washing 5 times for 3 min each 
with Tris-washing buffer, the membranes were then developed using Pierce® ECL 
Western Blotting Substrate and HyBlot CL autoradiography film.  Images were then 
scanned and prepared using Adobe Photoshop.  Blots shown are representative of at least 
three independent experiments. 
 
2.2.9 Colocalization studies 
Swiss 3T3 cells at 80% confluency were plated in a 1:12 ratio on 18mm circular 
coverslips (Fisher) in 12 well plates containing DMEM with 1% BGS. The next day the 
medium was changed 3–4 h before toxin treatment.  If chemical inhibitors were used, 
medium containing the indicated inhibitor, final concentration of 30 mM NH4Cl or 1 µM 
BFA, was added to the wells 15 min before toxin treatment.  After 15 min incubation 
with the inhibitor, PMTb-GFP was added to the wells at a final concentration of 100 
µg/mL.  CT subunit B Alexa Fluor®-594 conjugate (CTxB-594) was added to the wells at 
a final concentration of 1 µg/mL.  After 1 or 3 h of toxin treatment the medium was 
removed and the coverslips were fixed with 3.7% formaldehyde in DMEM with 10% 
BGS for 20 min.  Coverslips were washed 3 times with 1× PBS and mounted onto a No. 
1 ½, 22 × 50 mm coverslip using ProLong Gold mounting media.  Confocal microscopy 
was carried out with a Zeiss LSM 710 NLO.  
 
2.2.10 Labeling of the endosomes with transferrin-Texas Red 
Swiss 3T3 cells were plated at low density (103 cells per well) on coverslips in a 
12-well plate and grown overnight in 10% BGS-DMEM.  Before toxin treatment, the 
cells were washed 2 times with 1× PBS and PMTb-GFP was added to the wells at final 
concentration ranges of 100–260 µg/mL of PMTb-GFP.  After 15-h incubation, 20 µg/mL 
of Tfn-TR was added to each well and incubated for an additional 3.5 h.  Toxin treatment 
was terminated by washing the wells with 1× PBS and fixing the cells with 3.7% 
formaldehyde in PBS.  Coverslips were washed 3 times with 1× PBS and mounted using 
mounting medium consisting of 1× PBS, 180 mg/mL polyvinyl alcohol (PVA), 27% 
glycerol and 2 g/L DABCO anti-fade reagent.  Confocal microscopy was performed 
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using a Carl Zeiss Laser Scanning Microscope (LSM 510) with a 40× oil-immersion 
objective.  
 
2.2.11 Data analysis 
SRE-luciferase activity was determined by dividing the firefly luciferase activity 
by the Renilla luciferase activity.  Within each experiment SRE-luciferase activity was 
averaged and the average of the rPMT treated was divided by the average of the untreated 
SRE-luciferase activity to determine the fold activation. In the Arf6 overexpression 
experiments, the fold activation for the test vector was then divided by fold activation of 
the empty vector to obtain the fold activation, normalized to control.  In the Arf6 
experiments, data is expressed as the mean ± S.D. of results from eight independent 
experiments repeated in triplicate.  In the chemical inhibitor experiments, data is 
expressed as the mean ± S.D. of results from three independent experiments repeated in 
triplicate.  A student’s t-test was then used to compare the fold activation values of each 
test vector to the empty vector control in the Arf6 experiments and to compare the fold 
activation values of the treated and untreated in the experiments using chemical 
inhibitors. 
 
2.3 Results 
 
2.3.1. Colocalization of PMTb with Tfn 
A number of bacterial toxins are internalized via receptor-mediated endocytosis, 
yet the precise pathway taken varies among the different toxins.  To determine which 
pathway is utilized by PMT, we first sought whether PMT is internalized via the same 
pathway as Tfn, which traffics primarily through Arf6-positive early endosomes (11) and 
Rab5-associated recycling endosomes (18).  We examined the localization of a GFP-
tagged N-terminal fragment (residues 1–568) of PMT (PMTb-GFP), which harbors the 
putative domains responsible for cellular binding and internalization (38). Swiss 3T3 
fibroblastic cells were treated with PMTb-GFP, and Tfn-TR to visualize colocalization. 
Both PMTb-GFP and Tfn-TR were distributed in vesicles throughout the cytosol (Figure 
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2.1A,B) and appeared colocalized within endosomes (Figure 2.1C), as evidenced by its 
punctate appearance. 
 
2.3.2 PI3-kinase-mediated fusion of Arf6-positive and EEA1/Rab5-positive 
endosomes is not necessary for PMT intoxication 
It has been previously demonstrated that Arf6 is implicated in internalization of 
Tfn (11).  It is also known that Arf6-positive early endosomes can fuse with Rab5/EEA1-
positive endosomes in a process that is dependent on PI 3-kinase (32) and that this 
process can be inhibited using LY294002, a specific and reversible inhibitor of PI 3-
kinase (46).  We hypothesized that if the PMT-containing early endosomes, which also 
contain Tfn, fused with Rab5/EEA1-positive endosomes, then this fusion would be 
dependent on PI 3-kinase and therefore PMT trafficking could be prevented by treatment 
with LY294002.  As shown in Figure 2.1E, pretreatment of HEK 293T/17 cells with 
LY294002 had no effect on rPMT-induced SRE-luciferase reporter activity at 
concentrations up to 75 µM and only a slight inhibitory effect at 100 µM; however, this 
concentration is twice that used to prevent the fusion of Arf6-positive and Rab5/EEA1-
positive endosomes (32).  In control experiments, cell extracts were also blotted for 
phosphorylated Akt (P-Akt) and total Akt to demonstrate that LY294002 inhibited, as 
expected, phosphorylation and activation of Akt at concentrations of 10 µM or higher 
(Figure 2.1F).  These results suggest that despite initial colocalization of PMTb with Tfn, 
a PI 3-kinase-mediated fusion event of Arf6-positive and Rab5/EEA1-positive 
endosomes is not necessary for PMT trafficking to a translocation-productive 
compartment. 
 
2.3.3 Intra-endosomal acidification is a crucial step in PMT intoxication 
 Weak bases such as NH4Cl can be used to alkalinize the endosomal pH (35).  
Treating HEK 293T/17 cells with 2 mM NH4Cl caused a dose-dependent decrease in 
PMT-induced SRE-luciferase reporter activity, with complete inhibition observed at 
concentrations above 5 mM (Figure 2.2A).  BafA1, another specific inhibitor of 
endosomal acidification, slows the progression from early endosomes to late endosomes 
(29, 45).  It was previously demonstrated that BafA1 inhibits PMT-mediated 
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phosphorylation of FAK in Swiss 3T3 cells (4).  Similarly, when HEK 293T/17 cells 
were treated with BafA1 for 15 min prior to treatment with rPMT, there was a dose-
dependent decrease in PMT-induced SRE-luciferase reporter activity (Figure 2.2B).  
Taken together, the inhibition of PMT-induced SRE-luciferase reporter activity after 
treatment with BafA1 and NH4Cl demonstrates that acidification of the endosome is a 
crucial step in PMT intoxication of cells. 
 
2.3.4 Colocalization of PMTb with CT B subunit 
In contrast to PMT, intra-endosomal acidification does not play a role in entry and 
translocation of CT (16, 23), yet CT is present in Rab5-positive and Arf6-positive early 
endosomes and interacts with Arf6 during cellular intoxication (16, 44).  A CT subunit B 
Alexa Fluor®-594 conjugate (CtxB-594) was added to the cells concurrently with PMTb-
GFP and the distribution patterns were observed by confocal fluorescence microscopy 
after 3 h incubation in the absence or presence of 30mM NH4Cl (Figure 2.2C–J).  In the 
absence of NH4Cl, PMTb-GFP showed a punctate localization that is spread throughout 
the cytosol and is colocalized with CTxB-594 (Figure 2.2C–F).  In the presence of 
NH4Cl, the PMTb-GFP-containing endosomes localized to the periphery of the cell and 
did not colocalize with CTxB-594-containing endosomes (Figure 2.2G–J).  Moreover, the 
distribution of CtxB-594-positive endosomes was not affected by treatment with NH4Cl.  
These results demonstrate that in contrast to CtxB, a toxin where intra-endosomal 
acidification is not thought to be important for entry, blocking intra-endosomal 
acidification with NH4Cl drastically affects the trafficking and localization of PMTb-
GFP. 
 
2.3.5 The potential role of Arf6 in internalization and trafficking of PMT 
Previous studies have shown that intra-endosomal acidification by the V-ATPase 
results in recruitment of the small GTPase Arf6 and its GDP/GTP exchange factor (GEF) 
ADP-ribosylation factor nucleotide site opener (ARNO) to the endosomal membrane (27) 
where Arf6 binds to the c-subunit of the V-ATPase while ARNO binds to the a2-isoform 
(19).  This pH-driven recruitment of ARNO has been shown to be important for both 
receptor-mediated endocytosis and for trafficking between early and late endosomes.  
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Since our results demonstrate that inhibitors of endosomal acidification, such as NH4Cl 
and BafA1, inhibit PMT-induced SRE-luciferase reporter activity (Figure 2.2) and that 
PMT initially colocalizes with Tfn and CT in Arf6-positive vesicles, we hypothesized 
that the small GTPase Arf6 may play a role in internalization and trafficking of PMT. 
To investigate the role of Arf6 in PMT trafficking, we overexpressed wildtype 
and several mutants of Arf6 to observe their effects on rPMT-induced SRE-luciferase 
reporter activity.  Arf6 is a small GTPase that relies on hydrolysis of a bound GTP and 
subsequent release of GDP to function properly.  Therefore, any Arf6 mutants that have 
defects in GTP hydrolysis and subsequent GDP release will have impaired activity.  The 
Arf6 Q67L mutant is a constitutively active mutant, while the Arf6 T27N and Arf6 T44N 
mutants are dominant-negative mutants.  The Arf6 T157A mutant is constitutively 
cycling due to decreased binding of both GDP and GTP. 
Overexpression of wildtype Arf6 had no effect on PMT-induced SRE-luciferase 
reporter activity in HEK 293T/17 cells treated with rPMT (Figure 2.3A), in agreement 
with previous studies that showed overexpressing wildtype Arf6 does not perturb the 
function, localization or distribution of Arf6 (37).  On the other hand, overexpression of 
constitutively active Arf6 Q67L or dominant-negative Arf6 T44N reduced the activity by 
50% and 30%, respectively.  Overexpression of the Arf6 T157A constitutively cycling 
mutant also resulted in 50% inhibition. These data strongly suggest a regulatory role for 
Arf6 in the internalization of PMT, presumably by preventing PMT receptor-containing 
vesicles from cycling to the surface or by preventing formation of PMT-containing 
endosomes.  There was no significant effect of overexpression of the dominant-negative 
Arf6 T27N mutant on rPMT-induced SRE-luciferase reporter activity.  However, this 
mutant is less stable than the Arf6 T44N mutant (26), so the observed lack of effect of 
Arf6 T27N could be a result of instability.  
Next we wanted to determine if the effects of overexpression of Arf6 mutants on 
rPMT activity were dependent on the trafficking activity of Arf6.  It was previously 
demonstrated that mutating the glycine at position 2 of Arf6 to alanine results in a 
cytosolic, nonmyristolated Arf6 that does not associate with membranes and is unable to 
mediate endocytic trafficking (12).  We hypothesized that if a mutant Arf6 that 
previously demonstrated inhibition of PMT-mediated SRE-luciferase reporter activity 
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were mutated so that it could no longer associate with the membrane, then the ability of 
the mutant to decrease PMT intracellular activity would be abolished.  To test this 
hypothesis, we chose the two mutants that showed the greatest inhibitory effect on PMT 
cellular activity, Arf6 Q67L and Arf6 T157A, and made an additional mutation 
substituting alanine for glycine at position 2 in order to abolish their myristolation, 
therefore preventing membrane association.  Unlike their myristolated counterparts, the 
nonmyristolated Arf6 mutants, Arf6 G2A/Q67L and Arf6 G2A/T157A, did not block 
PMT-mediated SRE-luciferase reporter activity (Figure 2.3A).  Taken together these 
results suggest that the inhibition of PMT-induced SRE-luciferase reporter activity 
observed with the Arf6 Q67L and the Arf6 T157A mutants is a direct consequence of 
their disruption of PMT trafficking through Arf6-containing vesicles inside the cell.  
To explore whether PMT may exploit a similar Arf6-dependent pathway for 
initial entry as CT (28), despite their differences in dependence on intra-endosomal 
acidification, we co-treated Swiss 3T3 cells with PMTb-GFP and CtxB-594 and observed 
the cellular distribution of both after 1 or 3 h by confocal fluorescence microscopy 
(Figure 2.3).  After 1 h, PMTb-GFP and CtxB-594 were both observed in punctate 
vesicles localized throughout the cell (Figure 2.3A,B, respectively) and were largely 
colocalized (Figure 2.3D).  After 3 h, the PMTb-GFP was still located in punctate 
vesicles throughout the cell (Figure 2.3F); however, co-treatment for 3 h resulted in 
divergence of PMTb-GFP from CtxB-594 (Figure 2.3H), with an accumulation of CtxB-
594 to the perinuclear region (Figure 2.3G), while the PMTb-GFP remained 
predominantly localized in punctate vesicles throughout the cell (Figure 2.3F).  These 
results are consistent with previous research demonstrating that CtxB-594 is trafficked to 
the ER (22).  These data suggest that while PMTb-GFP and CTxB-594 may initially 
share a common entry pathway, CtxB-594 is then trafficked to the Golgi and 
subsequently to the ER, while PMT remains in endosomal compartments, which are 
subsequently subject to intra-endosomal acidification and rendered capable of PMT 
translocation. 
 
 
 
 66 
2.3.6 PMT trafficking is dependent on actin dynamics 
We next wanted to determine whether components of the cytoskeleton are 
important for PMT entry and trafficking.  We hypothesized that if actin dynamics play a 
prominent role in trafficking and internalization of PMT, pre-treating cells with 
cytochalasin D, an inhibitor of actin polymerization (10), would interfere with PMT 
trafficking pathways thereby inhibiting rPMT-induced SRE-luciferase reporter activity.  
To determine whether actin dynamics play a significant role in trafficking and 
internalization of PMT, HEK 293T/17 cells were pre-treated with varying concentrations 
of cytochalasin D for 15 min before rPMT treatment.  As shown in Figure 2.4A, 
cytochalasin D treatment caused a dose-dependent decrease in PMT-induced SRE-
luciferase reporter activity, with complete inhibition at concentrations over 0.3 µM, 
pointing towards the importance of actin dynamics for internalization and trafficking of 
PMT. 
 
2.3.7 PMT trafficking is dependent on microtubule dynamics 
Microtubules are required for trafficking from early sorting endosomes to late 
acidic endosomes (29).  Consequently, we next investigated whether the PMT trafficking 
pathway is also dependent on microtubule dynamics.  We hypothesized that if 
microtubule dynamics were important in the entry and trafficking of PMT, using an 
inhibitor of microtubule polymerization such as nocodazole would inhibit PMT-induced 
SRE-luciferase reporter activity.  To determine if disruption of the microtubule network 
also disrupts PMT trafficking, we pre-treated HEK 293T/17 cells with nocodazole, a 
microtubule inhibitor (14), for 15 min.  As shown in Figure 2.4B, pre-treatment of HEK 
293T/17 cells with nocodazole caused a dose-dependent decrease in PMT-induced SRE-
luciferase reporter activity, with complete inhibition observed at concentrations of 1 µM 
or higher.  Taken together these results demonstrate that both actin and microtubule 
dynamics play an important role in the entry and trafficking pathways of PMT. 
 
2.3.8 Treatment with brefeldin A causes an increase in PMT activity 
BFA interrupts trafficking between the Golgi apparatus and the ER, leading to the 
accumulation of secretory proteins in the ER (17, 31).  Although it was demonstrated that 
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BFA treatment does not affect the distribution of Arf6 (37), BFA treatment does induce 
morphological changes in the distribution of early endosomes resulting in the formation 
of a tubular network similar to that seen during redistribution of the Golgi after treatment 
with BFA (25).  We next determined whether these morphological changes produced by 
BFA affected the entry and trafficking of PMT.  Interestingly, pre-treatment of HEK 
293T/17 cells with BFA resulted in a dose-dependent increase in PMT-induced SRE-
luciferase reporter activity (Figure 2.5A), with as much as a six-fold increase in PMT 
activity observed upon treatment with 1 µM BFA.  These results suggest that the 
formation of a tubular endosomal system within the cell by BFA results in an increase in 
PMT activity. 
We further explored this phenomenon by determining whether translocation of 
PMT from the endosome was necessary for the observed BFA-mediated increase in PMT 
activity.  We hypothesized that if translocation from the endosome were necessary for the 
BFA-mediated increase in PMT activity, blocking translocation of PMT into the cytosol 
by treating with NH4Cl to prevent acidification of the endosome would effectively inhibit 
PMT activity.  To test this possibility, HEK 293T/17 cells were pre-treated for 15 min 
with both 1 µM BFA and varying concentrations of NH4Cl up to 20 mM.  As shown in 
Figure 2.5B, treatment of cells with as little as 2 mM NH4Cl significantly decreased the 
BFA-mediated increase in PMT activity, and indeed, at higher concentrations the 
inhibition by NH4Cl overrode the 5-fold activation observed in the absence of BFA.  
These data suggest that the BFA-mediated increase in PMT activity is dependent on 
translocation of PMT to the cytosol from acidic endosomes. 
We then attempted to elucidate the mechanism of this BFA-mediated increase in 
PMT activity by determining whether this effect was occurring downstream of the Arf6 
involvement in PMT trafficking.  We first overexpressed in HEK 293T/17 cells the Arf6 
mutants, Arf6 Q67L or Arf6 T157A, which we found to decrease PMT activity by 
preventing PMT entry and trafficking (Figure 2.3A).  The cells were then treated with 1 
µM BFA for 15 min, followed by PMT treatment as before.  As shown in Figure 2.5C, 
there was no increase in PMT-induced SRE-luciferase reporter activity in cells 
expressing either Arf6 Q67L or Arf6 T157A, as compared to cells transfected with an 
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empty vector.  These data suggest that the entry and trafficking of PMT into the cell via 
an Arf6 pathway occurs upstream of the BFA-mediated increase in PMT activity. 
Next, we determined the localization of PMTb-GFP and CtxB-594 in cells 
pretreated with BFA.  Swiss 3T3 cells were pretreated with 1 µM BFA for 15 min and 
subsequently co-treated with PMTb-GFP and CtxB-594 for 3 h, after which the cellular 
distribution of the toxin proteins were visualized by confocal fluorescence microscopy 
(Figure 2.5D,E, respectively).  After treatment for 3 h, the PMTb-GFP and CtxB-594 
appeared colocalized in large vesicles, predominantly near the perinucleolar region 
(Figure 2.5F).  These vesicles appeared to be larger than the PMTb-GFP containing 
vesicles observed in the absence of BFA treatment (compare with Figure 2.2C–E). 
 
2.4 Conclusions and Discussion 
This study further defines the trafficking pathways PMT uses to gain access to its 
intracellular targets.  Previous studies showed that PMT inserts into lipid membranes and 
that this membrane insertion is pH-dependent (4) and occurs at a pH that causes PMT 
unfolding (43), suggesting that endosome acidification is important for the unfolding of 
PMT and its insertion into the membrane to form a translocation pore.  In our 
experiments, we demonstrate that inhibiting endosomal acidification through the use of 
NH4Cl or BafA1 blocks PMT intracellular activity, as measured by PMT-mediated SRE-
luciferase reporter activity.  These results are in accordance with previous studies 
demonstrating that BafA1 inhibited PMT-mediated phosphorylation of FAK (4).  
Interestingly, these earlier studies used BafA1 concentrations of 10–100 µM, a 
concentration range that is more than 1000-fold higher than the concentration used in the 
current study.  Taken together these data indicate that intra-endosomal acidification is an 
essential step in PMT entry and translocation to the cytosol.  Preventing intra-endosomal 
acidification blocks this translocation step, and instead PMT remains trapped in the 
endosome with a concomitant block in downstream SRE-luciferase reporter activity.  
Blocking intra-endosomal acidification also affected the distribution of the PMTb-GFP-
containing vesicles as these vesicles were observed to accumulate near the membrane.  In 
contrast, CtxB-594 trafficking was not affected as vesicles containing the CtxB-594 were 
distributed evenly throughout the cell.  This would suggest that preventing intra-
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endosomal acidification not only blocks translocation and traps PMT in vesicles that 
remain near the cell membrane, but also affects trafficking of PMTb-GFP-containing 
vesicles within the cell. 
It has been demonstrated that intra-endosomal acidification recruits the small 
GTPase Arf6 to the endosomal membrane (27).  Overexpression of the constitutively 
active mutant of Arf6, Arf6 Q67L, results in a dramatic morphological change as many 
membrane invaginations labeled with Arf6 Q67L develop (37) and increases cell surface 
binding of Tfn, while decreasing the rate of Tfn internalization (11, 13).  This suggests 
that while the mutation results in increased binding of the ligand, the protein is unable to 
subsequently internalize it.  It is thought that GTP hydrolysis is essential for Arf6 
function and the GTPase-deficient Arf6 Q67L mutant results in a block in endocytosis 
through Arf6-mediated pathways (7, 52).  Accordingly, our results showing that 
overexpression of Arf6 Q67L decreases PMT-mediated SRE-luciferase reporter activity 
supports the notion that the mutation blocks PMT endocytosis through Arf6-mediated 
pathways. 
Overexpression of the dominant-negative mutant of Arf6, Arf6 T27N, results in 
accumulation of the mutant Arf6 in tubulovesicle structures (37), suggesting that both 
GTP hydrolysis and release of GDP are necessary for Arf6 function.  By disrupting the 
release of GDP, the dominant-negative mutant Arf6 T44N, which is more stable than the 
T27N mutant, should also disrupt the Arf6 trafficking pathway.  When we overexpressed 
the Arf6 T44N mutant we observed a decrease in PMT-mediated SRE-luciferase reporter 
activity, further implicating the Arf6 pathway in the endocytic trafficking of PMT.  The 
finding that the constitutively cycling mutant Arf6 T157A mutant, which binds, 
hydrolyzes and releases GTP faster than the wild-type Arf6 (41), also blocks PMT 
activity further supports these results.  It has been suggested that Arf6 activation is 
responsible for returning recycling endosomes back to the plasma membrane (13).  
Therefore, it is possible that a quick cycling version of the mutant may quickly recycle 
endosomes back to the membrane thereby preventing acidification of the endosome.  If 
the PMT-containing vesicles were recycled to the surface before the endosome is 
acidified, then PMT would be unable to translocate to the cytosol and hence show 
decreased activity.  
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Membrane localization of Arf6 is mediated through its N-terminal myristolation, 
and a mutation at the myristoylation site (Arf6 G2A) results in subsequent localization of 
Arf6 to the cytosol (37).  As our results show, abolishing this myristolation in the Arf6 
Q67L or Arf6 T157A mutants prevents the decrease in PMT-mediated SRE-luciferase 
reporter activity brought about by overexpression of the mutants.  This demonstrates that 
the decrease in PMT activity is dependent upon association of Arf6 with the plasma 
membrane and upon Arf6-dependent trafficking functions, as cytosolic mutants of Arf6 
showed no effect on PMT-induced SRE-luciferase reporter activity. 
As previously mentioned, Arf6 is not only an allosteric activator of CT (20, 33), 
but also has been implicated in trafficking of CT.  Arf6 is recruited to the endosomal 
membrane in CT-intoxicated cells (16).  In addition, it has been previously demonstrated 
that Arf6 plays a role in uptake of Tfn (11).  If PMT were to exploit the same initial 
trafficking pathway as CT and Tfn, then one would expect to see PMT colocalized in 
vesicles with CT and Tfn. Our results show that after 1 h of treatment PMTb-GFP does 
colocalize with CtxB-594 and Tfn-TR in punctate structures throughout the cell, 
suggesting that PMTb-GFP uptake occurs through Arf6-containing endosomes.  
However, after treatment for 3 h PMT trafficking diverges from that of CT and Tfn, as 
evidenced by the failure of PI3-kinase inhibitor LY294002, which blocks fusion with 
Rab5-positive recycling vesicles that are used by Tfn, to block PMT activity and by the 
buildup of CtxB-594 in the ER, while the PMTb-GFP remains localized in punctate 
vesicles throughout the cell.  These results support a model, whereby PMT, Tfn, and CT 
may share an initial trafficking pathway in Arf6-positive vesicles, but then these 
pathways diverge as CT is trafficked to the Golgi-ER and Tfn to recycling endosomes, 
while PMT traffics to an acidified endosome from which it can translocate. 
Given the evidence that PMT, Tfn and CT diverge in their trafficking pathways, 
we wanted to further explore the trafficking pathways of PMT downstream of Arf6.  
Other toxins, such as DT, that exhibit a dependence on intra-endosomal acidification for 
translocation (40) have been shown to colocalize with Rab5 and early endosome markers 
such as EEA1 (42).  Studies have implicated the translocation domain of DT in the 
modulation of Rab5 activity (2).  Vesicles taken up by clathrin-independent endocytosis 
with Arf6 have been shown to recruit EEA1 to their surfaces before fusion with 
 71 
endosomes from other pathways, such as the Rab5 Q79L pathway.  However, 
overexpression of Arf6 Q67L inhibits recruitment of EEA1 and subsequent fusion with 
other endosomal pathways (32).  This fusion of Arf6 and Rab5-positive vesicles was 
mediated by the activity of PI-3 kinase, as specific inhibitors of PI-3 kinase such as 
LY294002 prevent this fusion from occurring (32).  If PMT were acting in a manner 
similar to DT by exploiting Rab5 pathways for entry into the cell, it is conceivable that 
PMT/Arf6-positive vesicles would fuse with Rab5-positive vesicles in a PI-3 kinase 
dependent manner.  However, the specific PI-3 kinase LY294002 had no effect on PMT-
induced SRE-luciferase reporter activity, despite decreasing phosphorylation of Akt, 
suggesting that the Arf6-Rab5 PI-3 kinase-mediated fusion of vesicles is not important 
for PMT trafficking and translocation.  
Not only have we shown that PMT is trafficked through a compartment with 
Arf6, we have also demonstrated the importance of the cytoskeleton in these trafficking 
pathways.  Our results indicate that PMT trafficking is dependent upon both actin and 
microtubule dynamics, implicating both actin and microtubules in the trafficking 
pathways that PMT uses to enter the cell.  To further investigate where the PMT and CT 
trafficking pathways diverge, we investigated the effects of BFA on PMT-mediated SRE-
luciferase activity.  BFA interrupts trafficking between the Golgi apparatus and the ER 
and causes accumulation of secretory proteins in the ER (17, 31), uncoating of the Golgi 
apparatus (15), and subsequent formation of tubulovesicular processes that redistribute 
the contents of the Golgi into the ER (24). Furthermore, trafficking through the Golgi 
cisternae is interrupted.  It has been previously demonstrated that CT has a KDEL signal 
sequence (22) and that the toxin is trafficked in a retrograde manner from the Golgi to the 
ER, where it escapes to the cytoplasm to affect its intracellular target Gαs.  Interrupting 
this retrograde trafficking pathway from the Golgi to the ER with addition of BFA blocks 
CT-mediated cAMP accumulation (36).  
Our colocalization experiments demonstrated that, unlike CTxB-TR, PMTb-GFP 
was not trafficked to the ER. If PMTb-GFP were not trafficked to the ER, then BFA 
treatment would not be expected to affect PMT-mediated SRE-luciferase activity.  
However, we saw an increase in SRE-luciferase activity when cells were treated with 
BFA.  Interestingly, VacA from Helicobacter pylori has also been shown to exhibit 
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increased activity upon treatment with BFA (3).  There are several explanations that 
could account for this increase.  In addition to its effects on the Golgi apparatus, BFA 
induces similar effects on the endosomal system and causes the tubulation of both the 
endosomal system and lysosomes (25).  Although this mixed system is able to cycle 
between endosomes and the plasma membrane in a normal fashion, cycling between 
endosomes and lysosomes is impaired (25).  By impairing the pathway from the early 
endosome to the lysosome, PMT that may have otherwise been routed to a lysosome 
instead accumulates in the acidified endosome and translocates to the cytosol, resulting in 
the observed increased activity.  Similarly, perhaps during the course of PMT trafficking, 
a fraction of the PMT is shuttled through the Golgi to the ER, where it is unable to escape 
to the cytosol.  Blocking this non-productive trafficking through the use of BFA could 
result in more PMT trapped in the acidic endosomes and thus available for translocation.  
However, other data suggest that while the morphology of the endosomal system 
is changed by BFA, cycling between the early endosome and the lysosome is not 
impaired (49).  If a block in trafficking to the lysosome is not responsible for the increase 
in PMT-mediated SRE–luciferase reporter activity brought about by BFA treatment, 
perhaps the morphological changes induced by BFA to form tubular endosomes results in 
the observed increase in PMT activity.  It is possible that more PMT is able to translocate 
from the tubular endosomes, thereby resulting in an increase in PMT activity.  
Furthermore, studies have demonstrated that this BFA-induced tubulovesicle network 
associates with microtubules (50).  The association with microtubules is especially 
noteworthy as the decrease in PMT activity seen with nocodazole treatment implicates 
microtubules as part of the trafficking pathway of PMT. 
Alternatively, perhaps BFA treatment is responsible for increasing the number of 
PMT cell surface receptors.  It has been shown that treatment with BFA increases the 
amount of cell-surface associated mannose-6-phosphate receptor (M6PR) (50).  Although 
a protein receptor for PMT is as of yet unidentified, it is possible that BFA induces an 
increase in the amount of a putative plasma membrane-associated receptor, thereby 
allowing more PMT to bind to the cell surface and enter the cell via Arf6-mediated 
endocytosis.  Further studies are needed to elucidate the mechanism of this BFA-
mediated increase in PMT activity. 
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By overexpressing the Arf6 Q67L mutant that inhibited endocytosis, we were able 
to block the effects of BFA.  This would suggest that the BFA-mediated increase in PMT 
activity depends on PMT initially entering the cell.  In addition, we showed that treating 
the cells with NH4Cl blocks the BFA-mediated increase in PMT activity, indicating that 
translocation is necessary for this BFA-mediated increase in PMT activity.  These results 
support the assertion that the increase in SRE-luciferase reporter activity after treatment 
with BFA is dependent on the ability of PMT to enter the cell via endocytosis and to 
translocate from the endosome.  
In summary, we have implicated the Arf6 trafficking route as a mode of entry for 
PMT.  A model of PMT entry and trafficking that incorporates our findings as well as 
previous findings is shown in Figure 2.6.  We have demonstrated dependence on intra-
endosomal acidification for translocation and trafficking of PMT.  These data suggest 
that PMT may share an initial entry pathway with Tfn and CT, but these pathways later 
diverge as Tfn is trafficked to Rab5-positive recycling endosomes and CT is trafficked in 
a retrograde fashion from the Golgi to the ER, while PMT translocates from an acidified 
late endosome.  In addition, we have shown the importance of cytoskeletal dynamics of 
both actin and microtubules in PMT trafficking pathways.  Finally, we have shown that 
BFA increases PMT activity, through an as yet ill-defined mechanism that leads to more 
productive trafficking of the toxin to an acidic compartment for translocation. 
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2.5 Figures and Tables 
 
Figure 2.1 PMTb-GFP Initially Colocalizes with Tfn-Texas Red in Early 
Endosomes, but Then Diverges and Is Trafficked to Endosomes through a PI3-
kinase-Independent Process 
 
Swiss 3T3 cells were treated with 260 µg/mL PMTb-GFP and 20 µg/mL Tfn-TR for 3.5 h to visualize the 
endosomes. Cells were visualized by confocal microscopy using a 40× objective. (a-d) Shown are confocal 
microscope images of Swiss 3T3 cells after treatment with (a) PMTb-GFP, (b) Transferrin-Texas Red (Tfn-
TR); (c) merged image of (a) and (b); (d) corresponding phase-contrast image. Inset: Enlargement of the 
indicated section of the image, showing co-localization of PMTb-GFP and Tfn-TR; (e) HEK 293T/17 cells 
were transiently transfected with dual SRE-luciferase reporter plasmids and pcDNA3-Gαq as described in 
Methods. Seven h post-transfection cells were treated with LY294002 at the indicated concentrations and 
incubated for 15 min before treatment with 100 ng/mL PMT. After 15 h incubation, cells were harvested 
and assayed for SRE reporter gene activity, as described in Methods. SRE fold activation was determined 
by dividing SRE reporter gene activity in PMT-treated cells by SRE reporter gene activity in untreated 
control cells. Data are expressed as an average of three experiments ± S.D., with each experiment 
performed in triplicate, where ** p < 0.005; (f) HEK 293T/17 cell extracts treated with LY294002 at the 
indicated concentrations were subjected to western blot analysis to detect P-Akt and total Akt. 
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Figure 2.2 PMTb-GFP Initially Colocalizes with CTxB-594, but Then Diverges and 
Is Trafficked to and Translocated from Acidic Endosomes 
 
HEK 293T/17 cells were transiently transfected with dual SRE-luciferase reporter plasmids and pcDNA3- 
Gαq as described in Methods. (a-b) 7 h post-transfection cells were treated with (a) NH4Cl or (b) BafA1 at 
the indicated concentrations for 15 min before treatment with 100 ng/mL rPMT. After 15 h incubation, 
cells were harvested and assayed for SRE reporter gene activity, as described in the Methods. SRE fold 
activation was determined by dividing SRE reporter gene activity in PMT-treated cells by SRE reporter 
gene activity in untreated control cells. Data are expressed as an average of three experiments ± S.D. with 
each experiment performed in triplicate, where * p < 0.05, ** p < 0.005, and *** p < 0.000005. (c–j) Swiss 
3T3 cells were co-treated with PMTb-GFP and CT subunit B Alexa Fluor®-594 conjugate (CtxB-594) for 3 
h, as described in Methods, without (c–f) or with (g–j) pretreatment for 30 min with 30 mM NH4Cl. Cells 
were visualized by confocal microscopy. Panels (c) and (g), PMTb-GFP. Panels (d) and (h), CtxB-594. 
Panels (e) and (i), merged images of green and red channels. Panels (f) and (j), corresponding DIC images. 
Insets: Enlargement of the indicated section of the image, showing co-localization of PMTb-GFP and 
CtxB-594. 
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Figure 2.3 Arf6-Dependent Internalization and Trafficking of PMT  
 
HEK 293T/17 cells were transiently transfected with dual SRE-luciferase reporter plasmids, pcDNA3- 
Gαq, and plasmids containing Arf6 or Arf6 mutants, as described in Methods. (a) 7 hours post-transfection 
cells were treated with 100 ng/mL PMT and incubated for 15 h before assaying for SRE reporter gene 
activity. SRE fold activation was determined by dividing SRE reporter gene activity in PMT treated cells 
by SRE reporter gene activity in untreated control cells. Fold activation was then normalized to empty 
vector control (pcDNA3). Data are expressed as an average of eight experiments ± S.D., with each 
experiment performed in triplicate, where * p < 0.05 and ** p < 0.005. (b–i) Swiss 3T3 cells were co-
treated with PMTb-GFP and cholera toxin subunit B Alexa Fluor®-594 conjugate (CtxB-594) for 1 h (b–e) 
or 3 h (f–i). Cells were visualized by confocal microscopy. Panels (b) and (f), green channel image showing 
PMTb-GFP. Panels (c) and (i), red channel image showing CtxB-594. Panels (d) and (h), merged images of 
green and red channels. Panels (e) and (i), corresponding DIC images. Insets: Enlargement of the indicated 
section of the image, showing co-localization of PMTb-GFP and CtxB-594. 
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Figure 2.4 Both Actin and Microtubule Dynamics Are Important for PMT 
Trafficking to Translocation-Productive Acidic Late Endosomes  
 
HEK 293T/17 cells were transiently transfected with dual SRE-luciferase reporter plasmids and pcDNA3- 
Gαq as described in Methods. Seven h post-transfection cells were treated with cytochalasin D (a) or 
nocodazole (b) at the indicated concentrations for 15 min before treatment with 100 ng/mL PMT. After 15 
h incubation, cells were assayed for SRE reporter gene activity, as described in Methods. SRE fold 
activation was determined by dividing SRE reporter gene activity in PMT-treated cells by SRE reporter 
gene activity in untreated control cells. Data are expressed as an average of three experiments ±S.D., with 
each experiment performed in triplicate, where * p < 0.05 and ** p < 0.005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
 
Figure 2.5 Treatment with Brefeldin A Enhances PMT Activity 
 
HEK 293T/17 cells were transiently transfected with dual SRE-luciferase reporter plasmids and pcDNA3- 
Gαq as described in Methods. Seven h post-transfection cells were treated with BFA at the indicated 
concentrations (a) or with a combination of BFA (1 µM) and NH4Cl at the indicated concentrations (b) for 
15 min before treatment with 100 ng/mL PMT. After 15 h incubation, the cells were assayed for SRE 
reporter gene activity as described in Methods. (c) HEK 293T/17 cells were transiently transfected with 
dual SRE-luciferase reporter plasmids, pcDNA3-Gαq, and plasmids containing Arf6 Q67L or Arf6 T157A, 
as described in Methods. Seven h post-transfection cells were treated with BFA (1 µM) for 15 min before 
treatment with 100 ng/mL PMT. After 15 h incubation, cells were assayed for SRE reporter gene activity as 
described in Methods. SRE fold activation was determined by dividing SRE reporter gene activity in PMT 
treated cells by SRE reporter gene activity in untreated control cells. Data are expressed as an average of 
two experiments ± S.D., with each performed in triplicate, where * p < 0.005. (d–g) The effect of BFA (1 
µM) on the localization of PMTb-GFP and CtxB-594 in Swiss 3T3 cells after 3 h incubation. Cells were 
visualized by confocal microscopy. Panel (d), green channel image showing PMTb-GFP. Panel (e), red 
channel image showing CtxB-594. Panel (f), merged images of green and red channels. Panel (g), 
corresponding DIC image. Inset: Enlargement of the indicated section of the image, showing co-
localization of PMTb-GFP (green) and CtxB-594 (red). 
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Figure 2.6 Proposed Model of PMT Entry and Trafficking 
 
PMT enters the cell through an Arf6-dependent endocytic pathway that involves both actin and microtubule 
dynamics as evidenced by inhibition of PMT-mediated SRE activation upon expression of Arf6 mutants 
(Arf6-CA or Arf6-DN) or treatment with the inhibitors cytochalasin D (CcD) or nocodazole (Noc), 
respectively. PMT shares a similar route of endocytosis as transferrin (Tfn) and cholera toxin (CT); 
however, these pathways subsequently diverge. Tfn-bound receptors are trafficked to a Rab5-containing 
endosome in a PI 3-kinase-dependent vesicle fusion process, which is inhibited by LY294002. CT is 
trafficked retrograde through the trans-Golgi network (TGN) to the Golgi-ER. PMT is further trafficked 
through an endocytic vesicle that becomes acidified prior to translocation of PMT to the cytosol. Inhibitors 
of endosomal acidification, such as NH4Cl and BafA1, block the translocation of PMT, while BFA 
enhances this process by diverting any trafficking of PMT to the TGN instead to the acidified endocytic 
vesicles. 
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Table 2.1 Primers Used in Construction of Arf6 Mutants 
 
Primer Name Sequence (5' to 3')  
Arf6 T27N CGCGGCCGGCAAGAACACAATCCTGTACAAGTTG 
Arf6 T27Nr CAACTTGTACAGGATTGTGTTCTTGCCGGCCGCG 
Arf6-T44N GACCACCATTCCCAATGTGGGTTTCAACGT 
Arf6-T44Nr ACGTTGAAACCCACATTGGGAATGGTGGTC 
Arf6 Q67L ATGTGGGCGGCCTGGACAAGATCCG 
Arf6 Q67Lr CGGATCTTGTCCAGGCCGCCCACAT 
Arf6 Q67L 2 TATGGGATGTGGGCGGCCTGGACAAGATCCGGCCGCTCTG 
Arf6 Q67Lr 2 CAGAGCGGCCGGATCTTGTCCAGGCCGCCCACATCCCATA 
Arf6 T157A TCCTGTGCCGCCTCAGGGGACG 
Arf6 T157Ar CGTCCCCTGAGGCGGCACAGGA 
Arf6 G2A GTGGAATTCACCATGGCGAAGGTGCTATCCAAAATCTTC 
Arf6 G2Ar GAAGATTTTGGATAGCACCTTCGCCATGGTGAATTCCA 
pcDNAF CGCAAATGGGCGGTAGGCGTG 
BGHr2 CAACAGATGGCTGGCAAC 
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Chapter 3:  Investigation of the Trafficking  
Pathways of the PMT-related Dermonecrotic Toxins,  
CNF1, CNF2, CNFY, and DNT 
 
 
3.1 Introduction 
Members of the dermonecrotic toxin family, which includes the protein toxins 
from pathogenic E. coli (CNF1, CNF2, CNF3), Yersinia (CNFY), Bordetella (DNT), and 
Pasteurella multocida (PMT), modulate G-protein targets in host cells through selective 
deamidation and/or transglutamination of a critical active-site Gln residue in the G-
protein target, which results in activation of the intrinsic GTPase activity (reviewed in 
(23, 51, 52)). Structural and biochemical data have provided insight into the intracellular 
activity of these toxins. The CNFs and DNT act on a single Gln at position 61/63 in the 
switch II region of small Rho GTPases RhoA, Rac1 and Cdc42 (12, 16, 25, 43-47), while 
PMT is one of the few toxins known to act on a Gln at a functionally equivalent position 
209/205/229 in the switch II region of the α subunit of heterotrimeric Gq, Gi and G13 
proteins, respectively (33-35, 53, 55). The sequence and structural fold of the C-terminal 
deamidase domain of CNF1 (4) is completely unlike that of PMT (21), providing an 
intriguing example of convergent evolution of toxin structure-function (52). Indeed, the 
realization that many bacteria, including a number of known pathogens, produce and 
deliver into host cells deamidases/transglutaminases that affect cytoskeletal and 
mitogenic signaling pathways suggests that this may be a recurring strategy for bacteria 
to modulate the responses of their hosts (51).  
Limited information is available about the cellular entry mechanism or cellular 
and toxin determinants involved in cell binding, uptake and translocation of the 
dermonecrotic toxins. No crystal structure is available for the full-length protein or the 
receptor-binding or translocation domains of any member of the dermonecrotic toxin 
family. Yet, recent genome sequencing studies have also identified a large number of 
bacterial proteins of unknown function that share sequence similarity with the N-terminal 
receptor-binding domains of dermonecrotic toxins suggesting that other bacterial factors 
may utilize similar entry pathways as the dermonecrotic toxins. 
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The receptor-binding domain of CNF1 is located at the N-terminus (5), and the 
67-kDa laminin-receptor protein mediates entry of CNF1 (19) and CNF2 (29).  Although 
the binding of CNF1 does not influence the uptake of CNFY, conversely the binding of 
CNFY can affect the uptake of CNF1 suggesting that there may be overlap between the 
receptors (3). The receptor-binding domain of DNT has been localized to the N-terminus 
and the minimal N-terminal fragment that competes for cellular binding with full-length 
toxin is residues 1-54 (27). The N-terminus of PMT shares 46% similarity to the N-
terminal binding and translocation domain of CNF1 and 25% similarity to the N-terminal 
binding and translocation domain of DNT. 
Once bound to cells CNF1 enters via a clathrin-, dynamin-, and caveolae-
independent pathway (7). Similarly, uptake and internalization of CNFY appears to be 
independent of clathrin and lipid rafts (3).  CNF1 (7), CNF2 (36), CNFY (3), and PMT (2, 
41) are all dependent on endosomal acidification for entry and translocation.  In addition 
CNF1 (7), CNFY (3), and PMT (41) are thought to translocate from the late endosome. In 
contrast, DNT does not require an acidified endosome for translocation, nor is it affected 
by cytochalasin D, nocodazole, or brefeldin A (26).  The translocation domain of DNT is 
thought to be located in the region of residues 45-166 (26) and proteolytic cleavage of 
DNT by furin is necessary for its intracellular activity (26).  
We previously demonstrated the usefulness of the SRE-based luciferase reporter 
in measuring the mitogenic activity of PMT (1, 41). Because RhoA, Cdc42, and Rac 
activation also lead to transcription of SRE (13, 14), we used the SRE-based reporter 
assay to measure activity of CNF1, CNF2, CNFY, and DNT. Our studies reported here 
aim to characterize the SRE-luciferase reporter response to the dermonecrotic family of 
toxins.  Previous studies have demonstrated that acidification of the endosome is 
important for CNF1 translocation and that high concentrations of inhibitors of endosomal 
acidification block CNF1 activity.  We further characterize CNF1 and CNF2 signaling 
activity at a range of concentrations of these inhibitors to demonstrate that low 
concentrations of these inhibitors enhance CNF1 and CNF2 activity.  We also 
demonstrate that CNFY activity does not increase with low concentrations of endosomal 
acidification as was observed for both CNF1 and CNF2. We further show that CNF1, 
CNF2, and CNFY are all dependent on transport to the late endosome for translocation 
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and that the increase in CNF1 activity seen with low concentrations of inhibitors of 
endosomal acidification can be blocked through the use of nocodazole, demonstrating 
that this increase in activity is dependent upon trafficking of CNF1 to the late endosome.  
Finally, we show that HEK 293T/17 cells appear resistant to DNT as treatment with very 
high concentrations of DNT elicited only a minimal SRE-luciferase response. 
 
3.2 Materials and Methods 
 
3.2.1 Materials 
 Monensin and nigericin were purchased from Sigma.  All other reagents were 
obtained as described above.  
 
3.2.2 Plasmid constructs 
 pQE-CNF1 was obtained from Dr. Alison O’Brian at Uniformed Services 
University.  pProEx-CNF2 was obtained from Dr. Eric Oswald at the Institute Pasteur.  
pTHB-DNT was cloned by Melinda Faulkner and Dr. Mengfei Ho from two DNT 
fragments obtained from Dr. Alison Weiss at the University of Cincinnati.  pQE-CNFY 
was amplified from Y. pseudotuberculosis strains YPIII obtained from Dr. James Bliska 
at SUNY/Stonybrook and fragment exchanged into pQE-CNF1. 
 
3.2.3 Toxin preparations 
Recombinant toxins were expressed and purified using the protocol previously 
described for PMT (1). CNF1 was expressed in Escherichia coli cells (XL1-Blue) in the 
pQE-CNF1 vector under the induction of IPTG. CNF2 was expressed in Escherichia coli 
cells (XL1-Blue) harboring the pProEx-CNF2 vector under the induction of IPTG. CNFY 
was expressed in Escherichia coli cells (BL21) harboring the pQE-CNFY vector under 
the induction of IPTG. DNT was expressed in Escherichia coli cells (XL1-Blue) 
harboring the pTHB-DNT vector under the induction of IPTG.  
The cell extract was purified by Ni2+-NTA-agarose chromatography. Toxin 
containing fractions were further purified by FPLC using HiTrapQ anion exchange 
chromatography and desalted with a PD-10 column with phosphate-buffered saline (PBS) 
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containing 10% glycerol. Toxin concentration was determined by NIH Image J digital 
image analysis of Pierce GelCode Blue-stained SDS-PAGE gels using BSA as the 
standard. Toxin samples were stored in PBS containing 10% glycerol at −80 °C until use. 
 
3.2.4 Cell culture 
 HEK 293T/17 cells were cultured and maintained at 37°C and 5% CO2 in DMEM  
with 10% BGS, 100 U/mL penicillin G, and 100 µg/mL streptomycin. 
 
3.2.5 SRE-luciferase assay 
 HEK 293T/17 cells at 80% confluency were replated at a 1:7 ratio in 24 well 
plates.  The next day the medium was changed to DMEM with 2% BGS, 100 U/mL 
penicillin G and 100 µg/mL streptomycin, and cells were transfected using the CaCl2 
method (20).  The plasmid DNA (0.25 µg/mL of pSRE-luc, 0.025 µg/mL p-Renilla-TK 
(pGL 7.4 hRluc/TK) in a solution of 250 mM CaCl2 was added dropwise to a solution of 
2X HEPES-buffered saline while vortexing.  The solution was incubated at room 
temperature for 20 min and then added dropwise to each well.  Cells were incubated for 7 
hours, after which medium with or without CNF1 was added (at the indicated 
concentrations).  After incubation with CNF1 for the indicated incubation times 
indicated, the medium was removed, and cells were lysed by adding 150 µL of 1 x 
Passive Lysis Buffer and incubating for 15 min on a rotary shaker.  Cell lysates were 
analyzed using the Dual Luciferase Assay System, according to manufacturer’s protocol.  
Luminescence was measured using a Synergy-HT multi-detection microplate reader 
(BioTek) and results were reported as relative light units (sensitivity = 100, integration 
time = 1 s). 
 
3.2.6 SRE-luciferase assay with chemical inhibitor treatment 
 HEK 293T/17 cells were plated and transfected as described above.  Cells were 
incubated for 7 hours, after which medium containing the indicated inhibitor was added 
to the wells.  Stock solutions of 700 nM BafA1 and 100 µM nocodazole were created by 
dissolving the inhibitor in DMSO.  A stock solution of 350 mM NH4Cl was created by 
dissolving NH4Cl in water.  Stock solutions of 70 µM monensin and 35 µM nigericin 
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were created by dissolving the inhibitor in methanol.  After either 15 or 30 min 
incubation with the inhibitor, toxin was added to the wells at a final concentration of 100 
ng/mL.  After 8 hours of toxin treatment the medium was removed, and cells were lysed 
by adding 150 µL of 1 x Passive Lysis Buffer and incubating for 15 min on a rotary 
shaker.  Cell lysates were analyzed using the Dual Luciferase Assay System, according to 
manufacturer’s protocol.  Luminescence was measured using a Synergy-HT multi-
detection microplate reader (BioTek) and results were reported as relative light units 
(sensitivity = 100, integration time = 1 s). 
 
3.2.7 Data analysis 
 SRE-luciferase activity was determined by dividing the firefly luciferase activity 
by the Renilla luciferase activity.  Within each experiment SRE-luciferase activity was 
averaged and the average of the toxin treated was divided by the average of the untreated 
SRE-luciferase activity to determine the fold activation.  The fold activation for the 
inhibitor treated groups was then divided by fold activation of the untreated groups to 
obtain the fold activation, normalized to control.  Data are expressed as the mean ± S.D. 
of results from three independent experiments repeated in triplicate.  A student’s t-test 
was then used to compare the normalized fold activation values of the treated and 
untreated in the experiments using chemical inhibitors. 
 
3.3 Results 
 
3.3.1 Treatment of HEK 293T/17 cells with CNF1, CNF2, or CNFY induces SRE-
luciferase reporter activity 
We measured CNF1-induced SRE-luciferase reporter activity in HEK 293T/17 
cells treated with different doses of CNF1 for 16 hours (Fig 1A).  CNF1-induced SRE-
luciferase reporter activity is first detectable at doses of 100 pg/mL CNF1 with SRE-
luciferase reporter activity increasing three-fold and peaking at doses of 1 ng/mL CNF1.   
When cells were treated with 10 ng/mL CNF1 there was a 40% decrease in CNF1 
activity as compared to cells treated with 1 ng/mL CNF1.  At higher concentrations in the 
range of 100 ng/mL-10 µg/mL, there was a continued decrease in CNF1-induced SRE-
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luciferase reporter activity as compared to the peak reporter activity observed at 
concentrations of 1 ng/mL CNF1 (Figure 1A). 
We next wanted to further investigate the decrease in CNF1 activity over the 
range of 1 ng/mL-10 µg/mL CNF1 and to determine the time course of the effect of 
CNF1.  HEK 293T/17 cells were treated with 1 ng/mL, 10 ng/mL, or 100 ng/mL CNF1 at 
seven different time points ranging from 4-16 hours and subsequently assayed for CNF1 
activity (Fig 1B).  Cells treated with 1 ng/mL CNF1 show activation of CNF1-induced 
SRE-luciferase reporter activity at ten hours and SRE-luciferase reporter activity 
increases up until 16 hours (Fig 1B).  In cells treated with 10 ng/mL CNF1, SRE-
luciferase reporter activity is first detected at 6 hours, peaks at 12 hours, and subsequently 
decreases at 14 and 16 hours (Fig 1B).  Finally, HEK 293T/17 cells treated with 100 
ng/mL CNF1 first demonstrate detectable SRE-luciferase activity at 4 hours and 
subsequently peak in SRE-luciferase activity at 8 hours before steadily decreasing over 
the 10-16 hour time points (Fig 1B). 
When cells were treated with CNF2, the largest CNF2-induced SRE-luciferase 
reporter response was a 107-fold increase in SRE-luciferase reporter activity that was 
observed after treatment with 100 ng/mL CNF2 for 8 hours (Fig 1C). CNF2 is a stronger 
activator of the SRE response as the 107-fold SRE-luciferase reporter response observed 
with treatment of CNF2 at a concentration of 100 ng/mL for 8 hours is 3-fold higher than 
the 31-fold response observed with treatment of CNF1 at a concentration of 100 ng/mL 
for 8 hours (Fig 1C).  During an 8-hour incubation, lower concentrations of 10 ng/mL 
CNF2 were able to induce a 90-fold increase in SRE-luciferase reporter activity while 
higher concentrations of CNF2 on the order of 1 µg/mL were able to induce a 101-fold 
increase in SRE-luciferase reporter activity (Fig 1C).  SRE activity was first detectable as 
a 37-fold activation of signaling after an 8-hour treatment with 1 ng/mL CNF2 (Fig 1C).  
16 hour treatment with CNF2 elicited a similar SRE response over the concentration 
ranges of 1 ng/mL-1 µg/mL demonstrating 20-27 fold activation of signaling activity 
which was less than that observed for comparable concentrations over an 8-hour period 
(Fig 1C).  
In contrast to CNF1 and CNF2, which had a peak in SRE-luciferase reporter 
activity at a concentration of 100 ng/mL at 8 hour (Fig 1B and 1C), the peak induction of 
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SRE-luciferase reporter activity for CNFY was a 134-fold induction of reporter gene 
activity that occurred at concentrations of 1 µg/mL (Fig 1D).  After an 8-hour treatment 
reporter gene activity was first detected at 1 ng/mL with a 5-fold induction and increased 
to 50-fold and 105-fold reporter gene activity at concentrations of 10 ng/mL and 100 
ng/mL respectively (Fig 1D).  The 105-fold increase in SRE-luciferase activity observed 
for 100 ng/mL of CNFY is over three times that observed for CNF1 at the same 
concentration (Fig 1D) and is similar to the 107-fold activation seen with CNF2 at the 
same time and concentration (Fig 1C).   
After a 16-hr treatment with CNFY, the highest SRE-luciferase fold activity was 
observed as 58-fold activation of signaling pathways at 100 ng/mL (Fig 1D).  Activity 
was first detectable at concentrations of 1 ng/mL CNFY with a 26-fold increase in SRE-
signaling (Fig 1D).  Concentrations of 100 ng/mL and 1 µg/mL elicited a 58-fold and a 
54-fold increase in SRE-signaling, respectively (Fig 1D).  This 58-fold increase after 16-
hr treatment with 100 ng/mL CNFY is significantly higher than the 14-fold increase in 
SRE-signaling activity seen after treatment with 100 ng/mL CNF1 for 16 hours (Fig 1B) 
and two times higher than the 27-fold increase seen in SRE-signaling activity seen after 
treatment with 100 ng/mL CNF2 for 16 hours (Fig 1C). 
In an attempt to measure the SRE-luciferase response to treatment of HEK 
293T/17 cells with DNT, cells were treated with varying concentrations of DNT ranging 
from 1 pg/mL to 1 µg/mL and assayed for SRE-luciferase reporter activity after 8 or 16 
hours.  Treatment of HEK 293T/17 cells with concentrations of DNT ranging from 1 
pg/mL to 10 ng/mL for 8 or 16 hours did not induce any significant increase in SRE-
luciferase activity (Fig 1E).  Treatment of HEK 293T/17 cells with 1 µg/mL of DNT 
induced a moderate 7-fold increase in SRE-luciferase activity (Fig 1E).  Extending the 1 
µg/mL DNT treatment time to 16 hours induced a slight increase in SRE-luciferase 
activity to 10-fold (Fig 1E). 
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3.3.2 Low concentrations of inhibitors that prevent acidification of the endosome 
increase CNF1- and CNF2-mediated SRE-luciferase reporter activity while 
decreasing CNFY-mediated SRE-luciferase reporter activity 
Bafilomycin A1 (BafA1) is an inhibitor of the endosomal proton pump that can be 
used to inhibit acidification of the endosome therefore slowing the progression from early 
to late endosomes (28, 50).  Cells were pre-treated with BafA1 for 30 min and 
subsequently treated with 100 ng/mL CNF1, CNF2, or CNFY for 8 hours.  At 
concentrations of 10-20 nM BafA1 the CNF1-induced SRE-luciferase reporter activity 
increased as compared to HEK 293T/17 cells that were not pre-treated with BafA1.  
However, higher concentrations of BafA1 in the range of 60-100 nM decreased the 
CNF1-mediated SRE-luciferase reporter activity (Fig 2A).  Similarly, pre-treatment of 
HEK 293T/17 cells with 10 mM BafA1 before treatment with 100 ng/mL CNF2 induced 
a modest 1.2-fold increase in SRE-luciferase reporter activity (Fig 2A), which was less 
than the 1.4-1.6 fold activity induced by concentrations of BafA1 in the range of 10-20 
nM for treatment with 100 ng/mL CNF1 (Fig 2A).  Concentrations of 40 nM BafA1 were 
able to inhibit CNF2 signaling by approximately 60% with a 90% reduction in CNF2 
activity seen with concentrations of BafA1 on the order of 60-100 nM (Fig 2A). 
In contrast to CNF1 and CNF2, which demonstrated an increase in CNFY-
mediated SRE-luciferase activity with low concentrations of BafA1, treatment with 10 
nM BafA1 decreased CNFY -induced SRE-luciferase activity by 30% (Fig 2A).  Lower 
concentrations of BafA1 on the order of 5 nM decreased CNFY activity by about 10% 
with higher concentrations such as 20 nM decreasing CNFY activity by over 80% (Fig 
2A).  Concentrations of bafilomycin in the range of 40-100 nM resulted in complete 
inhibition of CNFY activity (Fig 2A). 
To determine whether these effects were dependent on the pre-treatment time of 
BafA1, a time course was conducted where cells were pre-treated with 5, 20, or 100 nM 
BafA1 for 15 or 30 min and then treated with 100 ng/mL of CNF1 for 8 hours.  Cells 
pretreated with 5 nM BafA1 for 15 and 30 min showed fold activation near that of BafA1 
untreated cells (Fig 2B).  Cells pretreated with 20 nM BafA1 for 15 and 30 min exhibited 
a 2 fold activation over BafA1 untreated cells with the 30 min pre-treatment group 
showing a slightly higher activation (Fig 2B).  Cells pretreated with 100 nM BafA1 for 
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15 and 30 min exhibited a decrease in fold activation with the 15 min pretreatment group 
exhibiting a 54% decrease and the 30 min pretreatment group exhibiting a 92% decrease 
from BafA1 untreated cells (Fig 2B). 
 Endosomal pH can also be increased by the addition of weak bases such as NH4Cl 
(32).  Cells were pre-treated with NH4Cl for 30 min and subsequently treated with 100 
ng/mL CNF1 for 8 hours.  The CNF1-induced SRE-luciferase reporter activity increased 
in cells treated with concentrations of 5-20 mM NH4Cl with the greatest fold increase 
occurring at concentrations of 20 mM NH4Cl.  However, the SRE-luciferase reporter 
activity decreased in cells treated with 30-50 mM NH4Cl (Fig 2C).  Treatment with low 
concentrations of NH4Cl, an inhibitor of endosomal acidification, in the range of 5-8 mM 
induced a 1.4-1.6-fold increase in CNF2 signaling activity (Fig 2C).  Higher 
concentrations of NH4Cl on the order of 40-50 mM NH4Cl were able to inhibit the SRE-
luciferase reporter activity by over 90% (Fig 2C). 
Similar to experiments using low concentrations of BafA1, low concentrations of 
NH4Cl were also unable to increase CNFY -mediated SRE-luciferase activity (Fig 2C).  
While concentrations of 8-20 mM NH4Cl induced a 1.7-2.6-fold increase in CNF1 
activity (Fig 2C) and concentrations of 5-8 mM induced a 1.4-1.6-fold increase in CNF2 
signaling activity (Fig 2C), no increase was observed for CNFY in this concentration 
range (Fig 2C).  Lower concentrations of NH4Cl did not inhibit CNFY activity (data not 
shown).  Treatment with 5 mM NH4Cl inhibited CNFY activity by 80%, while treatment 
with higher concentrations of NH4Cl in the range of 8-30 mM NH4Cl inhibited CNFY 
activity by over 90% (Fig 2C). 
To determine whether these effects were dependent on the time course of NH4Cl 
treatment, we then conducted a time course where cells were pre-treated with 5, 10, or 40 
mM NH4Cl for 15 or 30 minutes (Fig 2D).  Cells pre-treated with 5 mM NH4Cl for 15 or 
30 minutes showed a 1.8-fold increase in the CNF1-induced SRE-luciferase reporter 
activity while cells pre-treated with 20 mM NH4Cl for 15 or 30 minutes demonstrated a 
3-fold increase in CNF1 activity (Fig 2D).  However, treatment with higher 
concentrations of NH4Cl (40 mM) for 15 or 30 minutes resulted in a dramatic reduction 
(about 95%) in CNF1-mediated SRE-luciferase activity (Fig 2D). 
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Monensin is a Na+/H+ antiporter that has also been demonstrated to inhibit 
acidification of the endosome (28, 48).  Accordingly, treatment of HEK 293T/17 cells 
with 1 µM monensin increased CNF1 SRE-reporter activity nearly two-fold (Fig 2E).  
Higher concentrations of monensin such as 2 µM decreased CNF1 activity while 
concentrations in the range of 5-10 µM decreased CNF1 activity by greater than 90% 
(Fig 2E).  We also explored the effect of nigericin, a K+/H+ antiporter that has a similar 
structure to monensin, on CNF1 activity.  It has been previously shown that nigericin 
through its antiporter activity equilibrates the intravesicular pH with the extravesicular 
pH therefore preventing endosomal acidification (6, 42).  When HEK 293T/17 cells were 
treated with 0.5 µM nigericin there was a 1.5-fold increase in CNF1 SRE-reporter 
activity (Fig 2F).  However, treatment with higher concentrations of nigericin in the 
range of 1-2 µM decreased CNF1 activity with concentrations of 5 µM demonstrating a 
90% decrease in CNF1 activity (Fig 2F). 
 
3.3.3 Nocodazole inhibits the activity of CNF1, CNF2, and CNFY as well as the 
NH4Cl-mediated increase in CNF1 SRE-luciferase reporter activity 
Nocodazole is an inhibitor of microtubule polymerization that blocks trafficking 
from the early to late endosomes (28).  Previous studies have demonstrated that treatment 
with 30 µM nocodazole inhibits CNF1 activity, suggesting that CNF1 is transported to 
the late endosome before translocation (7).  Treatment of HEK 293T/17 cells with 250 
nM and 500 nM nocodazole decreased the CNF1-mediated SRE-reporter activity by 52% 
and 77% respectively (Fig 3A). Higher concentrations of nocodazole on the order of 
1,000-10,000 nM decreased CNF1 SRE-reporter activity by over 90% (data not shown).  
These observations led us to question whether CNF2 also translocates from the late 
endosome.  Pre-treatment of HEK 293T/17 cells with concentrations of nocodazole in the 
range of 50-100 nM before treatment with 100 ng/mL CNF2 inhibited the SRE-luciferase 
response by about 20%, while pre-treatment of HEK 293T/17 cells with 250 nM 
nocodazole before treatment with 100 ng/mL CNF2 inhibited the SRE-luciferase 
response by over 90% (Fig 3A).  Higher concentrations of nocodazole in the range of 
1000 nM were able to inhibit the SRE-luciferase response (data not shown).  Pre-
treatment with nocodazole also inhibited CNFY activity with 250 nM nocodazole 
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decreasing activity by 63% and 500 nM nocodazole decreasing activity by over 90% (Fig 
3A). 
We next wanted to determine whether inhibiting transport from the early to late 
endosome with nocodazole would block the NH4Cl-mediated increase in CNF1 activity.  
Low concentrations of nocodazole ranging from 50-100 nM were able to decrease the 
NH4Cl -mediated increase in CNF1 activity without affecting CNF1 Activity in NH4Cl 
untreated cells (Fig 3B).  Higher concentrations of nocodazole in the range of 250-500 
nM decreased the NH4Cl -mediated increase in CNF1 activity, while also decreasing the 
CNF1 SRE-reporter activity in NH4Cl-untreated cells (Fig 3B).  
 
3.4 Conclusions and Discussion 
We previously demonstrated the utility of using the SRE-luciferase assay for 
studying the action of PMT (1, 41).  Since CNFs activate the Rho family of proteins and 
the Rho proteins activate signaling pathways leading to SRE-responsive genes, we 
decided to take advantage of the SRE assay to explore CNF activity.  Our results 
demonstrate a new method for measuring CNF-induced activation of Rho.  Previous 
studies investigating the effect of CNF1 and DNT on RhoA have relied on visual 
indications of CNF1 activity such as multinucleation (7, 18) and formation of actin stress 
fibers (11, 17, 24); used electrophoretic mobility assays to detect a shift in Rho after 
deamidation (11, 17, 24); or relied upon measuring tyrosine phosphorylation of p125fak 
and paxillin (24).  Although examining cells for multinucleation allows one to determine 
a percentage of the total population of cells that are multinucleated upon treatment with 
toxin, it does not provide a quantifiable measure of activation of signaling pathways by 
the toxin.  Similarly, observing cells for the formation of actin stress fibers allows for the 
calculation of what percentage of cells have been affected by the toxin, but it is harder to 
quantify the formation of the actin stress fibers within individual cells.  Therefore, our 
assay for toxin activity is advantageous because measuring Rho activation of SRE-
luciferase allows for a more sensitive, quantifiable measure of signaling activity when 
cells are treated with CNF1, CNF2, or CNFY.  Although it is possible to determine 
whether Rho A has been modified in cell extracts, it is difficult to determine what 
percentage of the protein has been modified.  Our assay holds an advantage over this 
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technique in that it gives you a quantifiable measure of reporter gene activity, which can 
be correlated to high or low levels of dermonecrotic toxin activity.  When measuring 
CNF1-mediated SRE-luciferase reporter activity, it was observed that a dose of 1 ng/mL 
gave the highest SRE-luciferase reporter activity after 16 hours of toxin treatment.  
Interestingly, higher doses of CNF1 (10 ng/mL and 100 ng/mL) displayed a decrease in 
SRE-luciferase activation at a time point of 16 hours (Fig 1A).   
This led us to explore the time course of action for different doses of CNF1 (Fig 
1B), as the dose of CNF1 affects the time course of CNF1-mediated SRE-luciferase 
activation.  Cells treated with lower doses of CNF1 (1 ng/mL) required a longer CNF1-
treatment time for activation of SRE-luciferase signaling.  However, higher doses of 
CNF1 (100 ng/mL) result in an earlier SRE-luciferase response, which was first 
detectable at 4 hours and peaked at 8 hours with a subsequent decrease in SRE-luciferase 
reporter activity over the period of 10-16 hours (Fig 1B).  This agrees with current data in 
the literature, which suggests that although CNF1 causes transient activation of Rac1, it 
eventually causes depletion of Rac1 from the cells through a ubiquitin/proteasome-
mediated pathway (9), which would presumably lead to a loss of signaling through Rac1.   
In addition, it has been shown that CNF1-mediated activation of RhoA is also transient, 
although this mechanism is thought to be independent of the ubiquitin/proteasome-
mediated pathway (15).  Therefore, although high doses of CNF1 initially cause 
activation of Rho GTPases and an associated increase in SRE-luciferase activity, it is 
likely that depletion of Rho GTPases from the cells results in a decrease in signaling over 
longer time periods ranging from 10-16 hours.  This time-dependent response to different 
doses of CNF1 allows for a very flexible assay to study the effects of a low dose of CNF1 
over a longer time course or the effects of a high dose of CNF1 over a shorter time 
course. 
CNF2 proved to be a stronger activator of SRE-luciferase signaling as treatment 
with CNF2 induced an increase in SRE-luciferase activity that was over 3-fold higher 
than that for CNF1 (Fig 1C).  Similar to CNF1, CNF2 activity was higher at 8 hours than 
at 16 hours (Fig 1C) further, suggesting that CNF-induced SRE activation is transient due 
to degradation of the target proteins.  These results were also confirmed by CNFY, which 
was similar to CNF2 in its ability to induce SRE-signaling activity at 8 hours at a 
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concentration of 100 ng/mL (Fig 1D). After an 8-hour treatment with 100 ng/mL CNFY, 
SRE-signaling activity was detected at a level that was 3-fold higher than that of CNF1 
(Fig 1D). CNFY signaling activity also decreased at 16 hours (Fig 1D), further supporting 
the assertion that SRE activation is transient. CNFY was unique from CNF1 and CNF2 in 
that treatment with 1 µg/mL CNFY induced higher signaling activity than 100 ng/mL 
CNFY after 8 hours (Fig 1D).  This differs from both CNF1 and CNF2, in which peak 
signaling activity after 8 hours was at concentrations of 100 ng/mL (Fig 1B and 1C).  Our 
results demonstrate that application of the SRE assay to measure activity of CNFs is a 
useful method, as it provides a quantitative measure of toxin activity. 
Previous studies have demonstrated that concentrations of 100 nM BafA1 were 
able to inhibit CNF1-mediated multinucleating activity (7).  It has also been 
demonstrated that treatment with BafA1 inhibits the Rho shift due to CNF1-induced 
deamidation of Rho, and that treatment with BafA1 prevents detection of the 55-kDa 
catalytic domain in the cytosol, instead allowing for detection of full-length toxin in the 
early endosome (22).  While our results confirm previous data in that concentrations of 
100 nM BafA1 inhibited the CNF1-mediated SRE-luciferase reporter activity (Fig 2A), 
our results demonstrated that lower concentrations of BafA1 ranging from 10-20 nM 
actually increase CNF1 activity.  In addition, our data suggested that prolonged pre-
treatment with BafA1 enhances these effects, as pre-treatment with 20 nM BafA1 
resulted in a further increase in CNF1-mediated SRE-luciferase activity, while pre-
treatment for 30 minutes with 100 nM BafA1 resulted in a further decrease in SRE-
luciferase activity (Fig 2B).  While this increase in activity when treated with low 
concentrations of BafA1 and NH4Cl was also observed with CNF2 albeit at lower levels 
(Fig 1A and 1C), neither low concentrations of BafA1 nor low concentrations of NH4Cl 
were able to increase CNFY activity (Fig 1A and 1C).  Furthermore, we have 
demonstrated that treatment with nocodazole, which inhibits transport to the late 
endosome, decreases the enhancement in CNF1 activity observed with 10 mM NH4Cl 
(Fig 3B).  This would suggest that the NH4Cl-mediated enhancement depends on 
transport of CNF1 to the late endosome for translocation. 
Treatment with BafA1 inhibits transport from late endosomes to lysosomes (50).  
Furthermore, it has been demonstrated that treatment with BafA1 decreased degradation 
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of ricin through an increase in lysosomal pH and reduced transport to lysosomes (49).  
Therefore, it is possible that the increase in CNF1 and CNF2 activity seen with low 
concentrations of BafA1 is due to decreased degradation of CNF1 and CNF2 because of 
an increase in lysosomal pH and reduced transport of CNF1 and CNF2 to the lysosome, 
which may result in an unproductive infection.  However, this increase in activity was not 
observed for CNFY, nor was it observed in previous studies with PMT (41). 
Another possibility for the difference in the behavior between CNF1/CNF2 and 
CNFY might be due to a difference in the respective receptors.  The 67-kDa laminin-
receptor protein mediates entry of CNF1 (19) and CNF2 (29).  Although the binding of 
CNF1 does not influence the uptake of CNFY, conversely the binding of CNFY can affect 
the uptake of CNF1, suggesting that there may be overlap between the receptors (3).  One 
possibility for the increase in CNF1 and CNF2 activity at low concentrations of 
endosomal inhibitors could be that the pH alters their interaction with their receptor 
inside the endosome, thereby making translocation more favorable.  If CNFY is able to 
enter the cells via a different receptor, perhaps this CNFY-receptor interaction is not 
affected by the change in pH. 
It was previously demonstrated that CNF1 is transported across the membrane by 
a pH pulse of 5.2 or lower (7), suggesting that CNF1 translocates at an endosomal pH of 
around 5.2.  Therefore, it is possible that treatment with low concentrations of agents that 
inhibit endosomal acidification might provide an endosomal environment, where the pH 
is more favorable for translocation, while inhibiting CNF1 accumulation in the lysosome.  
Alternatively, higher concentrations of these agents might raise the pH to an unfavorable 
level for translocation, thus blocking toxin activity.  When examining the pIs of various 
regions of the CNF family it becomes apparent that the pIs of N-terminal regions of 
CNF1 and CNF2 differ from those of CNF3, CNFY and PMT (Figure 3.4).  The pIs of 
CNF1 and CNF2 are over 2 units higher than the pIs of CNF3, CNFY and PMT in the 
region encompassing residues 119-267 (where the residue numbers correspond to those 
in CNF1).  Furthermore, CNF1 and CNF2 have a net positive charge in this region of 2 
for CNF1 and 1 for CNF2, while CNF3, CNFY, and PMT all have a net negative charge 
of -4 for CNF3 and CNFY and -3 for PMT.  It has been suggested that two hydrophobic 
helices separated by an intervening hydrophilic loop encompassing residues 331-414 
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comprise the translocation domain of CNF1 (10). It is thought that as the pH in the 
endosome decreases, residues in this hydrophilic loop are protonated, leading to insertion 
of the translocation domain into the membrane (37).  While the previous study 
demonstrated the importance of protonation of the hydrophilic loop of the translocation 
domain, subsequent studies with DT have demonstrated the importance of other residues 
outside of this hydrophilic loop.  Indeed it has been shown that protonation of histidine 
residues of DT alters local protein folding, which in turn destabilizes tertiary structure 
and leads to subsequent interaction with the membrane (38).  Thus, perhaps 
destabilization of tertiary structure in these regions of pI difference adjacent to the 
translocation domain, attributable to differential protonation of residues and differential 
net charge, make the conditions for interaction of the translocation domain with the 
membrane more favorable for CNF1 and CNF2.  The proposed relationships between pH, 
pI, and inhibitor concentrations are depicted in Figure 3.5.  In order to confirm this, 
further studies with chimeric CNFs, in which these regions are swapped between CNF1 
and CNFY (or CNF2 and CNFY) and tested for their activity at various doses of NH4Cl 
and BafA, would be useful.  Alternatively, further studies mutating protonated residues in 
this region to observe their effect on toxin activity at various doses of NH4Cl and BafA 
might also provide insight into the mechanism of this increase. 
To determine whether this increase in CNF1 activity at low concentrations of 
BafA1 was a result of a general pH increase or was a specific characteristic of treatment 
with BafA1, we decided to see whether this phenomenon was also observed when 
NH4Cl, an inhibitor of endosomal acidification (32), was added to the cells.  This 
increase in CNF1 activity at low concentrations of BafA1 is apparently related to pH as 
concentrations of NH4Cl ranging from 5-20 mM increased CNF1-mediated SRE-
luciferase activity, while concentrations of 30-50 mM NH4Cl decreased CNF1-mediated 
SRE-luciferase activity (Fig 2C).  These trends held true despite changing the NH4Cl pre-
treatment time from 30 min to 15 min (Figure 2D).  In addition, the increase was also 
observed with monensin (Fig 2E) and nigericin (Fig 2F), two inhibitors of endosomal 
acidification that act as Na+/H+ and K+/H+ antiporters respectively.  
These results, in conjunction with the BafA1 data, suggest that while slightly 
raising the pH of the endosome may be beneficial for CNF1 translocation to the cytosol, 
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further inhibition of the pH drop prevents the entry of CNF1. Previous studies have 
demonstrated that there is a slight decrease in CNF1 multinucleating activity at CNF1 
concentrations of 2mM NH4Cl, with a more pronounced decrease in the range of 5-10 
mM (7).  Our results demonstrate that a much higher concentration of NH4Cl was 
necessary to inhibit CNF1 activity, as compared to previous data (7).  This could be due 
to the sensitivity of our assay in detecting trace amounts of CNF1 that have entered the 
cell.  
NH4Cl and BafA1 have also been demonstrated to enhance the activity of 
Helicobacter pylori vacuolating cytotoxin (VacA).  It was initially demonstrated that 
weak bases such as NH4Cl and trimethylamine were able to increase vacuolation induced 
by VacA (8).  Further research confirmed that 5 mM NH4Cl not only increased 
vacuolation, but also enhanced Bax activation (54).  Interestingly, BafA1 was 
demonstrated to inhibit VacA-induced vacuolation at concentrations of 5 nM, but it did 
not inhibit Bax activation (54).   The authors suggested that since H. pylori increases the 
ammonium concentration of gastric fluid (31), the addition of 5 mM NH4Cl to the cells 
more closely mimics the pH of the gastric fluid in H. pylori-infected people.  Similarly, 
perhaps this increase in CNF1 activity at lower concentrations of NH4Cl could be 
correlated to the environmental pH of the toxin in an infection. 
There are other examples of enhancement of toxin activity after treatment with 
agents that inhibit endosomal acidification.  It has been demonstrated that methylamine 
stimulates ricin activity, while the number and affinity of the ricin toxin receptors 
remains unchanged, suggesting that methylamine plays a role in entry of ricin (30).  We 
were also able to demonstrate an increase in CNF1-mediated SRE-luciferase activity with 
other agents that inhibit endosomal acidification, such as the antiporters monensin and 
nigericin (Fig 2E and F).  Similarly, these ionophores have been reported to increase the 
cytotoxicity of other toxins such as ricin, Pseudomonas toxin, and abrin (40), and it has 
been demonstrated that pre-treatment with nigericin enhances internalization of ricin 
(39). 
Our results reported here have introduced a new assay to quantitatively measure 
the activity of CNF1, CNF2, and CNFY.  Using a quantitative assay to measure CNF 
activity has allowed us to observe time and dose responses to each of the toxins, as well 
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as the effect of various inhibitors on these toxins.  These results show that although low 
concentrations of agents that inhibit endosomal acidification increase the activity of 
CNF1 and CNF2, they do not increase the activity of CNFY.  Higher concentrations of 
these inhibitors of endosomal acidification completely blocked toxin activity, reinforcing 
the importance of endosomal acidification in toxin translocation and activity.   
Furthermore, we have shown that CNF2, like CNF1 and CNFY, translocates from the late 
endosome.  Use of the SRE-luciferase assay in the study of the dermonecrotic toxins will 
provide a powerful tool for investigations into their activity and trafficking inside the cell.  
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3.5 Figures 
 
Figure 3.1 Treatment of HEK 293T/17 cells with CNF1, CNF2, or CNFY induces 
SRE-luciferase reporter activity   
 
HEK 293T/17 cells were transiently transfected with dual SRE-luciferase reporter plasmids, as described in 
Methods.  Seven hours post-transfection cells were either treated with the indicated concentrations of CNF1 
and incubated for16 hours (A); treated with 1 ng/mL, 10 ng/mL, or 100 ng/mL CNF1 and incubated for the 
indicated time (B); treated with the indicated concentrations of CNF2 and incubated for 8 (black) or 16  
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Figure 3.1 (cont.) 
(grey) hours (C); treated with the indicated concentrations of CNFY and incubated for 8 (black) or 16 
(white) hours (D); or treated with the indicated concentrations of DNT and incubated for 8 (black) or 16 
(striped) hours (E).  After incubation with the indicated toxin cells were assayed for SRE reporter gene 
activity, as described in Methods. Treatment with 100 ng/mL CNF1 was used as a control for comparison 
(C and D).  SRE fold activation was determined by dividing SRE reporter gene activity in toxin treated 
cells by SRE reporter gene activity in untreated control cells.  Data are expressed as an average of three 
experiments ± S.D., with each experiment performed in triplicate where * p<0.05 and ** p<0.005. 
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Figure 3.2 Low concentrations of inhibitors that prevent acidification of the 
endosome increase CNF1 and CNF2-mediated SRE-luciferase reporter activity 
while decreasing CNFY-mediated SRE-luciferase reporter activity   
 
HEK 293T/17 cells were transiently transfected with dual SRE-luciferase reporter plasmids, as described in 
Methods.  Seven hours post-transfection cells were then treated with either NH4Cl (A and C), bafilomycin 
A1 (B and D), monensin (E), or nigericin (F) at the indicated concentrations for 30 min (A, B, E, and F) or 
15 (black) and 30 min (grey) (C and D) before treatment with 100 ng/mL CNF1 (black), CNF2 (grey), or 
CNFY (white).  After 8 hours of incubation, cells were assayed for SRE-luciferase reporter gene activity, as 
described in Methods.  SRE fold activation was determined by dividing SRE reporter gene activity in CNF-
treated cells by SRE reporter gene activity in untreated control cells.  Fold activation was then normalized 
to control cells that were not treated with NH4Cl (A and C), bafilomycin A1 (B and D), monensin (E), or 
nigericin (F).  Data are expressed as an average of three experiments ± S.D., with each experiment 
performed in triplicate where * p<0.05 and ** p<0.005. 
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Figure 3.3  Nocodazole inhibits the activity of CNF1, CNF2, and CNFY as well as the 
NH4Cl-mediated increase in CNF1 SRE-luciferase reporter activity   
 
HEK 293T/17 cells were transiently transfected with dual SRE-luciferase reporter plasmids, as described in 
Methods.  Seven hours post-transfection cells were then treated with nocodazole at the indicated 
concentrations for 30 min before treatment with 100 ng/mL CNF1 (black), CNF2 (grey), or CNFY (white) 
(A).  Alternatively, 7 hours post-transfection cells were treated with a combination of 10 mM NH4Cl and 
nocodazole at the indicated concentrations for 30 min before treatment with 100 ng/mL CNF1 (B).  After 8 
hours of incubation, cells were assayed for SRE reporter gene activity, as described in Methods.  SRE fold 
activation was determined by dividing SRE reporter gene activity in CNF-treated cells by SRE reporter 
gene activity in untreated control cells (A and B).  Fold activation was then normalized to control cells that 
were not treated with NH4Cl or nocodazole (B).  Data are expressed as an average of three experiments ± 
S.D., with each experiment performed in triplicate, where * p<0.05 and ** p<0.005. 
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 Calc. pI value   Residues 119-267 a 
 1-536 a 1-267 267-536 1-119  Number R/K Number D/E Net Charge Calc. pI b  
CNF1 5.05 6.34 4.60 4.88  21 19 2 8.48 
CNF2 5.66 6.84 5.15 5.58  20 19 1 7.97 
CNF3 4.84 5.67 4.40 5.28  18 22 -4 5.72 
CNFy 4.80 5.17 4.57 5.20  18 22 -4 5.00 
PMT 4.99 5.34 4.70 5.18  16 19 -3 5.80 
a Numbers correspond to CNF1 amino acid residues. 
b pI values were calculated using ExPASy pI calculator at http://web.expasy.org/compute_pi/ 
 
CNF1 119 ------EEKMLPSEYLHFLQKCDFAGVYGKTLSDYWSKYYDKFKLLLKNYYISSALYLYK 
CNF2 119 ------EEKMLPSEYLYFLKGCDFSGIYGRFLSDYWSKYYDKFKLLLKNYYISSALYLYK 
CNF3 119 ------EAKMLPSEYLYFLKNCDFAGLYNKALSDYWSKNHEKFKLLLKNYYISSSLYLYK 
CNFy 119 ------EAKMLPSEYLYFLRDCDFSNLYNKALSDYWAENYEKFSTLLQNYYISSAYYLYK 
PMT  158 PVWGPNEQIYHSRVIADILYARSVWDEFKKYFMEYWQKYAQLYTEMLSDTFLAMAIQQYT 
               *    .     :*   .. . : : : :** :  : :. :*.: ::: :   *. 
 
CNF1 173 NGELDEREYNFSMNAL-NRSDNISLLFFDIYGYYASDIFVAKNN----DKVMLFIPGAKK 
CNF2 173 NGEIDEYEYNFSISAL-NRRDNISLFFFDIYGYYSSDMFVAKNN----ERVMLFIPGAKK 
CNF3 173 NNVISKDEHEFTMKAL-NRDDNIELFSFDIYGYYSSDIFGAKND----DRIMLFIPGATN 
CNFy 173 DSAISKDEYEFSIDAIFNKKSKILRYYFDVYGYYSSDMFVAMND----NKTMLFIPGATN 
PMT  218 RQTLTDEGFLMVCNTYYGNKEEVQITLLDIYGYPSTDIICIEQKGLPTPKVILYIPGGTQ 
            : .  . :  .:  .. .::    :*:*** ::*::   :.     : :*:***..: 
 
CNF1 228 PFLFKKNIADLRLTLKELIKDSDKQQLLSQHFSLYSRQDG 267  
CNF2 228 PFLFEKNIADLRISLKNLIKENDNKQLLSQHFSLYSRQDG 267  
CNF3 228 PFLFSENISHLRTHLKELIKENDNRELLSRHFSLYDCQDG 267  
CNFy 229 PFIFADNITDLRDKIKALISDKNTRELFSKHFSLYDRQDG 268  
PMT  278 PFVEFLNTDDLKQWIAWHLKDNKHMVAFRKHFSLKQRQEG 317  
         **:   *  .*:  :   :.:..    : :**** . *:* 
 
 
Figure 3.4 PIs of selected regions of CNF1, CNF2, CNF3, CNFY, and PMT 
 
The left side of this table depicts pI values for selected regions of the N-terminus of CNF1, CNF2, CNF3, 
CNFY, and PMT (numbers correspond to residues of CNF1).  The right side of this table depicts the number 
of acidic residues, the number of basic residues, the net charge, and the calculated pI for regions of CNF1, 
CNF2, CNF3, CNFY, and PMT aligned with residues 119-267 of CNF1. The bottom of the figure depicts 
an alignment of residues 119-267 of CNF1, CNF2, and CNF3; residues 119-268 of CNFY, and residues 
158-317 of PMT.  An asterisk (*) is used to denote positions with a single, fully conserved residue, a colon 
(:) denotes conservation between groups with strongly similar properties, and a period (.) denotes 
conservation between groups with weakly similar properties.  Red indicates acidic residues (DE).  Blue 
indicates basic residues (RK).  pI values were calculated using ExPASy pI calculator at 
http://web.expasy.org/compute_pi/. 
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Figure 3.5 Model of Increased CNF1/2 activity with low concentrations of BafA1 
and NH4Cl   
 
This figure depicts the proposed effects of pH on the translocation of CNFs.  The green box represents the 
pH range where translocation of CNF1/2 is most favorable therefore accounting for the increase in CNF1/2 
activity seen at concentrations of BafA in the range of 10-20 nM and at concentrations of NH4Cl in the 
range of 5-20 mM.  Because of the difference in pIs for regions of the N-terminus of CNF1/2 and CNFY we 
propose that pH’s inside of the range of the green box provide a favorable pH, at which certain residues of 
CNF1/2 are protonated thereby allowing for interaction of the translocation domain with the membrane and 
leading to an increase in translocation of the catalytic domain. 
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Chapter 4:  Conclusions and Future Directions 
 
4.1 SRE-Luciferase Assay as a Useful Tool 
This thesis took advantage of SRE-luciferase activity as an assay to quantify PMT 
intracellular signaling (1) to further define the trafficking pathways PMT uses to enter the 
cell and translocate to the cytosol.  Using the SRE-luciferase assay allowed for a 
quantifiable measure of PMT-induced intracellular signaling, which was useful when 
attempting to further delineate intracellular trafficking pathways of PMT. 
As the SRE-reporter assay proved a useful quantitative assay for measuring PMT 
activity, we decided to use the SRE-luciferase assay to investigate the trafficking 
pathways of other dermonecrotic toxins.  Before this thesis, previous studies with the 
CNF family and DNT relied on visual indication of activity such as multinucleation (5, 
12) and formation of actin stress fibers (9, 11, 17); used electrophoretic mobility assays to 
detect a shift in Rho after deamidation (9, 11, 17); or relied upon measuring tyrosine 
phosphorylation of p125fak and paxillin (17).  The SRE-luciferase assay provided a novel 
method of quantifying SRE signaling activity induced by treatment with these toxins, 
while also allowing us to quantitatively compare the signaling activity across the 
dermonecrotic family.  In the case of the CNFs, we were able to demonstrate that CNF1, 
CNF2 and CNFY were all able to activate SRE signaling.   
For both CNF1 and CNF2 the peak in SRE signaling occurred after treatment for 
8 hours with 100 ng/mL of toxin (Fig 3.1A and C).  For CNFY the peak in signaling 
occurred after an 8-hour treatment with 1 µg/mL CNFY (Fig 3.1D), which was the highest 
concentration tested.  CNF2 and CNFY proved to be the strongest activators of SRE 
signaling after an 8-hour incubation and induced SRE-signaling that was more than two-
fold higher than that of CNF1.  Furthermore, we discovered that signaling activity peaked 
after an 8-hour treatment for all of the CNFs.  This was in contrast to PMT where activity 
peaked after a 16-hour treatment (data not shown).  This decrease in activity after 8 hours 
could be attributed to the degradation of the CNF target proteins.   
 We observed minimal SRE signaling activity when treating HEK 293T/17 cells 
with DNT.  Cells treated with 100 ng/mL DNT for 8 or 16 hours did not exhibit any 
increase in SRE-signaling activity.  Treatment with higher concentrations of DNT in the 
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range of 1 mg/mL induced 7-fold and 10-fold increases in SRE-signaling activity at 8 and 
16 hours respectively (Fig 3.1E).  The failure of DNT to induce SRE signaling activity 
may be attributed to lack of a DNT receptor on the HEK 293T/17 cells. 
 Possible directions for future research include using the SRE-luciferase assay to 
measure the signaling activity of mutant or chimeric toxins.  For example, residues in the 
translocation domain of a dermonecrotic toxin could be mutated, and the activity of the 
mutant could be subsequently tested in the SRE-luciferase assay.  In this case the SRE-
luciferase assay could serve as a useful tool to screen various mutants for their effects on 
toxin activity. 
These experiments demonstrate that the SRE-luciferase assay is a useful tool for 
quantitative analysis of signaling across the dermonecrotic toxin family.  Another 
potential direction for future research includes determining whether CNF3, another 
member of the CNF family, is able to induce SRE signaling.  The SRE-luciferase assay 
would provide a simple way to compare the level of SRE-luciferase activation induced by 
CNF3 as compared to CNF1, CNF2, and CNFY.  Little is known about the trafficking 
pathways of CNF3, thus it would also be useful to use the SRE-luciferase assay to 
characterize the entry of CNF3.  The SRE-luciferase assay could be used to determine 
whether CNF3 translocates from an acidified endosome through the use of inhibitors such 
as NH4Cl and bafilomycin A1 (BafA1).  It could also be determined whether low 
concentrations of these inhibitors increase CNF3 activity as they do for CNF1 and CNF2.  
Experiments using nocodazole could also determine whether or not CNF3 translocates 
from the late endosome.  Such studies on trafficking would allow for a model of CNF3 
entry and for comparison of CNF3 toxin trafficking pathways with the trafficking 
pathways of other dermonecrotic toxins.  
Another possible direction for future experiments would be to use the SRE-
luciferase assay to determine protein receptors for CNFY and CNF3.  One could perform 
RNAi against potential receptor targets, such as the 67-kDa laminin-receptor protein, and 
then measure the CNF-induced SRE-luciferase activity.  RNAi against various potential 
receptors could be tested in order to further define the binding and entry of CNFY and 
CNF3. 
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Toxins are often used as tools to study signal transduction.  Before a toxin can be 
used in a particular cell line it is necessary to determine whether the cell line is sensitive 
to the toxin.  In this thesis we hypothesized that DNT was unable to induce a large 
increase in SRE-signaling activity in HEK 293T/17 cells because this cell line lacks the 
receptor for DNT entry.  Thus, this assay could prove a quick and easy way to determine 
whether a particular cell line is sensitive to any member of the dermonecrotic toxin 
family.  Various transfectable cell lines can be transfected with the reporter plasmids, 
treated with the appropriate toxin, and then assayed for activity to determine cell line 
sensitivity. 
 
4.2 Toxin Trafficking and the Role of Acidification 
Since we established a novel quantitative measure of CNF activity we next 
wanted to explore the effect of agents that inhibit endosomal acidification on CNF 
activity.  It has previously been demonstrated that CNF1 (5), CNF2 (26), and CNFY (3), 
are all dependent on endosomal acidification for entry and translocation as treatment with 
these inhibitors blocks CNF activity.  Since we have developed a quantitative assay for 
CNF activity, we wanted to quantitate the SRE-signaling response of toxin treated cells 
over a range of inhibitor concentrations.  This led to the observation that while high 
concentrations of inhibitors of endosomal acidification inhibit CNF activity, low 
concentrations of these inhibitors actually increase the SRE-signaling activity of CNF1 
and CNF2.  This increase was not observed for CNFY (Fig 3.2) or PMT (Fig 2.2A and B). 
There are several possible reasons for the increase in CNF1 and CNF2 activity 
with low concentrations of agents that inhibit endosomal acidification.  It has been 
previously suggested that CNF1 translocates from the endosome at a pH of 5.2 (5).  
Perhaps the endosomal pH induced by the low concentrations of inhibitors is more 
conducive to translocation of CNF1. Analysis of the pIs of various regions of the CNF 
family demonstrates that the pIs of N-terminal regions of CNF1 and CNF2 differ from 
those of CNF3, CNFY and PMT (Figure 3.4).  The pIs of CNF1 and CNF2 are over 2 
units higher than the pIs of CNF3, CNFY and PMT in the regions encompassing residues 
119-267 (these residues correspond to CNF1).  Furthermore, CNF1 and 2 have a net 
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positive charge in this region, 2 for CNF1 and 1 for CNF2, while CNF3, CNFY, and PMT 
all have a net negative charge, -4 for CNF3/Y and -3 for PMT.   
Protonation of residues has been shown to be important for translocation of toxins 
(27, 28).  As outlined in Figure 3.5, we propose that altering the endosomal pH to a value 
that is lower than the pI of the N-terminal regions of CNF1/2 creates a favorable 
environment for translocation.  At this favorable pH protonation of residues and 
differences in net charge leads to destabilization of tertiary structure and an increased 
probability of interaction with the membrane, thus facilitating translocation.  Under this 
model endosomes in untreated cells would be more acidic and thus not optimal for 
translocation.  The addition of NH4Cl or BafA in small amounts creates a relatively more 
basic environment allowing higher levels of toxin translocation.  
Furthermore, it is known that BafA1 inhibits transport from late endosomes to 
lysosomes (33) and that bafilomycin decreased the degradation of ricin by increasing 
lysosomal pH and reducing transport of ricin to lysosomes (32). This increase in activity 
was not noted for CNFY or PMT, thus it is less likely that the increase is solely due to 
reduced transport to lysosomes.  However, perhaps it is a combination of a reduction in 
degradation of CNF1/2 coupled with a favorable environmental pH that increases 
translocation.  It is notable that this increase is observed with several different inhibitors 
of endosomal acidification.  Monensin, nigericin, NH4Cl, and BafA1 all have different 
mechanisms of inhibiting endosomal acidification; however, the increase in CNF1/2 
activity was observed with all of them, suggesting that the increase is due to modulation 
of pH.   
Another possibility is that the association of CNF1 and CNF2 with their receptors 
is affected by endosomal pH and modifying endosomal pH modifies the binding of toxin 
and receptor.  In such a model it is possible that preventing endosomal acidification 
modifies the toxin-receptor interaction so that the toxin is more readily able to 
translocate.  This possibility is supported by the fact that CNF1 and CNF2 are thought to 
share the same receptor (15, 21), while the protein receptors for CNFY and PMT remain 
unidentified.  Another possibility is that treatment with these inhibitors increases surface 
expression of the toxin receptor, while high concentrations of inhibitor override the 
increase in receptors since translocation is blocked. 
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There are several potential future directions for this work.  It is necessary to 
further investigate the mechanism behind the increase in CNF1 and CNF2 activity after 
treatment with low concentrations of inhibitors of endosomal acidification.  We 
previously suggested that destabilization of tertiary structure in the regions of pI 
difference, attributable to differential protonation of residues, make the conditions for 
interaction of the translocation domain with the membrane more favorable for CNF1/2.  
In order to confirm this, further studies with chimeric CNFs, in which the regions with 
the pI difference are swapped between CNF1 and CNFY (or CNF2 and CNFY) and tested 
for their activity at various doses of NH4Cl and BafA, would be useful.  Alternatively, 
further studies mutating protonatable residues in this region to observe their effect on 
toxin activity at various doses of NH4Cl and BafA might also provide insight into the 
mechanism of this increase. 
We also previously mentioned that BafA1 inhibits transport from late endosomes 
to lysosomes (33) and that bafilomycin decreased the degradation of ricin by increasing 
lysosomal pH and reducing transport of ricin to lysosomes (32).  To test whether this 
might also occur with CNF1/2, it would be possible to look at colocalization of CNF1/2 
with lysosomal markers in cells treated with varying concentrations of BafA1.  One 
would expect to see a decrease in colocalization of CNF1/2 with the lysosome at 
concentrations of BafA1 that increase CNF1/2 activity. 
Furthermore, since a receptor for CNF1/2 has been identified, it would also be 
possible to determine the effect of different concentrations of BafA1 on the receptor 
density.  Membrane extracts of cells treated with varying concentrations of BafA1 could 
be examined for receptor level changes using western blotting.  Alternatively one could 
label the cell surface with antibodies to laminin receptor and detect the amount of 
antibody through binding of a fluorescent secondary antibody and subsequent analysis by 
flow cytometry. 
Our results also provide the first images of PMTb-GFP trafficking under 
conditions in which acidification of the endosome was inhibited (Fig 2.2G-J).  Future 
experiments could determine the cellular localization of toxins when treated with various 
chemical inhibitors such as nocodazole or cytochalasin D.  These studies could reinforce 
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the current knowledge of how these inhibitors affect toxin activity by providing visual 
clues as to the trafficking compartments of the toxins. 
Although we did not investigate the effect of inhibitors of endosomal acidification 
on DNT activity, it is known that DNT does not require an acidified endosome for 
translocation, nor is DNT affected by nocodazole (19).  Alternatively, it has been 
demonstrated that proteolytic cleavage of DNT by furin is necessary for its intracellular 
activity (19).  Therefore, since DNT does not translocate from a late endosome, it is 
unlikely that these inhibitors would have any effect on DNT activity. 
 
4.3 Toxin Trafficking and the Role of Arf6 
One of the primary aims of this work was to characterize the entry pathways of 
PMT.  Before this thesis, little was known concerning the pathways PMT exploits to gain 
access to the cytosol.  PMT is an intracellularly acting toxin that enters the cell through 
endosomal trafficking (31).  It had been previously shown that PMT is trafficked through 
a low pH compartment before translocation to the cytosol and that this acidification was 
important for PMT unfolding and translocation (2). 
Initial studies in our laboratory showed that PMTb-GFP colocalized in endosomes 
with transferrin (Tfn) (Figure 2.1A-D), a marker of the early endosome that colocalizes 
with both Arf6 (6) and Rab5 (13).  Although we demonstrated that PMTb-GFP 
colocalizes with Tfn in these early endosomes, PMT activity is not affected by 
LY294002, an inhibitor of PI3-kinase (Figure 2.1E) which inhibits fusion of Arf6 and 
Rab5 endosomes (22). 
 Since PMTb-GFP colocalized with Tfn, we next wanted to determine whether 
Arf6 plays a role in trafficking of PMT.  Arf6 is a small GTPase involved in endocytosis.  
Both constitutively active and dominant negative mutants of Arf6 disrupt the binding and 
subsequent hydrolysis of GTP, thus altering the function of the protein (29).  
Accordingly, both dominant negative and constitutively active mutants of Arf6 decreased 
PMT activity (Figure 2.3A), suggesting that Arf6 is involved in endocytosis of PMT.  
Furthermore, mutations abolishing the membrane attachment of Arf6 (7) abolished the 
effect of Arf6 on PMT activity (Figure 2.3A).  We were also able to demonstrate that 
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PMTb-GFP colocalized in vesicles with CtxB-594, another toxin that recruits Arf6 to the 
endosomal membrane (8). 
One possible direction for future work is to determine whether small GTP-binding 
proteins other than Arf6 are involved in internalization of PMT.  Future studies could 
look at whether PMT colocalizes with other small GTPases of the Rab family.  These 
studies could further define the trafficking pathways that PMT exploits to gain access to 
the cell.  Further experiments with members of the CNF family could determine the 
involvement of small GTPases in CNF trafficking.  This thesis looked at the involvement 
of Arf6 in the trafficking of PMT.  Further studies could investigate the involvement of 
small GTPases of both the Arf and Rab families in the trafficking of CNFs.  Future 
experiments could determine whether the CNFs colocalize with these GTPases or how 
mutant GTPases affect the SRE signaling activity of the various CNFs. 
Although this thesis implicates Arf6 in the trafficking of PMT, it is not known if 
Arf6 interacts with PMT in a manner similar to which it interacts with cholera toxin.  
Cholera toxin has been shown to recruit Arf6 to endosomal membranes during its 
trafficking and internalization and to increase rates of endosomal acidification (8).  
Further experiments could determine whether treatment with PMT increases the 
association of Arf6 with endosomal membranes or the rate of endosomal acidification 
when cells are treated with PMT.  Also, it has been shown that Arf6 is an allosteric 
activator of the CT-catalyzed ADP-ribosylation of Gαs (14, 23) and crystal structures of 
the complex have been determined (24).  It would therefore be interesting to see whether 
Arf6 binds to PMT and if such an interaction occurs, whether the interaction catalyzed 
PMT’s deamidation of other G-proteins. 
 
4.4 Toxin Trafficking and the Role of the Early to Late Endosomes Pathway 
We observed that nocodazole, an inhibitor of microtubule polymerization, was 
able to inhibit PMT–mediated SRE-luciferase activity (Figure 2.4). Microtubule 
dynamics are important for vectoral transport from early to late endosomes (4, 20).  Thus, 
these results indicate that PMT translocation occurs from the late endosome.  Since it has 
been previously demonstrated that both CNF1 (5) and CNFY (3) translocate from the late 
endosome, we wanted to determine whether CNF2 also translocates from the late 
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endosome, and whether the increase in CNF1 and CNF2 activity seen with low 
concentrations of inhibitors of endosomal acidification is dependent on translocation 
from the late endosome.  We demonstrated that treatment with nocodazole inhibited the 
SRE-signaling activity induced by CNF1, CNF2, and CNFY (Fig 3.3A).  We were also 
able to demonstrate that the increase in SRE-signaling activity seen with low 
concentrations of inhibitors of endosomal acidification was blocked by treatment with 
nocodazole (Fig 3.3B), thereby demonstrating that this increase in activity relies on 
translocation of CNF1 from the late endosome. 
Future experiments could potentially look at colocalization of these toxins with 
markers of the late endosome.  As previously stated, we were able to observe changes in 
the distribution of PMTb-GFP containing vesicles after treatment with NH4Cl (Fig 2. 2G-
J).  Further experiments could determine whether the use of nocodazole affects 
colocalization of the dermonecrotic toxins with markers of the late endosome.  Such 
colocalization studies would complement existing data, demonstrating the effects of 
nocodazole on dermonecrotic toxin activity. 
 
4.5 Toxin Trafficking and the Effect of BrefeldinA 
 Although PMTb-GFP and CtxB-594 initially colocalized in vesicles, we wanted 
to determine if and where these trafficking pathways diverge.  CT has a KDEL signal and 
after initial endocytosis in an Arf6-positive vesicle, it undergoes trafficking through the 
Golgi, retrograde to the ER where the catalytic domain escapes to the cytosol (18).  The 
activity of CT can be inhibited with brefeldin A (25), an inhibitor of Golgi to ER 
transport (10).  We therefore wanted to determine the effect of brefeldin A on the activity 
of PMT.  Our results indicate that treatment with brefeldin A enhances PMT activity 
(Figure 2.5A), suggesting that this increase in PMT activity with brefeldin A treatment 
seems to be physiologically relevant, as agents which inhibit translocation, such as 
NH4Cl (Figure 2.5B), and Arf6 mutants that inhibit entry (Figure 2.5C), both inhibit this 
brefeldin A-mediated increase in PMT activity.  This also suggests that while PMTb-GFP 
and CtxB-594 initially colocalize in vesicles upon entering the cell, the trafficking 
pathways diverge.   
 123 
 Although our work has further defined the pathways of PMT trafficking inside the 
cell, much is still unknown concerning PMT’s internalization.  A protein receptor for 
PMT has not been identified.  Although we hypothesize that the use of brefeldin A 
diverts any PMT from the Golgi apparatus, thereby preventing a nonproductive infection, 
there are other possibilities to explain this increase.  Since brefeldin A redistributes the 
contents of the Golgi, it is conceivable that treatment with this inhibitor actually causes 
an increase in PMT surface receptors. It is known that treatment with brefeldin A 
increases the number of cell-associated mannose-6-phosphate-receptor (M6PR) (34).  
Perhaps brefeldin A acts in a similar manner to increase cell-surface expression of the 
PMT receptor.  If this were the case, treatment with brefeldin A would be a useful tool to 
elucidate the PMT receptor.  Cells could be treated with brefeldin A to increase 
expression of the surface receptor before performing pull-down experiments to bind the 
PMT receptor.  
 If brefeldin A is not increasing the number of receptors present on the cell 
surface, another possible future direction for this work is to determine the nature of 
brefeldin A-mediated increase in PMT activity.  Brefeldin A induces a tubulovesicle 
structure whose formation is dependent upon microtubules (34).  If the tubulovesicle 
structure plays a role in PMT translocation then treatment with inhibitors of microtubule 
polymerization, such as nocodazole, should block the brefeldin A-mediated increase in 
PMT activity. 
 
4.6 Conclusions 
Overall, through the use of the SRE-luciferase assay in this thesis has enable us to 
further define the trafficking pathways of the dermonecrotic toxins.  The knowledge of 
trafficking pathways gained through the experiments within this thesis is applicable to a 
variety of scientific advances.  As previously mentioned, recombinant immunotoxins are 
currently being used for treatment of cancer (reviewed in (16, 30)).  Knowledge of the 
binding and entry of toxins is essential when designing a hybrid toxin that is intended to 
deliver a therapeutic molecule to a subset of cells.  This thesis has demonstrated that 
various chemicals increase toxin activity, including brefeldin A, which was demonstrated 
to increase PMT activity, and NH4Cl which was demonstrated to increase CNF1 and 
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CNF2 activity at low doses.  Deciphering the mechanism of this increase could prove 
beneficial, as it could potentially be applied to immunotoxins to deliver an increased 
amount of the therapeutic molecule. 
 This thesis also addressed various ways in which toxin activity is inhibited.  Our 
results indicate that mutants of Arf6, inhibitors of endosomal acidification, and 
nocodazole were all able to inhibit PMT activity.  PMT has proven to be a problem in 
agriculture, where it is responsible for the symptoms of atrophic rhinitis in pigs.  
Knowledge gained from this thesis can be applied towards potential therapeutics to 
prevent PMT-induced atrophic rhinitis or PMT-induced pasteurellosis.  The more we 
understand the specific trafficking pathways that PMT is exploiting to gain access to its 
intracellular targets, the easier it will be to design targeted therapeutics. 
Overall this thesis has contributed to the knowledge of the trafficking pathways of 
the dermonecrotic toxins PMT, CNF1, CNF2, CNFY, and DNT.  We have demonstrated 
herein that translocation of PMT occurs from a late endosome and is dependent on 
endosomal acidification.  PMT activity is dependent upon both actin and microtubules as 
inhibitors of their polymerization also inhibit PMT activity.  We have also demonstrated 
that brefeldin A increases PMT activity.  Our results extended to members of the 
dermonecrotic toxin family and demonstrated that CNF2 and CNFY are stronger 
activators of the SRE signaling pathway than CNF1.  In addition, low concentrations of 
inhibitors of endosomal acidification increased CNF1 and CNF2 activity, and this 
increase was dependent upon translocation from the late endosome.  We have 
demonstrated that CNF2, like CNF1 and CNFY translocates from the late endosome.  
Altogether these experiments have helped to further delineate the intracellular trafficking 
pathways of the dermonecrotic toxins. 
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